EA011883B1 - Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови - Google Patents
Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови Download PDFInfo
- Publication number
- EA011883B1 EA011883B1 EA200701469A EA200701469A EA011883B1 EA 011883 B1 EA011883 B1 EA 011883B1 EA 200701469 A EA200701469 A EA 200701469A EA 200701469 A EA200701469 A EA 200701469A EA 011883 B1 EA011883 B1 EA 011883B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cpp
- agonist
- test compound
- yloxy
- piperidin
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 146
- 239000008280 blood Substances 0.000 title claims abstract description 146
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 52
- 230000001668 ameliorated effect Effects 0.000 title claims abstract 4
- 238000011282 treatment Methods 0.000 title claims description 26
- 238000002648 combination therapy Methods 0.000 title description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 claims abstract description 296
- 239000003112 inhibitor Substances 0.000 claims abstract description 202
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 54
- 239000008103 glucose Substances 0.000 claims abstract description 54
- 230000000694 effects Effects 0.000 claims abstract description 37
- -1 5-cyanopyridin-2-yl Chemical group 0.000 claims description 1074
- 150000001875 compounds Chemical class 0.000 claims description 331
- 108020003175 receptors Proteins 0.000 claims description 156
- 238000000034 method Methods 0.000 claims description 112
- 238000012360 testing method Methods 0.000 claims description 104
- 239000000203 mixture Substances 0.000 claims description 99
- 101710117545 C protein Proteins 0.000 claims description 94
- 230000028327 secretion Effects 0.000 claims description 94
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 76
- 150000001413 amino acids Chemical group 0.000 claims description 75
- 239000002773 nucleotide Substances 0.000 claims description 49
- 125000003729 nucleotide group Chemical group 0.000 claims description 49
- 241000124008 Mammalia Species 0.000 claims description 42
- 239000003446 ligand Substances 0.000 claims description 38
- 239000002552 dosage form Substances 0.000 claims description 35
- 210000003158 enteroendocrine cell Anatomy 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 150000003384 small molecules Chemical group 0.000 claims description 30
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 27
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims description 27
- 229940095074 cyclic amp Drugs 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 23
- 238000009739 binding Methods 0.000 claims description 23
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 101800000594 Capsid protein 1 Proteins 0.000 claims description 17
- 101800000838 Neutrophil cationic peptide 1 Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000003752 polymerase chain reaction Methods 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 230000007812 deficiency Effects 0.000 claims description 12
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 11
- 208000006011 Stroke Diseases 0.000 claims description 11
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
- 102000043136 MAP kinase family Human genes 0.000 claims description 10
- 108091054455 MAP kinase family Proteins 0.000 claims description 10
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 201000001421 hyperglycemia Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 9
- 239000000021 stimulant Substances 0.000 claims description 9
- 230000036765 blood level Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 claims description 7
- 150000001982 diacylglycerols Chemical class 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 6
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 claims description 6
- 230000006931 brain damage Effects 0.000 claims description 6
- 231100000874 brain damage Toxicity 0.000 claims description 6
- 208000029028 brain injury Diseases 0.000 claims description 6
- 201000003723 learning disability Diseases 0.000 claims description 6
- 210000003574 melanophore Anatomy 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 208000010444 Acidosis Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 5
- 206010018473 Glycosuria Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 208000026072 Motor neurone disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 231100000318 excitotoxic Toxicity 0.000 claims description 5
- 230000003492 excitotoxic effect Effects 0.000 claims description 5
- 230000035780 glucosuria Effects 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 5
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 230000028252 learning or memory Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000013600 Diabetic vascular disease Diseases 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 claims description 2
- 102400000739 Corticotropin Human genes 0.000 claims description 2
- 101800000414 Corticotropin Proteins 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
- 229960000258 corticotropin Drugs 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims 5
- 102100040705 Low-density lipoprotein receptor-related protein 8 Human genes 0.000 claims 4
- 102000011855 MAP Kinase Kinase Kinase 1 Human genes 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims 4
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 4
- 108010031117 low density lipoprotein receptor-related protein 8 Proteins 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- AKWUNZFZIXEOPV-UHFFFAOYSA-N 2-[4-[[3-[7-chloro-1-(oxan-4-ylmethyl)indol-3-yl]-1,2,4-oxadiazol-5-yl]methyl]piperazin-1-yl]acetamide Chemical compound C1CN(CC(=O)N)CCN1CC1=NC(C=2C3=CC=CC(Cl)=C3N(CC3CCOCC3)C=2)=NO1 AKWUNZFZIXEOPV-UHFFFAOYSA-N 0.000 claims 2
- 101100280477 Caenorhabditis elegans lbp-1 gene Proteins 0.000 claims 2
- 206010029333 Neurosis Diseases 0.000 claims 2
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims 2
- 208000015238 neurotic disease Diseases 0.000 claims 2
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 4
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 abstract 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 230000000580 secretagogue effect Effects 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 118
- 125000000217 alkyl group Chemical group 0.000 description 117
- 229910052736 halogen Inorganic materials 0.000 description 91
- 150000002367 halogens Chemical class 0.000 description 89
- NVMHDJQDTCMXLH-UHFFFAOYSA-N propan-2-yl piperidine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCCCC1 NVMHDJQDTCMXLH-UHFFFAOYSA-N 0.000 description 79
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 74
- 102000005962 receptors Human genes 0.000 description 73
- 125000003545 alkoxy group Chemical group 0.000 description 72
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 69
- 125000001072 heteroaryl group Chemical group 0.000 description 69
- 125000004093 cyano group Chemical group *C#N 0.000 description 65
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 62
- 125000002252 acyl group Chemical group 0.000 description 61
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 150000003857 carboxamides Chemical class 0.000 description 54
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 49
- 125000004423 acyloxy group Chemical group 0.000 description 48
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 48
- 125000001424 substituent group Chemical group 0.000 description 47
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 45
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 45
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 43
- 229910052799 carbon Inorganic materials 0.000 description 43
- 125000000623 heterocyclic group Chemical group 0.000 description 43
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 42
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 40
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 40
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 39
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 38
- 125000003118 aryl group Chemical group 0.000 description 37
- 229910052739 hydrogen Inorganic materials 0.000 description 37
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 36
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 36
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 36
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 34
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 32
- 125000003282 alkyl amino group Chemical group 0.000 description 31
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 30
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 29
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 29
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 28
- 125000004663 dialkyl amino group Chemical group 0.000 description 28
- 150000001412 amines Chemical class 0.000 description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 26
- 101710152019 Centromere-binding protein 1 Proteins 0.000 description 25
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 23
- 125000004432 carbon atom Chemical group C* 0.000 description 22
- 125000004771 (C1-C4) haloalkylsulfinyl group Chemical group 0.000 description 21
- 125000004414 alkyl thio group Chemical group 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 20
- 230000003834 intracellular effect Effects 0.000 description 20
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 20
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 19
- 125000005422 alkyl sulfonamido group Chemical group 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 125000002947 alkylene group Chemical group 0.000 description 16
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 16
- 125000004995 haloalkylthio group Chemical group 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 125000005363 dialkylsulfonamide group Chemical group 0.000 description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 14
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 14
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 238000007410 oral glucose tolerance test Methods 0.000 description 11
- CGTRVJQMKJCCRF-UHFFFAOYSA-N 3-(3-carbazol-9-ylphenyl)-9-[3-[3-(3-carbazol-9-ylphenyl)carbazol-9-yl]phenyl]carbazole Chemical compound C12=CC=CC=C2C2=CC(C=3C=CC=C(C=3)N3C4=CC=CC=C4C4=CC=CC=C43)=CC=C2N1C1=CC=CC(N2C3=CC=C(C=C3C3=CC=CC=C32)C=2C=C(C=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)=C1 CGTRVJQMKJCCRF-UHFFFAOYSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 10
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 9
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 9
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 125000004494 ethyl ester group Chemical group 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000004031 partial agonist Substances 0.000 description 8
- 229940124530 sulfonamide Drugs 0.000 description 8
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 7
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 125000004474 heteroalkylene group Chemical group 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 6
- NGXGHWAPEVIOJK-UHFFFAOYSA-N 2-methylpropyl piperidine-1-carboxylate Chemical compound CC(C)COC(=O)N1CCCCC1 NGXGHWAPEVIOJK-UHFFFAOYSA-N 0.000 description 6
- OTTQGWMXVGSRII-UHFFFAOYSA-N 2-propanoylbenzenesulfonamide Chemical compound CCC(=O)C1=CC=CC=C1S(N)(=O)=O OTTQGWMXVGSRII-UHFFFAOYSA-N 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002484 inorganic compounds Chemical class 0.000 description 6
- 229910010272 inorganic material Inorganic materials 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 150000002894 organic compounds Chemical class 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 150000003456 sulfonamides Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ZSOPWZQRZHWYFY-NUXPJIRBSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)N1CCSC1 ZSOPWZQRZHWYFY-NUXPJIRBSA-N 0.000 description 5
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 5
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 5
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000014384 Type C Phospholipases Human genes 0.000 description 5
- 108010079194 Type C Phospholipases Proteins 0.000 description 5
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000003709 fluoroalkyl group Chemical group 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000010802 sludge Substances 0.000 description 5
- 125000003831 tetrazolyl group Chemical group 0.000 description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 239000004146 Propane-1,2-diol Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 4
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 4
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 4
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 4
- 239000000859 incretin Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 125000003396 thiol group Chemical class [H]S* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- QGUCBSXNMDKGML-UHFFFAOYSA-N 5-(4-propylcyclohexyl)-3-(3-pyridinyl)-1,2,4-oxadiazole Chemical compound C1CC(CCC)CCC1C1=NC(C=2C=NC=CC=2)=NO1 QGUCBSXNMDKGML-UHFFFAOYSA-N 0.000 description 3
- OAAGDVLVOKMRCQ-UHFFFAOYSA-N 5-piperidin-4-yl-3-pyridin-4-yl-1,2,4-oxadiazole Chemical compound C1CNCCC1C1=NC(C=2C=CN=CC=2)=NO1 OAAGDVLVOKMRCQ-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- GLMHJKQHYAVPMZ-UHFFFAOYSA-N butyl piperidine-1-carboxylate Chemical compound CCCCOC(=O)N1CCCCC1 GLMHJKQHYAVPMZ-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000002993 cycloalkylene group Chemical group 0.000 description 3
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 3
- MKKLYVIKFVIRKV-UHFFFAOYSA-N cyclopentyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OC1CCCC1 MKKLYVIKFVIRKV-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000014101 glucose homeostasis Effects 0.000 description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HLTMUYBTNSVOFY-UHFFFAOYSA-N pentylcyclohexane Chemical compound CCCCCC1CCCCC1 HLTMUYBTNSVOFY-UHFFFAOYSA-N 0.000 description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- XCKPUZAGEYMHKH-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methoxypropan-2-ol Chemical compound C1CN(CC(O)COC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C XCKPUZAGEYMHKH-UHFFFAOYSA-N 0.000 description 2
- DFUAXIBBYPOMIV-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]hexan-2-one Chemical compound C1CN(CC(=O)CCCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C DFUAXIBBYPOMIV-UHFFFAOYSA-N 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 2
- KBRFTJUEHZNTLD-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-pyridin-2-ylethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC=N1 KBRFTJUEHZNTLD-UHFFFAOYSA-N 0.000 description 2
- IHBAVXVTGLANPI-QMMMGPOBSA-N 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one Chemical group CC(C)[C@H](N)C(=O)N1CCCC1 IHBAVXVTGLANPI-QMMMGPOBSA-N 0.000 description 2
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- PGRVGFHSZHVGTA-UHFFFAOYSA-N 2-methoxyethyl piperidine-1-carboxylate Chemical compound COCCOC(=O)N1CCCCC1 PGRVGFHSZHVGTA-UHFFFAOYSA-N 0.000 description 2
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- GBEVJTUHCCPTDP-UHFFFAOYSA-N 4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(C(O)=O)CC1 GBEVJTUHCCPTDP-UHFFFAOYSA-N 0.000 description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241001182632 Akko Species 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000004860 Dipeptidases Human genes 0.000 description 2
- 108090001081 Dipeptidases Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- DGUBIAFSRFMCKF-UHFFFAOYSA-N [1-[6-(2-fluoroanilino)-5-nitropyrimidin-4-yl]piperidin-4-yl]-(4-fluorophenyl)methanone Chemical compound N1=CN=C(N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)C([N+](=O)[O-])=C1NC1=CC=CC=C1F DGUBIAFSRFMCKF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000005596 alkyl carboxamido group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- GGBJHURWWWLEQH-UHFFFAOYSA-N butylcyclohexane Chemical compound CCCCC1CCCCC1 GGBJHURWWWLEQH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- LTUGMEGZRAZLKK-UHFFFAOYSA-N ethyl 1-[6-[4-(dimethylsulfamoyl)anilino]-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)S(=O)(=O)N(C)C)=C1[N+]([O-])=O LTUGMEGZRAZLKK-UHFFFAOYSA-N 0.000 description 2
- YSPVHAUJXLGZHP-UHFFFAOYSA-N ethyl piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCCCC1 YSPVHAUJXLGZHP-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- VYGZRRKABMHIHB-UHFFFAOYSA-N n-tert-butylpiperidine-1-carboxamide Chemical compound CC(C)(C)NC(=O)N1CCCCC1 VYGZRRKABMHIHB-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000004971 nitroalkyl group Chemical group 0.000 description 2
- MLNVZMBQJNTFDE-UHFFFAOYSA-N oxolan-3-yl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OC1CCOC1 MLNVZMBQJNTFDE-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YXBKRUFCMRJIQY-UHFFFAOYSA-N pentyl piperidine-1-carboxylate Chemical compound CCCCCOC(=O)N1CCCCC1 YXBKRUFCMRJIQY-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- GMIOZGYLKIQXSX-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[[6-(propylamino)pyridin-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(NCCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#N GMIOZGYLKIQXSX-UHFFFAOYSA-N 0.000 description 2
- UAGMIFWTVRQHCS-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-morpholin-4-ylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)N2CCOCC2)F)=C1C UAGMIFWTVRQHCS-UHFFFAOYSA-N 0.000 description 2
- ZWGMYSLDSCSTGG-UHFFFAOYSA-N propyl piperidine-1-carboxylate Chemical compound CCCOC(=O)N1CCCCC1 ZWGMYSLDSCSTGG-UHFFFAOYSA-N 0.000 description 2
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- IHTJOXCTNVRHKN-UHFFFAOYSA-N tert-butyl 4-[5-cyano-6-[(6-methylsulfanylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(SC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)(C)C)=C1C#N IHTJOXCTNVRHKN-UHFFFAOYSA-N 0.000 description 2
- LNSPBFXCTHPXMV-UHFFFAOYSA-N tert-butyl 4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 LNSPBFXCTHPXMV-UHFFFAOYSA-N 0.000 description 2
- MOWTZYWSBQQDOW-UHFFFAOYSA-N tert-butyl 4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O MOWTZYWSBQQDOW-UHFFFAOYSA-N 0.000 description 2
- HDNLCVYUCUEBDC-UHFFFAOYSA-N tert-butyl 4-[[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O HDNLCVYUCUEBDC-UHFFFAOYSA-N 0.000 description 2
- ZPMVWRVSMSTFOR-UHFFFAOYSA-N tert-butyl 4-[[[6-(2-fluoro-4-methylsulfonylanilino)-5-methylpyrimidin-4-yl]-propan-2-ylamino]methyl]piperidine-1-carboxylate Chemical compound N=1C=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C(C)C=1N(C(C)C)CC1CCN(C(=O)OC(C)(C)C)CC1 ZPMVWRVSMSTFOR-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- DRFVYRIANGQDOP-UHFFFAOYSA-N (2-chlorophenyl) piperidine-1-carboxylate Chemical compound ClC1=CC=CC=C1OC(=O)N1CCCCC1 DRFVYRIANGQDOP-UHFFFAOYSA-N 0.000 description 1
- GNXFVIIWULQUBL-UHFFFAOYSA-N (2-chloropyridin-3-yl)-[4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)C=2C(=NC=CC=2)Cl)=C1[N+]([O-])=O GNXFVIIWULQUBL-UHFFFAOYSA-N 0.000 description 1
- WCRLBFHWFPELKW-YUMQZZPRSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCSC1 WCRLBFHWFPELKW-YUMQZZPRSA-N 0.000 description 1
- XKDUIEMPOJNANI-UHFFFAOYSA-N (4-chlorophenyl) piperidine-1-carboxylate Chemical compound C1=CC(Cl)=CC=C1OC(=O)N1CCCCC1 XKDUIEMPOJNANI-UHFFFAOYSA-N 0.000 description 1
- DXTPIMILZQNZKA-UHFFFAOYSA-N (4-fluorophenyl) piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1OC(=O)N1CCCCC1 DXTPIMILZQNZKA-UHFFFAOYSA-N 0.000 description 1
- MWOJZFOWMUFWMD-UHFFFAOYSA-N (4-fluorophenyl)-[1-[5-nitro-6-[4-(1,2,4-triazol-1-yl)anilino]pyrimidin-4-yl]piperidin-4-yl]methanone Chemical compound N1=CN=C(N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)C([N+](=O)[O-])=C1NC(C=C1)=CC=C1N1C=NC=N1 MWOJZFOWMUFWMD-UHFFFAOYSA-N 0.000 description 1
- FTYPIEJTBPMMCU-UHFFFAOYSA-N (4-methoxycarbonylphenyl) piperidine-1-carboxylate Chemical compound N1(CCCCC1)C(=O)OC1=CC=C(C=C1)C(=O)OC FTYPIEJTBPMMCU-UHFFFAOYSA-N 0.000 description 1
- CVZPPRFFBYYCGE-UHFFFAOYSA-N (4-methylphenyl) piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1OC(=O)N1CCCCC1 CVZPPRFFBYYCGE-UHFFFAOYSA-N 0.000 description 1
- ZOHQOOYPQIBHSS-UHFFFAOYSA-N (4-methylphenyl)-[4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1CCC(OCC=2ON=C(N=2)C=2C=CN=CC=2)CC1 ZOHQOOYPQIBHSS-UHFFFAOYSA-N 0.000 description 1
- XVTAWIPNHJCHPD-UHFFFAOYSA-N (5,6-dichloropyridin-3-yl)-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=NC=2)=NC=N1 XVTAWIPNHJCHPD-UHFFFAOYSA-N 0.000 description 1
- FOSPHQSCWSFXGX-UHFFFAOYSA-N (5-bromopyridin-3-yl)-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)C=2C=C(Br)C=NC=2)=NC=N1 FOSPHQSCWSFXGX-UHFFFAOYSA-N 0.000 description 1
- PBNMEKRQLUGZFA-UHFFFAOYSA-N (5-butylpyridin-2-yl)-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound N1=CC(CCCC)=CC=C1C(=O)N1CCC(OC=2N=CN=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)C=2)CC1 PBNMEKRQLUGZFA-UHFFFAOYSA-N 0.000 description 1
- HQCHNHZGVSEWLF-UHFFFAOYSA-N (5-butylpyridin-2-yl)-[4-[[[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(CCCC)=CC=C1C(=O)N1CCC(CNCC=2N=CN=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)C=2)CC1 HQCHNHZGVSEWLF-UHFFFAOYSA-N 0.000 description 1
- NVAUAEAIPCUOBK-UHFFFAOYSA-N (5-methyl-2-propan-2-ylcyclohexyl) 4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC(C)C1CCC(C)CC1OC(=O)N1CCC(OC=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)[N+]([O-])=O)CC1 NVAUAEAIPCUOBK-UHFFFAOYSA-N 0.000 description 1
- JCZNELDPUPQIOL-UHFFFAOYSA-N (6-aminopyridin-3-yl)-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1C(=O)C1=CC=C(N)N=C1 JCZNELDPUPQIOL-UHFFFAOYSA-N 0.000 description 1
- CPZYECLLEHOQPD-UHFFFAOYSA-N (6-bromopyridin-2-yl)-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)C=2N=C(Br)C=CC=2)=NC=N1 CPZYECLLEHOQPD-UHFFFAOYSA-N 0.000 description 1
- UYDMQNYSUYFELE-UHFFFAOYSA-N (6-chloropyridin-2-yl)-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]methanone Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)C=2N=C(Cl)C=CC=2)=NC=N1 UYDMQNYSUYFELE-UHFFFAOYSA-N 0.000 description 1
- 125000004749 (C1-C6) haloalkylsulfinyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- XOIYZMDJFLKIEI-UHFFFAOYSA-N (hydroxysulfonimidoyl)oxybenzene Chemical compound NS(=O)(=O)OC1=CC=CC=C1 XOIYZMDJFLKIEI-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- RVZFZQWLTJQPLS-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound COC1=CC(OC)=CC=C1C(=O)CN1CCC(OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)CC1 RVZFZQWLTJQPLS-UHFFFAOYSA-N 0.000 description 1
- BYOVXZGDVJRLSG-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound CC1=CC(C)=CC=C1C(=O)CN1CCC(OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)CC1 BYOVXZGDVJRLSG-UHFFFAOYSA-N 0.000 description 1
- FXCOOELGVLFKQL-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound COC1=CC=C(OC)C(C(=O)CN2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)=C1 FXCOOELGVLFKQL-UHFFFAOYSA-N 0.000 description 1
- ZGQWNYLFEIIJJA-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC=C1Cl ZGQWNYLFEIIJJA-UHFFFAOYSA-N 0.000 description 1
- AGYJGOBTVGVHCQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(Cl)C(Cl)=C1 AGYJGOBTVGVHCQ-UHFFFAOYSA-N 0.000 description 1
- WTRLCDYYFXPAPD-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(F)C(F)=C1 WTRLCDYYFXPAPD-UHFFFAOYSA-N 0.000 description 1
- PHJXLUZEMQGAHL-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC(Cl)=C1 PHJXLUZEMQGAHL-UHFFFAOYSA-N 0.000 description 1
- AKFARRXTBWPOSU-UHFFFAOYSA-N 1-(4-chloro-3-methylphenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound C1=C(Cl)C(C)=CC(C(=O)CN2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)=C1 AKFARRXTBWPOSU-UHFFFAOYSA-N 0.000 description 1
- BMIUMSRQZZKLPW-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(Cl)C=C1 BMIUMSRQZZKLPW-UHFFFAOYSA-N 0.000 description 1
- YCMRXJUMUXVERL-UHFFFAOYSA-N 1-[1-[6-(2-fluoro-4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]piperidin-4-yl]hexan-1-one Chemical compound C1CC(C(=O)CCCCC)CCN1C1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1[N+]([O-])=O YCMRXJUMUXVERL-UHFFFAOYSA-N 0.000 description 1
- YPXRIOYBDVXGIO-UHFFFAOYSA-N 1-[1-[6-(4-acetylphenoxy)-3-nitropyridin-2-yl]piperidin-4-yl]ethanone Chemical compound C1CC(C(=O)C)CCN1C1=NC(OC=2C=CC(=CC=2)C(C)=O)=CC=C1[N+]([O-])=O YPXRIOYBDVXGIO-UHFFFAOYSA-N 0.000 description 1
- PRBMRQPCVSEOCV-UHFFFAOYSA-N 1-[1-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]piperidin-4-yl]hexan-1-one Chemical compound C1CC(C(=O)CCCCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O PRBMRQPCVSEOCV-UHFFFAOYSA-N 0.000 description 1
- VOQZIYNVRLBGCV-UHFFFAOYSA-N 1-[4-(1-benzylazetidin-3-yl)oxy-6-[(6-methylsulfonylpyridin-3-yl)amino]pyrimidin-5-yl]ethanone Chemical compound N1=CN=C(OC2CN(CC=3C=CC=CC=3)C2)C(C(=O)C)=C1NC1=CC=C(S(C)(=O)=O)N=C1 VOQZIYNVRLBGCV-UHFFFAOYSA-N 0.000 description 1
- OILAFPLLAZHETH-UHFFFAOYSA-N 1-[4-(diethylamino)phenyl]-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound C1=CC(N(CC)CC)=CC=C1C(=O)CN1CCC(OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)CC1 OILAFPLLAZHETH-UHFFFAOYSA-N 0.000 description 1
- GDBJBLFDRZEHSX-UHFFFAOYSA-N 1-[4-(difluoromethoxy)phenyl]-2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(OC(F)F)C=C1 GDBJBLFDRZEHSX-UHFFFAOYSA-N 0.000 description 1
- GQYLPBOLAJSQNX-UHFFFAOYSA-N 1-[4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1OCC1=NC(C=2C=CN=CC=2)=NO1 GQYLPBOLAJSQNX-UHFFFAOYSA-N 0.000 description 1
- UYZMRNXBHUIYIL-UHFFFAOYSA-N 1-[4-[3-[4-(methoxymethyl)piperidin-1-yl]-4-nitrophenoxy]phenyl]ethanone Chemical compound C1CC(COC)CCN1C1=CC(OC=2C=CC(=CC=2)C(C)=O)=CC=C1[N+]([O-])=O UYZMRNXBHUIYIL-UHFFFAOYSA-N 0.000 description 1
- FMLOEBLGSXIREX-UHFFFAOYSA-N 1-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]butan-1-one Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C(=O)CCC)=CC=C1[N+]([O-])=O FMLOEBLGSXIREX-UHFFFAOYSA-N 0.000 description 1
- DBULFMSJWWTZHT-UHFFFAOYSA-N 1-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]ethanone Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C(C)=O)=CC=C1[N+]([O-])=O DBULFMSJWWTZHT-UHFFFAOYSA-N 0.000 description 1
- PZJDKUSWONJXFN-UHFFFAOYSA-N 1-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]hexan-1-one Chemical compound C1=CC(C(=O)CCCCC)=CC=C1OC1=CC=C([N+]([O-])=O)C(N2CCC(CCC)CC2)=C1 PZJDKUSWONJXFN-UHFFFAOYSA-N 0.000 description 1
- UDUBLFGDNOWYFL-UHFFFAOYSA-N 1-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]pentan-1-one Chemical compound C1=CC(C(=O)CCCC)=CC=C1OC1=CC=C([N+]([O-])=O)C(N2CCC(CCC)CC2)=C1 UDUBLFGDNOWYFL-UHFFFAOYSA-N 0.000 description 1
- QGCMNWAITFFWRS-UHFFFAOYSA-N 1-[4-[4-nitro-3-(4-pyridin-2-ylsulfanylpiperidin-1-yl)phenoxy]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1OC1=CC=C([N+]([O-])=O)C(N2CCC(CC2)SC=2N=CC=CC=2)=C1 QGCMNWAITFFWRS-UHFFFAOYSA-N 0.000 description 1
- OTEOXAURHOATIC-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylanilino)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methylbutan-1-one Chemical compound C1CN(C(=O)CC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C OTEOXAURHOATIC-UHFFFAOYSA-N 0.000 description 1
- XYTIQXINBAEKPT-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylanilino)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C XYTIQXINBAEKPT-UHFFFAOYSA-N 0.000 description 1
- RIAXTBCAPSTEGQ-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylanilino)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]pentan-1-one Chemical compound C1CN(C(=O)CCCC)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C RIAXTBCAPSTEGQ-UHFFFAOYSA-N 0.000 description 1
- XRVMQLBTZWLEMK-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-2-[4-(trifluoromethoxy)phenoxy]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1C(=O)COC1=CC=C(OC(F)(F)F)C=C1 XRVMQLBTZWLEMK-UHFFFAOYSA-N 0.000 description 1
- FTMRLCTWSIIMHS-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-2-[4-(trifluoromethoxy)phenoxy]propan-1-one Chemical compound C1CC(OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)CCN1C(=O)C(C)OC1=CC=C(OC(F)(F)F)C=C1 FTMRLCTWSIIMHS-UHFFFAOYSA-N 0.000 description 1
- NVBZXAUUEARXHX-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-2-pyridin-2-ylethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1C(=O)CC1=CC=CC=N1 NVBZXAUUEARXHX-UHFFFAOYSA-N 0.000 description 1
- ZZAIZOQHTKLWHY-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3,3-dimethylbutan-2-one Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(CC(=O)C(C)(C)C)CC1 ZZAIZOQHTKLWHY-UHFFFAOYSA-N 0.000 description 1
- CXRLTEZAZIALOU-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-[(2-methylpropan-2-yl)oxy]propan-1-one Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(C(=O)CCOC(C)(C)C)CC1 CXRLTEZAZIALOU-UHFFFAOYSA-N 0.000 description 1
- VSTLULYTHRCXMH-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-hydroxypropan-1-one Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(C(=O)CCO)CC1 VSTLULYTHRCXMH-UHFFFAOYSA-N 0.000 description 1
- PWBXXIOZUSDWDA-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methoxypropan-1-one Chemical compound C1CN(C(=O)CCOC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C PWBXXIOZUSDWDA-UHFFFAOYSA-N 0.000 description 1
- IRPQZOIPWFFUFR-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methylbutan-1-one Chemical compound C1CN(C(=O)CC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C IRPQZOIPWFFUFR-UHFFFAOYSA-N 0.000 description 1
- WEGGIOFKNSQVOI-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-propan-2-yloxypropan-1-one Chemical compound C1CN(C(=O)CCOC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C WEGGIOFKNSQVOI-UHFFFAOYSA-N 0.000 description 1
- GDMSHVWMVACSPP-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-methylpentan-1-one Chemical compound C1CN(C(=O)CCC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C GDMSHVWMVACSPP-UHFFFAOYSA-N 0.000 description 1
- YURFFJUCUZYWPB-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-methylpentan-2-one Chemical compound C1CN(CC(=O)CC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C YURFFJUCUZYWPB-UHFFFAOYSA-N 0.000 description 1
- ZZFRFTMOUJBJFW-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-propan-2-yloxybutan-1-one Chemical compound C1CN(C(=O)CCCOC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C ZZFRFTMOUJBJFW-UHFFFAOYSA-N 0.000 description 1
- WWJJXDCIMSWYSV-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-5-methylhexan-1-one Chemical compound C1CN(C(=O)CCCC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C WWJJXDCIMSWYSV-UHFFFAOYSA-N 0.000 description 1
- WZZOIYZLYDIDQZ-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-5-methylhexan-2-one Chemical compound C1CN(CC(=O)CCC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C WZZOIYZLYDIDQZ-UHFFFAOYSA-N 0.000 description 1
- GMVBSZZFAASGFW-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-6-methylheptan-2-one Chemical compound C1CN(CC(=O)CCCC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C GMVBSZZFAASGFW-UHFFFAOYSA-N 0.000 description 1
- YLLHCNUBAGBJKE-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C YLLHCNUBAGBJKE-UHFFFAOYSA-N 0.000 description 1
- RNAIEELRXPBMCX-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]butan-2-one Chemical compound C1CN(CC(=O)CC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C RNAIEELRXPBMCX-UHFFFAOYSA-N 0.000 description 1
- NJZWVOSVDFHKLH-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]hexan-1-one Chemical compound C1CN(C(=O)CCCCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C NJZWVOSVDFHKLH-UHFFFAOYSA-N 0.000 description 1
- PFEZROZBSJJCRX-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]pentan-1-one Chemical compound C1CN(C(=O)CCCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C PFEZROZBSJJCRX-UHFFFAOYSA-N 0.000 description 1
- PNAPSQUNPXDMNE-UHFFFAOYSA-N 1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]pentan-2-one Chemical compound C1CN(CC(=O)CCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C PNAPSQUNPXDMNE-UHFFFAOYSA-N 0.000 description 1
- IBNIPRMVXVNXAW-UHFFFAOYSA-N 1-[4-[[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]amino]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1NC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O IBNIPRMVXVNXAW-UHFFFAOYSA-N 0.000 description 1
- FABWZDHUYWQDKR-UHFFFAOYSA-N 1-[5-(4-ethenylphenoxy)-2-nitrophenyl]-4-propylpiperidine Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(C=C)=CC=2)=CC=C1[N+]([O-])=O FABWZDHUYWQDKR-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VCYBBLXSOSDGKQ-UHFFFAOYSA-N 1-carbamoyloxyethyl acetate Chemical compound CC(=O)OC(C)OC(N)=O VCYBBLXSOSDGKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004899 1-ethylpropylamino group Chemical group C(C)C(CC)N* 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- CHXNUYSBXDNVRN-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC(Cl)(Cl)Cl)CCC1OCC1=NC(C=2C=CN=CC=2)=NO1 CHXNUYSBXDNVRN-UHFFFAOYSA-N 0.000 description 1
- HSVYHERZYHUMAW-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-[[methyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]piperidine-1-carboxylate Chemical compound N=1C(C=2C=CN=CC=2)=NOC=1CN(C)CC1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1 HSVYHERZYHUMAW-UHFFFAOYSA-N 0.000 description 1
- NKWPBDOGGJDHOD-UHFFFAOYSA-N 2,2,2-trichloroethyl piperidine-1-carboxylate Chemical compound ClC(Cl)(Cl)COC(=O)N1CCCCC1 NKWPBDOGGJDHOD-UHFFFAOYSA-N 0.000 description 1
- GGMJFGFKFRAWTH-UHFFFAOYSA-N 2,2-dimethyl-1-[4-[[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]amino]piperidin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCC1NC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O GGMJFGFKFRAWTH-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- UEPJYVVKJMZBTQ-UHFFFAOYSA-N 2,2-dimethylpropyl piperidine-1-carboxylate Chemical compound CC(C)(C)COC(=O)N1CCCCC1 UEPJYVVKJMZBTQ-UHFFFAOYSA-N 0.000 description 1
- VOLFOEVWRSBNNA-UHFFFAOYSA-N 2,5-difluoro-4-[[6-[4-(4-propan-2-yloxyphenyl)piperazin-1-yl]pyrimidin-4-yl]amino]benzonitrile Chemical compound C1=CC(OC(C)C)=CC=C1N1CCN(C=2N=CN=C(NC=3C(=CC(=C(F)C=3)C#N)F)C=2)CC1 VOLFOEVWRSBNNA-UHFFFAOYSA-N 0.000 description 1
- QVNRCUJEZJNZRI-UHFFFAOYSA-N 2-(3-chlorophenyl)-n,6-dimethylpyrimidin-4-amine Chemical compound CNC1=CC(C)=NC(C=2C=C(Cl)C=CC=2)=N1 QVNRCUJEZJNZRI-UHFFFAOYSA-N 0.000 description 1
- OKGRXAGCJBIGJA-UHFFFAOYSA-N 2-(4-bromophenyl)-6-methyl-n-(pyridin-3-ylmethyl)pyrimidin-4-amine Chemical compound N=1C(C=2C=CC(Br)=CC=2)=NC(C)=CC=1NCC1=CC=CN=C1 OKGRXAGCJBIGJA-UHFFFAOYSA-N 0.000 description 1
- OHSJFWDPQZRDTI-UHFFFAOYSA-N 2-(4-bromophenyl)-n,6-dimethylpyrimidin-4-amine Chemical compound CNC1=CC(C)=NC(C=2C=CC(Br)=CC=2)=N1 OHSJFWDPQZRDTI-UHFFFAOYSA-N 0.000 description 1
- HJAOVGGBJLDHCO-UHFFFAOYSA-N 2-(dimethylamino)ethyl piperidine-1-carboxylate Chemical compound CN(C)CCOC(=O)N1CCCCC1 HJAOVGGBJLDHCO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BZQSVOJMQLADPO-UHFFFAOYSA-N 2-[1-[2-nitro-5-[4-(1,2,4-triazol-1-yl)phenoxy]phenyl]piperidin-4-yl]sulfanylpyridine Chemical compound C1=C(N2CCC(CC2)SC=2N=CC=CC=2)C([N+](=O)[O-])=CC=C1OC(C=C1)=CC=C1N1C=NC=N1 BZQSVOJMQLADPO-UHFFFAOYSA-N 0.000 description 1
- BNHXXPBMPCCDAX-UHFFFAOYSA-N 2-[1-[5-(4-methylsulfonylphenoxy)-2-nitrophenyl]piperidin-4-yl]sulfanylpyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1=CC=C([N+]([O-])=O)C(N2CCC(CC2)SC=2N=CC=CC=2)=C1 BNHXXPBMPCCDAX-UHFFFAOYSA-N 0.000 description 1
- FVDQYAZTBFZBHS-UHFFFAOYSA-N 2-[2-[(5-nitropyridin-2-yl)amino]ethylamino]-1-pyrrolidin-1-ylethanone;dihydrochloride Chemical compound Cl.Cl.N1=CC([N+](=O)[O-])=CC=C1NCCNCC(=O)N1CCCC1 FVDQYAZTBFZBHS-UHFFFAOYSA-N 0.000 description 1
- JVKNQSNKBPRGGO-UHFFFAOYSA-N 2-[3-fluoro-4-[5-methyl-6-(1-propan-2-yloxycarbonylpiperidin-4-yl)oxypyrimidin-4-yl]oxyphenyl]acetic acid Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(O)=O)=CC=2)F)=C1C JVKNQSNKBPRGGO-UHFFFAOYSA-N 0.000 description 1
- HRYZKEMKQDTASY-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]piperazin-1-yl]acetic acid Chemical compound FC1=C(C=CC(=C1)S(=O)(=O)C)NC1=CC(=NC=N1)N1CCN(CC1)CC(=O)O HRYZKEMKQDTASY-UHFFFAOYSA-N 0.000 description 1
- AODBBNYSKQZUCS-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(2-methyl-4-phenylfuran-3-yl)ethanone Chemical compound CC=1OC=C(C=2C=CC=CC=2)C=1C(=O)CN(CC1)CCC1OC(C=1C)=NC=NC=1OC1=CC=C(S(C)(=O)=O)C=C1F AODBBNYSKQZUCS-UHFFFAOYSA-N 0.000 description 1
- KMRWDTYHXJTJMK-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(3-fluorophenyl)ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC(F)=C1 KMRWDTYHXJTJMK-UHFFFAOYSA-N 0.000 description 1
- XBUBBGIMTPSSQO-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(4-fluorophenyl)ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(F)C=C1 XBUBBGIMTPSSQO-UHFFFAOYSA-N 0.000 description 1
- HYARXWARKOIYRN-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1C(=O)CN1CCC(OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)CC1 HYARXWARKOIYRN-UHFFFAOYSA-N 0.000 description 1
- MJQKSBDLAPJBIJ-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(4-methylsulfonylphenyl)ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(S(C)(=O)=O)C=C1 MJQKSBDLAPJBIJ-UHFFFAOYSA-N 0.000 description 1
- UDOJPPPKOOURIB-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(5-phenylthiophen-2-yl)ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C(S1)=CC=C1C1=CC=CC=C1 UDOJPPPKOOURIB-UHFFFAOYSA-N 0.000 description 1
- KSKUVUKLKZSZLR-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-(5-pyridin-2-ylthiophen-2-yl)ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C(S1)=CC=C1C1=CC=CC=N1 KSKUVUKLKZSZLR-UHFFFAOYSA-N 0.000 description 1
- NSHHEMAHAAEYJH-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-[3-(trifluoromethyl)phenyl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC(C(F)(F)F)=C1 NSHHEMAHAAEYJH-UHFFFAOYSA-N 0.000 description 1
- VGKJEXKKZYGQGF-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(OC(F)(F)F)C=C1 VGKJEXKKZYGQGF-UHFFFAOYSA-N 0.000 description 1
- GCSBEPIRNMWBPR-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(C(F)(F)F)C=C1 GCSBEPIRNMWBPR-UHFFFAOYSA-N 0.000 description 1
- JTMYPOICVRARKK-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-morpholin-4-ylethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)N1CCOCC1 JTMYPOICVRARKK-UHFFFAOYSA-N 0.000 description 1
- ILUJEJKVTTZYGJ-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-phenylethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC=C1 ILUJEJKVTTZYGJ-UHFFFAOYSA-N 0.000 description 1
- VQAKENAYCYDJEL-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-pyridin-4-ylethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=NC=C1 VQAKENAYCYDJEL-UHFFFAOYSA-N 0.000 description 1
- DQDOQWDMORTGOE-UHFFFAOYSA-N 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1-thiophen-2-ylethanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CS1 DQDOQWDMORTGOE-UHFFFAOYSA-N 0.000 description 1
- YVCMBGPPTCBEDP-UHFFFAOYSA-N 2-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]-5-(trifluoromethyl)pyridine Chemical compound C1CC(CCC)CCN1C1=CC(OC=2N=CC(=CC=2)C(F)(F)F)=CC=C1[N+]([O-])=O YVCMBGPPTCBEDP-UHFFFAOYSA-N 0.000 description 1
- JYJXSHCMXPJVMD-UHFFFAOYSA-N 2-[[2-(4-bromophenyl)-6-methylpyrimidin-4-yl]-methylamino]ethanol Chemical compound OCCN(C)C1=CC(C)=NC(C=2C=CC(Br)=CC=2)=N1 JYJXSHCMXPJVMD-UHFFFAOYSA-N 0.000 description 1
- RVRZBVYJKYHONI-UHFFFAOYSA-N 2-amino-1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methylbutan-1-one Chemical compound C1CN(C(=O)C(N)C(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C RVRZBVYJKYHONI-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- OJQUDOGHLNVJIY-UHFFFAOYSA-N 2-cyclopentyl-1-[4-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]ethanone Chemical compound C1CC(C=2ON=C(N=2)C=2C=CN=CC=2)CCN1C(=O)CC1CCCC1 OJQUDOGHLNVJIY-UHFFFAOYSA-N 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- CTRHWJHUOVIWML-UHFFFAOYSA-N 2-ethoxy-1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound C1CN(C(=O)COCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C CTRHWJHUOVIWML-UHFFFAOYSA-N 0.000 description 1
- CUGNLNFKIWFXNS-UHFFFAOYSA-N 2-ethylbutyl piperidine-1-carboxylate Chemical compound CCC(CC)COC(=O)N1CCCCC1 CUGNLNFKIWFXNS-UHFFFAOYSA-N 0.000 description 1
- VBJYSFVJPYTZMR-UHFFFAOYSA-N 2-ethylhexyl piperidine-1-carboxylate Chemical compound C(C)C(COC(=O)N1CCCCC1)CCCC VBJYSFVJPYTZMR-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- MFCHYWIMSNKJMB-UHFFFAOYSA-N 2-methyl-5-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]-1,3,4-oxadiazole Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C=2OC(C)=NN=2)=CC=C1[N+]([O-])=O MFCHYWIMSNKJMB-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- MWGKFCJRULSBHG-UHFFFAOYSA-N 2-methylpropyl 4-[5-acetyl-6-[(6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC(C)C)CCC1OC1=NC=NC(NC=2C=NC(=CC=2)S(C)(=O)=O)=C1C(C)=O MWGKFCJRULSBHG-UHFFFAOYSA-N 0.000 description 1
- TWQUDCYVXFEJJM-UHFFFAOYSA-N 2-methylpropyl 4-[9-(6-methylsulfonylpyridin-3-yl)purin-6-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC(C)C)CCC1OC1=NC=NC2=C1N=CN2C1=CC=C(S(C)(=O)=O)N=C1 TWQUDCYVXFEJJM-UHFFFAOYSA-N 0.000 description 1
- HTOQALXUSKONGW-UHFFFAOYSA-N 2-methylpropyl cyclohexanecarboxylate Chemical compound CC(C)COC(=O)C1CCCCC1 HTOQALXUSKONGW-UHFFFAOYSA-N 0.000 description 1
- SMQAQNWCDKDKKO-UHFFFAOYSA-N 2-methylpyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=C(C)C=C21 SMQAQNWCDKDKKO-UHFFFAOYSA-N 0.000 description 1
- AJSUOFFQMSMEOJ-UHFFFAOYSA-N 2-morpholin-4-ylethyl piperidine-1-carboxylate Chemical compound O=C(OCCN1CCOCC1)N1CCCCC1 AJSUOFFQMSMEOJ-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- UBWBVRSSIHWAQL-UHFFFAOYSA-N 2-tert-butylpiperidine-1-carboxylic acid Chemical compound CC(C)(C)C1CCCCN1C(O)=O UBWBVRSSIHWAQL-UHFFFAOYSA-N 0.000 description 1
- RHMYEOYYPYBQCN-UHFFFAOYSA-N 3,3,3-trichloropropanoic acid Chemical compound OC(=O)CC(Cl)(Cl)Cl RHMYEOYYPYBQCN-UHFFFAOYSA-N 0.000 description 1
- MWPYGSNIIWFGJW-UHFFFAOYSA-N 3,3-dimethyl-1-[4-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C1=NC(C=2C=CN=CC=2)=NO1 MWPYGSNIIWFGJW-UHFFFAOYSA-N 0.000 description 1
- WFRWDJZTEDLJAW-UHFFFAOYSA-N 3,3-dimethyl-1-[4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O WFRWDJZTEDLJAW-UHFFFAOYSA-N 0.000 description 1
- MDZBNPSMIWSWGH-UHFFFAOYSA-N 3,3-dimethyl-1-[4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidin-1-yl]butan-2-one Chemical compound C1CN(CC(=O)C(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O MDZBNPSMIWSWGH-UHFFFAOYSA-N 0.000 description 1
- YNQPKGKVZNKSEN-UHFFFAOYSA-N 3,3-dimethylbutyl piperidine-1-carboxylate Chemical compound CC(C)(C)CCOC(=O)N1CCCCC1 YNQPKGKVZNKSEN-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 1
- KXSYUPYYQLCSAQ-UHFFFAOYSA-N 3-[2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]acetyl]benzonitrile Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=CC(C#N)=C1 KXSYUPYYQLCSAQ-UHFFFAOYSA-N 0.000 description 1
- DPLLVROAWZVABY-UHFFFAOYSA-N 3-[4-[3-(4-ethoxycarbonylpiperidin-1-yl)-4-nitrophenoxy]phenyl]-2-oxopropanoic acid Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C=CC(CC(=O)C(O)=O)=CC=2)=CC=C1[N+]([O-])=O DPLLVROAWZVABY-UHFFFAOYSA-N 0.000 description 1
- GFWQTXLDRGKEFG-UHFFFAOYSA-N 3-[4-[3-(4-ethoxycarbonylpiperidin-1-yl)-4-nitrophenoxy]phenyl]propanoic acid Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C=CC(CCC(O)=O)=CC=2)=CC=C1[N+]([O-])=O GFWQTXLDRGKEFG-UHFFFAOYSA-N 0.000 description 1
- WWNKXJCYOXVTGI-UHFFFAOYSA-N 3-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]-2-oxopropanoic acid Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(CC(=O)C(O)=O)=CC=2)=CC=C1[N+]([O-])=O WWNKXJCYOXVTGI-UHFFFAOYSA-N 0.000 description 1
- CEQVJPOYQDBGNE-UHFFFAOYSA-N 3-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]propanoic acid Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(CCC(O)=O)=CC=2)=CC=C1[N+]([O-])=O CEQVJPOYQDBGNE-UHFFFAOYSA-N 0.000 description 1
- LWNRMDVXXLXCFI-UHFFFAOYSA-N 3-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-oxopropane-1-sulfonic acid Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(C(=O)CCS(O)(=O)=O)CC1 LWNRMDVXXLXCFI-UHFFFAOYSA-N 0.000 description 1
- IVZCZIQKXOTBQW-UHFFFAOYSA-N 3-[[2-(4-bromophenyl)-6-methylpyrimidin-4-yl]amino]propanenitrile Chemical compound CC1=CC(NCCC#N)=NC(C=2C=CC(Br)=CC=2)=N1 IVZCZIQKXOTBQW-UHFFFAOYSA-N 0.000 description 1
- ILSMGGRXRKWAEN-UHFFFAOYSA-N 3-amino-1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-methylpentan-1-one Chemical compound C1CN(C(=O)CC(N)C(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C ILSMGGRXRKWAEN-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- GGUXFXPGTFEOGQ-UHFFFAOYSA-N 3-ethyl-5-[4-[5-ethynyl-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CCC1=NOC(N2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C#C)=N1 GGUXFXPGTFEOGQ-UHFFFAOYSA-N 0.000 description 1
- ZICSYHWVNYHXEV-UHFFFAOYSA-N 3-ethyl-5-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-1,2,4-oxadiazole Chemical compound CCC1=NOC(N2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)=N1 ZICSYHWVNYHXEV-UHFFFAOYSA-N 0.000 description 1
- GSPKHYLJWLZJLS-UHFFFAOYSA-N 3-fluoro-4-[4-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]oxyquinolin-8-yl]benzonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C3=CC=CC(=C3N=CC=2)C=2C(=CC(=CC=2)C#N)F)=N1 GSPKHYLJWLZJLS-UHFFFAOYSA-N 0.000 description 1
- UAATYYSKEGEMJS-UHFFFAOYSA-N 3-fluoro-4-[4-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)cyclohexyl]oxyquinolin-8-yl]benzonitrile Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2C3=CC=CC(=C3N=CC=2)C=2C(=CC(=CC=2)C#N)F)=N1 UAATYYSKEGEMJS-UHFFFAOYSA-N 0.000 description 1
- KZMAXLPGELOJRP-UHFFFAOYSA-N 3-fluoro-4-[5-methyl-6-(1-propan-2-yloxycarbonylpiperidin-4-yl)oxypyrimidin-4-yl]oxybenzenesulfonic acid Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(O)(=O)=O)F)=C1C KZMAXLPGELOJRP-UHFFFAOYSA-N 0.000 description 1
- GYVQSDVQPGRVGW-UHFFFAOYSA-N 3-fluoro-4-[5-methyl-6-(1-propan-2-yloxycarbonylpiperidin-4-yl)oxypyrimidin-4-yl]oxybenzoic acid Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C(O)=O)F)=C1C GYVQSDVQPGRVGW-UHFFFAOYSA-N 0.000 description 1
- HRQCIRVQDUDKHS-UHFFFAOYSA-N 3-fluoro-4-[6-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]oxypurin-9-yl]benzonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C=3N=CN(C=3N=CN=2)C=2C(=CC(=CC=2)C#N)F)=N1 HRQCIRVQDUDKHS-UHFFFAOYSA-N 0.000 description 1
- QTOGZCDRJAWYNT-UHFFFAOYSA-N 3-fluoro-4-[6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)cyclohexyl]oxypurin-9-yl]benzonitrile Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2C=3N=CN(C=3N=CN=2)C=2C(=CC(=CC=2)C#N)F)=N1 QTOGZCDRJAWYNT-UHFFFAOYSA-N 0.000 description 1
- AMFXBGLDNJOXCK-UHFFFAOYSA-N 3-fluoro-4-[7-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)cyclohexyl]oxypyrazolo[1,5-a]pyrimidin-3-yl]benzonitrile Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2N3N=CC(=C3N=CC=2)C=2C(=CC(=CC=2)C#N)F)=N1 AMFXBGLDNJOXCK-UHFFFAOYSA-N 0.000 description 1
- JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- YSIKHBWUBSFBRZ-UHFFFAOYSA-N 3-methoxypropanoic acid Chemical compound COCCC(O)=O YSIKHBWUBSFBRZ-UHFFFAOYSA-N 0.000 description 1
- LEXHQPSGNJBARN-UHFFFAOYSA-N 3-methyl-1-[4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CC(C)C)CCC1OCC1=NC(C=2C=CN=CC=2)=NO1 LEXHQPSGNJBARN-UHFFFAOYSA-N 0.000 description 1
- VFVIASZDGVBAEW-UHFFFAOYSA-N 3-methyl-5-[3-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]-1,2,4-oxadiazole Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=C(C=CC=2)C=2ON=C(C)N=2)=CC=C1[N+]([O-])=O VFVIASZDGVBAEW-UHFFFAOYSA-N 0.000 description 1
- 125000004897 3-methylbutylamino group Chemical group CC(CCN*)C 0.000 description 1
- QHUOGCTUALLQAW-UHFFFAOYSA-N 3-pyridin-3-ylpropyl piperidine-1-carboxylate Chemical compound N1=CC(=CC=C1)CCCOC(=O)N1CCCCC1 QHUOGCTUALLQAW-UHFFFAOYSA-N 0.000 description 1
- JZFCBKUAMUYDSE-UHFFFAOYSA-N 3-pyridin-4-yl-5-[(1-pyridin-3-ylpiperidin-4-yl)oxymethyl]-1,2,4-oxadiazole Chemical group N=1C(C=2C=CN=CC=2)=NOC=1COC(CC1)CCN1C1=CC=CN=C1 JZFCBKUAMUYDSE-UHFFFAOYSA-N 0.000 description 1
- KVIVOKHZDMAFKP-UHFFFAOYSA-N 3-pyridin-4-yl-5-[(1-pyrimidin-2-ylpiperidin-4-yl)oxymethyl]-1,2,4-oxadiazole Chemical compound N=1C(C=2C=CN=CC=2)=NOC=1COC(CC1)CCN1C1=NC=CC=N1 KVIVOKHZDMAFKP-UHFFFAOYSA-N 0.000 description 1
- MBPWZHDZEVESMX-UHFFFAOYSA-N 4-(1-butylpiperidin-4-yl)oxy-6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidine Chemical compound C1CN(CCCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C MBPWZHDZEVESMX-UHFFFAOYSA-N 0.000 description 1
- AZQKDCFSKVWQQO-UHFFFAOYSA-N 4-(1-formylpiperidin-4-yl)oxy-6-(4-methylsulfonylanilino)pyrimidine-5-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C=O)=C1C#N AZQKDCFSKVWQQO-UHFFFAOYSA-N 0.000 description 1
- VIOOOBWVQCZXIP-UHFFFAOYSA-N 4-(2,4-difluorophenoxy)-5-nitro-6-(4-pyridin-2-ylsulfanylpiperidin-1-yl)pyrimidine Chemical compound N1=CN=C(N2CCC(CC2)SC=2N=CC=CC=2)C([N+](=O)[O-])=C1OC1=CC=C(F)C=C1F VIOOOBWVQCZXIP-UHFFFAOYSA-N 0.000 description 1
- PGHCNXHAKQGQKA-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-5-methyl-6-(1-pentylpiperidin-4-yl)oxypyrimidine Chemical compound C1CN(CCCCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C PGHCNXHAKQGQKA-UHFFFAOYSA-N 0.000 description 1
- NUCBMLTYQHSURX-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-5-methyl-6-[1-(2-pyridin-3-ylethyl)piperidin-4-yl]oxypyrimidine Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CCC1=CC=CN=C1 NUCBMLTYQHSURX-UHFFFAOYSA-N 0.000 description 1
- WKDDGTJMOBLSEP-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-5-methyl-6-[1-(3-methylbutyl)piperidin-4-yl]oxypyrimidine Chemical compound C1CN(CCC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C WKDDGTJMOBLSEP-UHFFFAOYSA-N 0.000 description 1
- JZQGRHDMONUUBS-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-5-methyl-6-[1-(5-methylhexyl)piperidin-4-yl]oxypyrimidine Chemical compound C1CN(CCCCC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C JZQGRHDMONUUBS-UHFFFAOYSA-N 0.000 description 1
- HSWSVHVEPTZPHW-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-6-(1-hexylpiperidin-4-yl)oxy-5-methylpyrimidine Chemical compound C1CN(CCCCCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C HSWSVHVEPTZPHW-UHFFFAOYSA-N 0.000 description 1
- DKAKENLLKAAJLB-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-6-[1-(3-methoxypropyl)piperidin-4-yl]oxy-5-methylpyrimidine Chemical compound C1CN(CCCOC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C DKAKENLLKAAJLB-UHFFFAOYSA-N 0.000 description 1
- FMPWSSDQCGMCEM-UHFFFAOYSA-N 4-(2-fluoro-4-methylsulfonylphenoxy)-6-[1-(4-methoxycyclohexyl)piperidin-4-yl]oxy-5-methylpyrimidine Chemical compound C1CC(OC)CCC1N1CCC(OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)CC1 FMPWSSDQCGMCEM-UHFFFAOYSA-N 0.000 description 1
- FHDLQRHYTSOMNV-UHFFFAOYSA-N 4-(4-methylsulfanylanilino)-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidine-5-carbonitrile Chemical compound C1=CC(SC)=CC=C1NC1=NC=NC(N2CCC(CC2)C=2ON=C(N=2)C(C)C)=C1C#N FHDLQRHYTSOMNV-UHFFFAOYSA-N 0.000 description 1
- KXIDQKYSJZODOI-UHFFFAOYSA-N 4-(4-methylsulfinylanilino)-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidine-5-carbonitrile Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)=O)N=CN=2)C#N)=N1 KXIDQKYSJZODOI-UHFFFAOYSA-N 0.000 description 1
- DBOSVHCPPHXLBM-UHFFFAOYSA-N 4-(4-methylsulfonylanilino)-6-[1-(oxolane-2-carbonyl)piperidin-4-yl]oxypyrimidine-5-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)C2OCCC2)=C1C#N DBOSVHCPPHXLBM-UHFFFAOYSA-N 0.000 description 1
- FLKMZINWQJKEFD-UHFFFAOYSA-N 4-(4-methylsulfonylanilino)-6-[1-(pyridine-2-carbonyl)piperidin-4-yl]oxypyrimidine-5-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)C=2N=CC=CC=2)=C1C#N FLKMZINWQJKEFD-UHFFFAOYSA-N 0.000 description 1
- YINWJAMYSUYNSJ-UHFFFAOYSA-N 4-(4-methylsulfonylanilino)-6-[1-(pyridine-3-carbonyl)piperidin-4-yl]oxypyrimidine-5-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)C=2C=NC=CC=2)=C1C#N YINWJAMYSUYNSJ-UHFFFAOYSA-N 0.000 description 1
- SXDKQBADJIVKAE-UHFFFAOYSA-N 4-(4-methylsulfonylanilino)-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidine-5-carbonitrile Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)C#N)=N1 SXDKQBADJIVKAE-UHFFFAOYSA-N 0.000 description 1
- IMSWXVXQPSEOIU-UHFFFAOYSA-N 4-(4-methylsulfonylphenoxy)-5-nitro-6-(4-phenylsulfanylcyclohexyl)pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1=NC=NC(C2CCC(CC2)SC=2C=CC=CC=2)=C1[N+]([O-])=O IMSWXVXQPSEOIU-UHFFFAOYSA-N 0.000 description 1
- XWSTXBAOJHDPRK-UHFFFAOYSA-N 4-(4-methylsulfonylphenoxy)-5-nitro-6-(4-pyridin-2-ylsulfanylcyclohexyl)pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1=NC=NC(C2CCC(CC2)SC=2N=CC=CC=2)=C1[N+]([O-])=O XWSTXBAOJHDPRK-UHFFFAOYSA-N 0.000 description 1
- PBKMHXCTKFHYJC-UHFFFAOYSA-N 4-(4-methylsulfonylphenoxy)-5-nitro-6-(4-pyridin-4-ylsulfanylcyclohexyl)pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1OC1=NC=NC(C2CCC(CC2)SC=2C=CN=CC=2)=C1[N+]([O-])=O PBKMHXCTKFHYJC-UHFFFAOYSA-N 0.000 description 1
- OBTFDFKKMPJGQN-UHFFFAOYSA-N 4-(4-methylsulfonylphenoxy)-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidine-5-carbonitrile Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)C#N)=N1 OBTFDFKKMPJGQN-UHFFFAOYSA-N 0.000 description 1
- LIGNNMGXVMPANI-UHFFFAOYSA-N 4-[1-(3,3-dimethyl-2-oxobutyl)piperidin-4-yl]oxy-6-(4-methylsulfonylanilino)pyrimidine-5-carbonitrile Chemical compound C1CN(CC(=O)C(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1C#N LIGNNMGXVMPANI-UHFFFAOYSA-N 0.000 description 1
- OXSWPFICEVAYLI-UHFFFAOYSA-N 4-[2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]acetyl]benzonitrile Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1CC(=O)C1=CC=C(C#N)C=C1 OXSWPFICEVAYLI-UHFFFAOYSA-N 0.000 description 1
- CZJBSMLOCJUQJW-UHFFFAOYSA-N 4-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-6-[4-(thiadiazol-4-yl)phenoxy]pyrimidine-5-carbaldehyde Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)C=3N=NSC=3)N=CN=2)C=O)=N1 CZJBSMLOCJUQJW-UHFFFAOYSA-N 0.000 description 1
- QVNISXFLVXAVCU-UHFFFAOYSA-N 4-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-6-[4-(thiadiazol-4-yl)phenoxy]pyrimidine-5-carboxylic acid Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)C=3N=NSC=3)N=CN=2)C(O)=O)=N1 QVNISXFLVXAVCU-UHFFFAOYSA-N 0.000 description 1
- QTVLQPAOZWHNFH-UHFFFAOYSA-N 4-[4-[2-nitro-5-(4-propylpiperidin-1-yl)phenoxy]phenyl]butan-2-one Chemical compound C1CC(CCC)CCN1C1=CC=C([N+]([O-])=O)C(OC=2C=CC(CCC(C)=O)=CC=2)=C1 QTVLQPAOZWHNFH-UHFFFAOYSA-N 0.000 description 1
- SSZRMWSKPKWIIG-UHFFFAOYSA-N 4-[4-[3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-4-nitrophenoxy]phenyl]butan-2-one Chemical compound C1=CC(CCC(=O)C)=CC=C1OC1=CC=C([N+]([O-])=O)C(N2CCC(CC2)C=2ON=C(C)N=2)=C1 SSZRMWSKPKWIIG-UHFFFAOYSA-N 0.000 description 1
- HIBOMQBOJFSMRJ-UHFFFAOYSA-N 4-[4-[3-[4-(methoxymethyl)piperidin-1-yl]-4-nitrophenoxy]phenyl]butan-2-one Chemical compound C1CC(COC)CCN1C1=CC(OC=2C=CC(CCC(C)=O)=CC=2)=CC=C1[N+]([O-])=O HIBOMQBOJFSMRJ-UHFFFAOYSA-N 0.000 description 1
- QAQHPPBTEWEEJM-UHFFFAOYSA-N 4-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]butan-2-one Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(CCC(C)=O)=CC=2)=CC=C1[N+]([O-])=O QAQHPPBTEWEEJM-UHFFFAOYSA-N 0.000 description 1
- JFIDBMRSEIBNAE-UHFFFAOYSA-N 4-[4-[4-nitro-3-(4-pyridin-2-ylsulfanylpiperidin-1-yl)phenoxy]phenyl]butan-2-one Chemical compound C1=CC(CCC(=O)C)=CC=C1OC1=CC=C([N+]([O-])=O)C(N2CCC(CC2)SC=2N=CC=CC=2)=C1 JFIDBMRSEIBNAE-UHFFFAOYSA-N 0.000 description 1
- SOMGOTJVNWMMAF-UHFFFAOYSA-N 4-[4-[5-nitro-6-(4-propylpiperidin-1-yl)pyridin-2-yl]oxyphenyl]butan-2-one Chemical compound C1CC(CCC)CCN1C1=NC(OC=2C=CC(CCC(C)=O)=CC=2)=CC=C1[N+]([O-])=O SOMGOTJVNWMMAF-UHFFFAOYSA-N 0.000 description 1
- CQDBBMXEJJUGIO-UHFFFAOYSA-N 4-[4-[5-nitro-6-(4-pyridin-2-ylsulfanylpiperidin-1-yl)pyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1=CC(CCC(=O)C)=CC=C1OC1=NC=NC(N2CCC(CC2)SC=2N=CC=CC=2)=C1[N+]([O-])=O CQDBBMXEJJUGIO-UHFFFAOYSA-N 0.000 description 1
- MBFIERWVMWYQNG-UHFFFAOYSA-N 4-[4-[5-nitro-6-[4-(propoxymethyl)piperidin-1-yl]pyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1CC(COCCC)CCN1C1=NC=NC(OC=2C=CC(CCC(C)=O)=CC=2)=C1[N+]([O-])=O MBFIERWVMWYQNG-UHFFFAOYSA-N 0.000 description 1
- KZDBVWHQNGGDHM-UHFFFAOYSA-N 4-[4-[5-nitro-6-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]pyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1=CC(CCC(=O)C)=CC=C1OC1=NC=NC(N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=C1[N+]([O-])=O KZDBVWHQNGGDHM-UHFFFAOYSA-N 0.000 description 1
- UZBYFVFRWANJMR-UHFFFAOYSA-N 4-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-oxobutanoic acid Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(C(=O)CCC(O)=O)CC1 UZBYFVFRWANJMR-UHFFFAOYSA-N 0.000 description 1
- JRFBERKQAWMFIA-UHFFFAOYSA-N 4-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]butanoic acid Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(CCCC(O)=O)CC1 JRFBERKQAWMFIA-UHFFFAOYSA-N 0.000 description 1
- OPVUBJGKKGMRHF-UHFFFAOYSA-N 4-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]cyclohexane-1-carboxylic acid Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1C1CCC(C(O)=O)CC1 OPVUBJGKKGMRHF-UHFFFAOYSA-N 0.000 description 1
- NACUMEUULNCYGO-UHFFFAOYSA-N 4-[4-[6-[4-(2-methylpropoxymethyl)piperidin-1-yl]-5-nitropyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1CC(COCC(C)C)CCN1C1=NC=NC(OC=2C=CC(CCC(C)=O)=CC=2)=C1[N+]([O-])=O NACUMEUULNCYGO-UHFFFAOYSA-N 0.000 description 1
- IFQNJVZMNAJLGZ-UHFFFAOYSA-N 4-[4-[6-[4-(4-fluorobenzoyl)piperidin-1-yl]-5-nitropyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1=CC(CCC(=O)C)=CC=C1OC1=NC=NC(N2CCC(CC2)C(=O)C=2C=CC(F)=CC=2)=C1[N+]([O-])=O IFQNJVZMNAJLGZ-UHFFFAOYSA-N 0.000 description 1
- FDBRCFDCKVFGPN-UHFFFAOYSA-N 4-[4-[6-[4-(butoxymethyl)piperidin-1-yl]-5-nitropyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1CC(COCCCC)CCN1C1=NC=NC(OC=2C=CC(CCC(C)=O)=CC=2)=C1[N+]([O-])=O FDBRCFDCKVFGPN-UHFFFAOYSA-N 0.000 description 1
- UQGQQTQKNHKMRH-UHFFFAOYSA-N 4-[4-[6-[4-(cyclopropylmethoxymethyl)piperidin-1-yl]-5-nitropyrimidin-4-yl]oxyphenyl]butan-2-one Chemical compound C1=CC(CCC(=O)C)=CC=C1OC1=NC=NC(N2CCC(COCC3CC3)CC2)=C1[N+]([O-])=O UQGQQTQKNHKMRH-UHFFFAOYSA-N 0.000 description 1
- FYMGHZVNXYNHGK-UHFFFAOYSA-N 4-[5-amino-6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(O)=O)=C1N FYMGHZVNXYNHGK-UHFFFAOYSA-N 0.000 description 1
- JJGIOCLSQXHBNN-UHFFFAOYSA-N 4-[6-(2,5-difluoroanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound FC1=C(C=C(C=C1)F)NC1=CC(=NC=N1)OC1CCN(CC1)C(=O)O JJGIOCLSQXHBNN-UHFFFAOYSA-N 0.000 description 1
- VQDQRSNWHQFNRN-UHFFFAOYSA-N 4-[6-(2,5-difluorophenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound FC1=C(OC2=CC(=NC=N2)OC2CCN(CC2)C(=O)O)C=C(C=C1)F VQDQRSNWHQFNRN-UHFFFAOYSA-N 0.000 description 1
- DCGNEJIPVWTQLV-UHFFFAOYSA-N 4-[6-(4-acetamido-3-methylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound C(C)(=O)NC1=C(C=C(C=C1)NC1=CC(=NC=N1)OC1CCN(CC1)C(=O)O)C DCGNEJIPVWTQLV-UHFFFAOYSA-N 0.000 description 1
- GQIQMAKBSRJVRI-UHFFFAOYSA-N 4-[6-(pyridin-4-ylamino)pyrimidin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound N1=CC=C(C=C1)NC1=CC(=NC=N1)OC1CCN(CC1)C(=O)O GQIQMAKBSRJVRI-UHFFFAOYSA-N 0.000 description 1
- JOOONLNEXWRIGL-UHFFFAOYSA-N 4-[8-(4-methylsulfanylphenyl)quinolin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound C1=CC(SC)=CC=C1C(C1=NC=C2)=CC=CC1=C2OC1CCN(C(O)=O)CC1 JOOONLNEXWRIGL-UHFFFAOYSA-N 0.000 description 1
- ZAXXSSISSPGJOW-UHFFFAOYSA-N 4-[8-(4-methylsulfonylphenyl)quinolin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C1=NC=C2)=CC=CC1=C2OC1CCN(C(O)=O)CC1 ZAXXSSISSPGJOW-UHFFFAOYSA-N 0.000 description 1
- YZJCWTSYUMUZLY-UHFFFAOYSA-N 4-[8-(4-propan-2-yloxyphenyl)quinolin-4-yl]oxypiperidine-1-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C(C1=NC=C2)=CC=CC1=C2OC1CCN(C(O)=O)CC1 YZJCWTSYUMUZLY-UHFFFAOYSA-N 0.000 description 1
- QZCFFYWGAJONKV-UHFFFAOYSA-N 4-[9-(4-methylsulfonylphenyl)purin-6-yl]oxypiperidine-1-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C2=NC=NC(OC3CCN(CC3)C(O)=O)=C2N=C1 QZCFFYWGAJONKV-UHFFFAOYSA-N 0.000 description 1
- GHLZCPGUOZCNKM-UHFFFAOYSA-N 4-[[5-ethynyl-6-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]oxypyrimidin-4-yl]amino]-3-fluorobenzonitrile Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C(=C(NC=3C(=CC(=CC=3)C#N)F)N=CN=2)C#C)=N1 GHLZCPGUOZCNKM-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- YJUXGYJYVIYEJW-UHFFFAOYSA-N 4-methylpentyl piperidine-1-carboxylate Chemical compound CC(C)CCCOC(=O)N1CCCCC1 YJUXGYJYVIYEJW-UHFFFAOYSA-N 0.000 description 1
- UZZBXCUUTXRYAY-UHFFFAOYSA-N 5-[(1-diphenoxyphosphorylpiperidin-4-yl)oxymethyl]-3-pyridin-4-yl-1,2,4-oxadiazole Chemical compound C=1C=CC=CC=1OP(N1CCC(CC1)OCC=1ON=C(N=1)C=1C=CN=CC=1)(=O)OC1=CC=CC=C1 UZZBXCUUTXRYAY-UHFFFAOYSA-N 0.000 description 1
- ZLAHUUQGNRAKSF-UHFFFAOYSA-N 5-[(1-pyrazin-2-ylpiperidin-4-yl)oxymethyl]-3-pyridin-4-yl-1,2,4-oxadiazole Chemical compound N=1C(C=2C=CN=CC=2)=NOC=1COC(CC1)CCN1C1=CN=CC=N1 ZLAHUUQGNRAKSF-UHFFFAOYSA-N 0.000 description 1
- CSWMUBFXTSMLFU-UHFFFAOYSA-N 5-[1-[5-(1,3-dioxolan-2-yl)-6-(4-methylsulfonylphenoxy)pyrimidin-4-yl]piperidin-4-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)C2OCCO2)=N1 CSWMUBFXTSMLFU-UHFFFAOYSA-N 0.000 description 1
- VMCQUTXUDKCUNQ-UHFFFAOYSA-N 5-[1-[5-(1,3-dioxolan-2-yl)-6-[4-(thiadiazol-4-yl)phenoxy]pyrimidin-4-yl]piperidin-4-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)C=3N=NSC=3)N=CN=2)C2OCCO2)=N1 VMCQUTXUDKCUNQ-UHFFFAOYSA-N 0.000 description 1
- HPPQAPANBWHEBE-UHFFFAOYSA-N 5-[1-[6-(4-methylsulfonylphenoxy)pyrimidin-4-yl]piperidin-4-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2N=CN=C(OC=3C=CC(=CC=3)S(C)(=O)=O)C=2)=N1 HPPQAPANBWHEBE-UHFFFAOYSA-N 0.000 description 1
- UJBGOVWMNPUHQR-UHFFFAOYSA-N 5-[2-[[6-methyl-2-(2,4,5-trifluorophenyl)pyrimidin-4-yl]amino]ethyl]-1h-pyridin-2-one Chemical compound N=1C(C=2C(=CC(F)=C(F)C=2)F)=NC(C)=CC=1NCCC=1C=CC(=O)NC=1 UJBGOVWMNPUHQR-UHFFFAOYSA-N 0.000 description 1
- QSCXUIPSVNVQAJ-UHFFFAOYSA-N 5-[4-[1-(2,5-difluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C=3C=NN(C=3N=CN=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 QSCXUIPSVNVQAJ-UHFFFAOYSA-N 0.000 description 1
- YJRDRIQABPPLRA-UHFFFAOYSA-N 5-[4-[3-(2,5-difluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2N3N=C(C)C(=C3N=CC=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 YJRDRIQABPPLRA-UHFFFAOYSA-N 0.000 description 1
- MFDRTLFTQWPQPM-UHFFFAOYSA-N 5-[4-[3-(2,5-difluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2N3N=C(C)C(=C3N=CC=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 MFDRTLFTQWPQPM-UHFFFAOYSA-N 0.000 description 1
- HASKNHLYZSZNRH-UHFFFAOYSA-N 5-[4-[3-(2,5-difluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2N3N=CC(=C3N=CC=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 HASKNHLYZSZNRH-UHFFFAOYSA-N 0.000 description 1
- HXLUQIZOAXZQDD-UHFFFAOYSA-N 5-[4-[3-(2,5-difluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2N3N=CC(=C3N=CC=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 HXLUQIZOAXZQDD-UHFFFAOYSA-N 0.000 description 1
- OOQQHYAABSVACC-UHFFFAOYSA-N 5-[4-[3-(2-fluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2N3N=C(C)C(=C3N=CC=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 OOQQHYAABSVACC-UHFFFAOYSA-N 0.000 description 1
- KCFYAPMLZUWYTQ-UHFFFAOYSA-N 5-[4-[3-(2-fluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2N3N=C(C)C(=C3N=CC=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 KCFYAPMLZUWYTQ-UHFFFAOYSA-N 0.000 description 1
- VPNKPVKLLCJIFI-UHFFFAOYSA-N 5-[4-[3-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2N3N=CC(=C3N=CC=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 VPNKPVKLLCJIFI-UHFFFAOYSA-N 0.000 description 1
- OFEUIPKONJEKAF-UHFFFAOYSA-N 5-[4-[3-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2N3N=CC(=C3N=CC=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 OFEUIPKONJEKAF-UHFFFAOYSA-N 0.000 description 1
- HIZKFFZASKYLCW-UHFFFAOYSA-N 5-[4-[3-(4-fluoro-6-methoxypyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound C1=NC(OC)=CC(F)=C1C1=C2N=CC=C(OC3CCC(CC3)C=3ON=C(N=3)C(C)C)N2N=C1C HIZKFFZASKYLCW-UHFFFAOYSA-N 0.000 description 1
- IAQLMHGBVQYMSZ-UHFFFAOYSA-N 5-[4-[3-(4-fluoro-6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound C1=NC(OC)=CC(F)=C1C1=C2N=CC=C(OC3CCC(CC3)C=3ON=C(N=3)C(C)C)N2N=C1 IAQLMHGBVQYMSZ-UHFFFAOYSA-N 0.000 description 1
- WSQGMXYYDLAOGU-UHFFFAOYSA-N 5-[4-[3-(4-fluoro-6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound C1=NC(OC)=CC(F)=C1C1=C2N=CC=C(OC3CCN(CC3)C=3ON=C(N=3)C(C)C)N2N=C1 WSQGMXYYDLAOGU-UHFFFAOYSA-N 0.000 description 1
- DEQXPTBZYKZWHI-UHFFFAOYSA-N 5-[4-[3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC1=NC(OC)=CC=C1C1=C2N=CC=C(OC3CCC(CC3)C=3ON=C(N=3)C(C)C)N2N=C1C DEQXPTBZYKZWHI-UHFFFAOYSA-N 0.000 description 1
- NCRLYXCBSQXYKK-UHFFFAOYSA-N 5-[4-[3-(6-methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC1=NC(OC)=CC=C1C1=C2N=CC=C(OC3CCN(CC3)C=3ON=C(N=3)C(C)C)N2N=C1 NCRLYXCBSQXYKK-UHFFFAOYSA-N 0.000 description 1
- HIQWBSMZSYOGER-UHFFFAOYSA-N 5-[4-[5-ethynyl-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C#C)=N1 HIQWBSMZSYOGER-UHFFFAOYSA-N 0.000 description 1
- ZWNVNAGORNWSJM-UHFFFAOYSA-N 5-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methyl-1,2,4-oxadiazole Chemical compound CC1=NOC(N2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)=N1 ZWNVNAGORNWSJM-UHFFFAOYSA-N 0.000 description 1
- OZKKNPMLZOJSHG-UHFFFAOYSA-N 5-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C(=C(OC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)=N1 OZKKNPMLZOJSHG-UHFFFAOYSA-N 0.000 description 1
- JOMRUCMOWQYVPH-UHFFFAOYSA-N 5-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-oxopentanenitrile Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(CC(=O)CCC#N)CC1 JOMRUCMOWQYVPH-UHFFFAOYSA-N 0.000 description 1
- GOTPPKKRNYLGNE-UHFFFAOYSA-N 5-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-4-oxopentanoic acid Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC1CCN(CC(=O)CCC(O)=O)CC1 GOTPPKKRNYLGNE-UHFFFAOYSA-N 0.000 description 1
- DSEYJRQXCPNOQS-UHFFFAOYSA-N 5-[4-[6-(4-bromo-2-fluorophenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C(=C(OC=3C(=CC(Br)=CC=3)F)N=CN=2)C)=N1 DSEYJRQXCPNOQS-UHFFFAOYSA-N 0.000 description 1
- DDGQIJRMIFYACD-UHFFFAOYSA-N 5-[4-[8-(2,5-difluoro-4-methylsulfonylphenyl)quinolin-4-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2C3=CC=CC(=C3N=CC=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 DDGQIJRMIFYACD-UHFFFAOYSA-N 0.000 description 1
- MMIBDVXAARGFKL-UHFFFAOYSA-N 5-[4-[8-(2,5-difluoro-4-methylsulfonylphenyl)quinolin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C3=CC=CC(=C3N=CC=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 MMIBDVXAARGFKL-UHFFFAOYSA-N 0.000 description 1
- XQKVIWBLHPOZRF-UHFFFAOYSA-N 5-[4-[8-(2-fluoro-4-methylsulfonylphenyl)quinolin-4-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2C3=CC=CC(=C3N=CC=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 XQKVIWBLHPOZRF-UHFFFAOYSA-N 0.000 description 1
- GYYHNTFWRCXOJR-UHFFFAOYSA-N 5-[4-[8-(2-fluoro-4-methylsulfonylphenyl)quinolin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C3=CC=CC(=C3N=CC=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 GYYHNTFWRCXOJR-UHFFFAOYSA-N 0.000 description 1
- XEXUWFGEXNBYJY-UHFFFAOYSA-N 5-[4-[8-(4-fluoro-6-methoxypyridin-3-yl)quinolin-4-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound C1=NC(OC)=CC(F)=C1C(C1=NC=C2)=CC=CC1=C2OC1CCC(C=2ON=C(N=2)C(C)C)CC1 XEXUWFGEXNBYJY-UHFFFAOYSA-N 0.000 description 1
- RPXSWLAEOQYWDT-UHFFFAOYSA-N 5-[4-[8-(4-fluoro-6-methoxypyridin-3-yl)quinolin-4-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound C1=NC(OC)=CC(F)=C1C(C1=NC=C2)=CC=CC1=C2OC1CCN(C=2ON=C(N=2)C(C)C)CC1 RPXSWLAEOQYWDT-UHFFFAOYSA-N 0.000 description 1
- ADJLAEQTLJWPQZ-UHFFFAOYSA-N 5-[4-[8-(6-methoxy-2-methylpyridin-3-yl)quinolin-4-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC1=NC(OC)=CC=C1C(C1=NC=C2)=CC=CC1=C2OC1CCC(C=2ON=C(N=2)C(C)C)CC1 ADJLAEQTLJWPQZ-UHFFFAOYSA-N 0.000 description 1
- FUXKOOLZOBRZLO-UHFFFAOYSA-N 5-[4-[9-(2,5-difluoro-4-methylsulfonylphenyl)purin-6-yl]oxycyclohexyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(C2CCC(CC2)OC=2C=3N=CN(C=3N=CN=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 FUXKOOLZOBRZLO-UHFFFAOYSA-N 0.000 description 1
- IOUSRUKCPUAVKN-UHFFFAOYSA-N 5-[4-[9-(2,5-difluoro-4-methylsulfonylphenyl)purin-6-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C=3N=CN(C=3N=CN=2)C=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=N1 IOUSRUKCPUAVKN-UHFFFAOYSA-N 0.000 description 1
- ZXVJTHCOASJPBM-UHFFFAOYSA-N 5-[4-[9-(2-fluoro-4-methylsulfonylphenyl)purin-6-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C=3N=CN(C=3N=CN=2)C=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 ZXVJTHCOASJPBM-UHFFFAOYSA-N 0.000 description 1
- PHCHBZTWVZJVTH-UHFFFAOYSA-N 5-[4-[9-(6-methoxy-2-methylpyridin-3-yl)purin-6-yl]oxypiperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC1=NC(OC)=CC=C1N1C2=NC=NC(OC3CCN(CC3)C=3ON=C(N=3)C(C)C)=C2N=C1 PHCHBZTWVZJVTH-UHFFFAOYSA-N 0.000 description 1
- JMRGHLDQKHXRES-UHFFFAOYSA-N 5-[[2-(4-bromophenyl)-6-ethylpyrimidin-4-yl]amino]pentan-1-ol Chemical compound CCC1=CC(NCCCCCO)=NC(C=2C=CC(Br)=CC=2)=N1 JMRGHLDQKHXRES-UHFFFAOYSA-N 0.000 description 1
- AUZWGLPRXPPHDO-UHFFFAOYSA-N 5-bromo-1-[4-nitro-3-(4-propylpiperidin-1-yl)phenyl]pyridin-2-one Chemical compound C1CC(CCC)CCN1C1=CC(N2C(C=CC(Br)=C2)=O)=CC=C1[N+]([O-])=O AUZWGLPRXPPHDO-UHFFFAOYSA-N 0.000 description 1
- BMNJJEMCZIRGBX-UHFFFAOYSA-N 5-bromo-2-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]pyridine Chemical compound C1CC(CCC)CCN1C1=CC(OC=2N=CC(Br)=CC=2)=CC=C1[N+]([O-])=O BMNJJEMCZIRGBX-UHFFFAOYSA-N 0.000 description 1
- HZOHXUIECWRSJH-UHFFFAOYSA-N 5-ethylsulfonyl-2-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]aniline Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C(=CC(=CC=2)S(=O)(=O)CC)N)=CC=C1[N+]([O-])=O HZOHXUIECWRSJH-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- AMORTYLNSDSJNK-UHFFFAOYSA-N 6-[1-(2-ethoxyethyl)piperidin-4-yl]oxy-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound C1CN(CCOCC)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O AMORTYLNSDSJNK-UHFFFAOYSA-N 0.000 description 1
- UGGSPMQRNUCNBE-UHFFFAOYSA-N 6-[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound C1CN(CCC(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O UGGSPMQRNUCNBE-UHFFFAOYSA-N 0.000 description 1
- VGLGTLBVYJRXMY-UHFFFAOYSA-N 6-[1-(3-methylbutyl)piperidin-4-yl]oxy-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound C1CN(CCC(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O VGLGTLBVYJRXMY-UHFFFAOYSA-N 0.000 description 1
- RMQBCFUMFGANFC-UHFFFAOYSA-N 6-[4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(N2CCC(CC2)C=2ON=C(N=2)C2CC2)=C1[N+]([O-])=O RMQBCFUMFGANFC-UHFFFAOYSA-N 0.000 description 1
- VJNFWQAQCOXLMV-UHFFFAOYSA-N 6-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound CCC1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)[N+]([O-])=O)=N1 VJNFWQAQCOXLMV-UHFFFAOYSA-N 0.000 description 1
- JEUPGLYFAZECGZ-UHFFFAOYSA-N 6-[4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound CC1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)[N+]([O-])=O)=N1 JEUPGLYFAZECGZ-UHFFFAOYSA-N 0.000 description 1
- IZXAWMFOUJIWOK-UHFFFAOYSA-N 6-[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-n-(4-methylsulfonylphenyl)-5-nitropyrimidin-4-amine Chemical compound CC(C)(C)C1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)[N+]([O-])=O)=N1 IZXAWMFOUJIWOK-UHFFFAOYSA-N 0.000 description 1
- JWLMHLBURRASHZ-UHFFFAOYSA-N 6-[[6-[methyl-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]amino]pyrimidin-4-yl]amino]pyridine-3-carboxylic acid Chemical compound C=1C(NC=2N=CC(=CC=2)C(O)=O)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 JWLMHLBURRASHZ-UHFFFAOYSA-N 0.000 description 1
- RNPWVVWMMDDDDF-UHFFFAOYSA-N 6-n-(4-methylsulfonylphenyl)-5-nitro-4-n-piperidin-4-ylpyrimidine-4,6-diamine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(NC2CCNCC2)=C1[N+]([O-])=O RNPWVVWMMDDDDF-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- GNHFRVFMMDARPQ-UHFFFAOYSA-N BrC1=CC(=C(OC2=CC(=NC=N2)OC2CCN(CC2)C(=O)O)C=C1)F Chemical compound BrC1=CC(=C(OC2=CC(=NC=N2)OC2CCN(CC2)C(=O)O)C=C1)F GNHFRVFMMDARPQ-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- ZYSZPNJTQCSXQO-UHFFFAOYSA-N C#CC(C(OC1CCN(CCCC2=NC=CC=C2)CC1)=NC=N1)=C1OC(C=CC(N1N=CN=C1)=C1)=C1F Chemical compound C#CC(C(OC1CCN(CCCC2=NC=CC=C2)CC1)=NC=N1)=C1OC(C=CC(N1N=CN=C1)=C1)=C1F ZYSZPNJTQCSXQO-UHFFFAOYSA-N 0.000 description 1
- RGVRUBQMFKFDQP-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C(=CC=C1)Cl)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C(=CC=C1)Cl)F RGVRUBQMFKFDQP-UHFFFAOYSA-N 0.000 description 1
- RZFBDLHTIOORGA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)F)Br)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)F)Br)F RZFBDLHTIOORGA-UHFFFAOYSA-N 0.000 description 1
- RCTJCIKPCFAGKY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)Br)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)Br)F RCTJCIKPCFAGKY-UHFFFAOYSA-N 0.000 description 1
- WNRBDGYTCMNZPD-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)C#N)CC Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)C#N)CC WNRBDGYTCMNZPD-UHFFFAOYSA-N 0.000 description 1
- LCIKHLHWTWSTCY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)C)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)C)F LCIKHLHWTWSTCY-UHFFFAOYSA-N 0.000 description 1
- BYRJZONGVYATOV-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)F)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)F)F BYRJZONGVYATOV-UHFFFAOYSA-N 0.000 description 1
- DIRCNGCBGOUGEA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)S(=O)(=O)C)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)S(=O)(=O)C)F DIRCNGCBGOUGEA-UHFFFAOYSA-N 0.000 description 1
- BYDSFWFBGAPKMH-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)S(NCC)(=O)=O)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)S(NCC)(=O)=O)F BYDSFWFBGAPKMH-UHFFFAOYSA-N 0.000 description 1
- AODRVLBTQFLIAJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=CC(=C1)C(=O)O)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=CC(=C1)C(=O)O)F AODRVLBTQFLIAJ-UHFFFAOYSA-N 0.000 description 1
- JCGHNCIMUSLUFO-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=CC=C1)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=CC=C1)F JCGHNCIMUSLUFO-UHFFFAOYSA-N 0.000 description 1
- ZSQFWJCQZIZNRJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC(=CC(=C1)OC)OC Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC(=CC(=C1)OC)OC ZSQFWJCQZIZNRJ-UHFFFAOYSA-N 0.000 description 1
- ZALJSSKUSLJLRS-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC2=C(OC(O2)(F)F)C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC2=C(OC(O2)(F)F)C=C1 ZALJSSKUSLJLRS-UHFFFAOYSA-N 0.000 description 1
- AFITZHOUOUIXDF-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)C(CCC)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)C(CCC)=O AFITZHOUOUIXDF-UHFFFAOYSA-N 0.000 description 1
- AHPINTTXYJLPPA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)CCS(=O)(=O)C Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)CCS(=O)(=O)C AHPINTTXYJLPPA-UHFFFAOYSA-N 0.000 description 1
- ZMVJFGZSLRFBLK-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)S(N(C)C)(=O)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)S(N(C)C)(=O)=O ZMVJFGZSLRFBLK-UHFFFAOYSA-N 0.000 description 1
- GYOZDVXMCCKUPM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)S(NCC)(=O)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)S(NCC)(=O)=O GYOZDVXMCCKUPM-UHFFFAOYSA-N 0.000 description 1
- FDCAQCRMFRLTGX-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)SCC Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=CC=C(C=C1)SCC FDCAQCRMFRLTGX-UHFFFAOYSA-N 0.000 description 1
- BQWNRMMJDCNDLD-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=NC=C(C=C1)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=NC=C(C=C1)F BQWNRMMJDCNDLD-UHFFFAOYSA-N 0.000 description 1
- ZFRCRUJOEKVWGN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=NC=C(C=C1Br)C Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=NC=C(C=C1Br)C ZFRCRUJOEKVWGN-UHFFFAOYSA-N 0.000 description 1
- PEFXHZOHMWJQLV-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=NC=C(C=C1C)Br Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=NC=C(C=C1C)Br PEFXHZOHMWJQLV-UHFFFAOYSA-N 0.000 description 1
- SEPSFVJBMOYSBS-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C(=NC(=CC=1)OC)OC Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C(=NC(=CC=1)OC)OC SEPSFVJBMOYSBS-UHFFFAOYSA-N 0.000 description 1
- OONYKRKRXFXGKO-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C=NC(=CC=1)NC(C)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C=NC(=CC=1)NC(C)=O OONYKRKRXFXGKO-UHFFFAOYSA-N 0.000 description 1
- PFRSDUBZBFPOEC-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C=NC(=CC=1)OC Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C=NC(=CC=1)OC PFRSDUBZBFPOEC-UHFFFAOYSA-N 0.000 description 1
- OCFRGLCCAIHYOR-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C=NC(=CC=1)S(=O)(=O)C Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC=1C=NC(=CC=1)S(=O)(=O)C OCFRGLCCAIHYOR-UHFFFAOYSA-N 0.000 description 1
- DOHVTYDQKOEPHN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCC(C)OC1=CC=C(C=C1)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCC(C)OC1=CC=C(C=C1)F DOHVTYDQKOEPHN-UHFFFAOYSA-N 0.000 description 1
- FHTWFPJIZVSVFN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCC1=C(C=CC(=C1)F)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCC1=C(C=CC(=C1)F)F FHTWFPJIZVSVFN-UHFFFAOYSA-N 0.000 description 1
- JMAXGIJMFCEHSJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCC1=CC2=C(OCO2)C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCC1=CC2=C(OCO2)C=C1 JMAXGIJMFCEHSJ-UHFFFAOYSA-N 0.000 description 1
- ACMFIDKXYQCYKR-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCCOC1=C(C=CC=C1)Cl Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCCOC1=C(C=CC=C1)Cl ACMFIDKXYQCYKR-UHFFFAOYSA-N 0.000 description 1
- TVOKSGYUEYFGAW-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCCOC1=C(C=CC=C1)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NCCOC1=C(C=CC=C1)F TVOKSGYUEYFGAW-UHFFFAOYSA-N 0.000 description 1
- HFQMPDLBCSGKLL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)OC1=C(C=CC(=C1)F)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)OC1=C(C=CC(=C1)F)F HFQMPDLBCSGKLL-UHFFFAOYSA-N 0.000 description 1
- PETSDDVKQVLXEH-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)OC1=C(C=CC=C1)Cl Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)OC1=C(C=CC=C1)Cl PETSDDVKQVLXEH-UHFFFAOYSA-N 0.000 description 1
- VICLAIKHVXGFHA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)OC1=C(C=CC=C1)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)OC1=C(C=CC=C1)F VICLAIKHVXGFHA-UHFFFAOYSA-N 0.000 description 1
- AEDQJVIPKGLREC-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)F)Br)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)F)Br)F AEDQJVIPKGLREC-UHFFFAOYSA-N 0.000 description 1
- RSWFSWVABJAYIZ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)F)OC)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)F)OC)F RSWFSWVABJAYIZ-UHFFFAOYSA-N 0.000 description 1
- BQVDQTMTXIAORP-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)OC1=C(C=C(C(=C1)F)N)F Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)OC1=C(C=C(C(=C1)F)N)F BQVDQTMTXIAORP-UHFFFAOYSA-N 0.000 description 1
- IGESUYWOGGXMHR-UHFFFAOYSA-N C(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)NCCN)C#N)F Chemical compound C(C)(C)OC(=O)N1CCC(CC1)CNCCC1=NC=NC(=C1)NC1=C(C=C(C(=C1)NCCN)C#N)F IGESUYWOGGXMHR-UHFFFAOYSA-N 0.000 description 1
- LDARMEAYYFGMCX-UHFFFAOYSA-N C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C2=NN(C)C(O)=C2)=CC=C1[N+]([O-])=O Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C2=NN(C)C(O)=C2)=CC=C1[N+]([O-])=O LDARMEAYYFGMCX-UHFFFAOYSA-N 0.000 description 1
- OQYAIJBPOFKNQP-UHFFFAOYSA-N C1CN(CCC1CNCC2=CC(=NC=N2)NC3=CC4=C(C=C3)OCO4)C(=O)O Chemical compound C1CN(CCC1CNCC2=CC(=NC=N2)NC3=CC4=C(C=C3)OCO4)C(=O)O OQYAIJBPOFKNQP-UHFFFAOYSA-N 0.000 description 1
- YNHHPLRNNJHSKN-WKILWMFISA-N C1C[C@@H](NC(=O)OC(C)C)CC[C@@H]1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C Chemical compound C1C[C@@H](NC(=O)OC(C)C)CC[C@@H]1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C YNHHPLRNNJHSKN-WKILWMFISA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- JZGYGHGMJDHHFW-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)CN(C)C2=NC=NC(=C2)NCCC3=CC=CN(C3)O Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)CN(C)C2=NC=NC(=C2)NCCC3=CC=CN(C3)O JZGYGHGMJDHHFW-UHFFFAOYSA-N 0.000 description 1
- HRTFMPCFMDEAQV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=CC(=C(C=C3)F)C(=O)O Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=CC(=C(C=C3)F)C(=O)O HRTFMPCFMDEAQV-UHFFFAOYSA-N 0.000 description 1
- JLBQVLKVIVVYBS-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NCC3=C(C=C(C=C3)S(=O)(=O)C)F Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NCC3=C(C=C(C=C3)S(=O)(=O)C)F JLBQVLKVIVVYBS-UHFFFAOYSA-N 0.000 description 1
- MLRMWEYIDFTHEY-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CNCCc2cc(Nc3cc(F)c(cc3F)S(C)(=O)=O)ncn2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CNCCc2cc(Nc3cc(F)c(cc3F)S(C)(=O)=O)ncn2)CC1 MLRMWEYIDFTHEY-UHFFFAOYSA-N 0.000 description 1
- JRQPZENHZBSRIA-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3cc(F)c(cc3F)C#N)ncn2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3cc(F)c(cc3F)C#N)ncn2)CC1 JRQPZENHZBSRIA-UHFFFAOYSA-N 0.000 description 1
- UAPSXQXMBDOJDT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3cc(F)c(cc3F)S(C)(=O)=O)ncn2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3cc(F)c(cc3F)S(C)(=O)=O)ncn2)CC1 UAPSXQXMBDOJDT-UHFFFAOYSA-N 0.000 description 1
- IRYDAFXRXKGNEA-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3cc(ccc3F)S(C)(=O)=O)ncn2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3cc(ccc3F)S(C)(=O)=O)ncn2)CC1 IRYDAFXRXKGNEA-UHFFFAOYSA-N 0.000 description 1
- GVNFQEOYLBMSPB-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3ccc(cc3F)C#N)ncn2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCC(CNCc2cc(Nc3ccc(cc3F)C#N)ncn2)CC1 GVNFQEOYLBMSPB-UHFFFAOYSA-N 0.000 description 1
- BWAPCZACGABTFM-UHFFFAOYSA-N CC(C)C1=NOC(=N1)N2CCC(CC2)OC3=NC=NC4=C3N=CN4C5=CC(=C(C=C5)S(=O)(=O)N)C(=O)CCF Chemical compound CC(C)C1=NOC(=N1)N2CCC(CC2)OC3=NC=NC4=C3N=CN4C5=CC(=C(C=C5)S(=O)(=O)N)C(=O)CCF BWAPCZACGABTFM-UHFFFAOYSA-N 0.000 description 1
- ZOKDCZJOZBXMBA-UHFFFAOYSA-N CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C#N)F Chemical compound CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C#N)F ZOKDCZJOZBXMBA-UHFFFAOYSA-N 0.000 description 1
- ASQGGXIYFOEZFG-UHFFFAOYSA-N CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C(=O)O)F Chemical compound CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C(=O)O)F ASQGGXIYFOEZFG-UHFFFAOYSA-N 0.000 description 1
- RXKXOJLROMIIML-UHFFFAOYSA-N CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)S(=O)(=O)C)F Chemical compound CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)S(=O)(=O)C)F RXKXOJLROMIIML-UHFFFAOYSA-N 0.000 description 1
- PYHATUDFQWWXIN-UHFFFAOYSA-N CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=CC(=C3)F)F Chemical compound CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=CC(=C3)F)F PYHATUDFQWWXIN-UHFFFAOYSA-N 0.000 description 1
- PKADAVDVTJJFIE-UHFFFAOYSA-N CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=CC(=C(C=C3F)O)F Chemical compound CC(C)COC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=CC(=C(C=C3F)O)F PKADAVDVTJJFIE-UHFFFAOYSA-N 0.000 description 1
- HJARBOAIESRNKF-UHFFFAOYSA-N CC(C)COC(=O)N1CCC(CNCc2cc(Nc3ccc(cc3F)C(N)=N)ncn2)CC1 Chemical compound CC(C)COC(=O)N1CCC(CNCc2cc(Nc3ccc(cc3F)C(N)=N)ncn2)CC1 HJARBOAIESRNKF-UHFFFAOYSA-N 0.000 description 1
- AKHJPQKWNULLIH-UHFFFAOYSA-N CC(C)NS(=O)(=O)c1ccc(Nc2cc(CNCC3CCN(CC3)C(=O)OC(C)(C)C)ncn2)c(F)c1 Chemical compound CC(C)NS(=O)(=O)c1ccc(Nc2cc(CNCC3CCN(CC3)C(=O)OC(C)(C)C)ncn2)c(F)c1 AKHJPQKWNULLIH-UHFFFAOYSA-N 0.000 description 1
- YIVQEJUWJCNAPR-UHFFFAOYSA-N CC(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C#N)F Chemical compound CC(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C#N)F YIVQEJUWJCNAPR-UHFFFAOYSA-N 0.000 description 1
- POIFPAPEJLCQHB-UHFFFAOYSA-N CC(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)S(=O)(=O)C)F Chemical compound CC(C)OC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)S(=O)(=O)C)F POIFPAPEJLCQHB-UHFFFAOYSA-N 0.000 description 1
- QJZKZFPPRDYPJU-UHFFFAOYSA-N CC(C)OC(=O)N1CCC(CC1)CNCCC2=CC(=NC=N2)NC3=C(C=C(C(=C3)F)C#N)F Chemical compound CC(C)OC(=O)N1CCC(CC1)CNCCC2=CC(=NC=N2)NC3=C(C=C(C(=C3)F)C#N)F QJZKZFPPRDYPJU-UHFFFAOYSA-N 0.000 description 1
- UTEXPVLRFVZXGK-UHFFFAOYSA-N CC(CCOC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)S(=O)(=O)C)F)C Chemical compound CC(CCOC(=O)N1CCC(CC1)CNCC1=NC=NC(=C1)NC1=C(C=C(C=C1)S(=O)(=O)C)F)C UTEXPVLRFVZXGK-UHFFFAOYSA-N 0.000 description 1
- CWQNYHXKHVIILX-UHFFFAOYSA-N CC1=C(N=CN=C1OC2=C(CN(C=C2)O)F)OC3CCN(CC3)C(=O)OC(C)C Chemical compound CC1=C(N=CN=C1OC2=C(CN(C=C2)O)F)OC3CCN(CC3)C(=O)OC(C)C CWQNYHXKHVIILX-UHFFFAOYSA-N 0.000 description 1
- ZBCHGXSMZAMUNT-UHFFFAOYSA-N CC1=C(N=CN=C1OC2CCC(CC2)C(C(C)C)C(=O)N)OC3=C(C=C(C=C3)S(=O)(=O)C)F Chemical compound CC1=C(N=CN=C1OC2CCC(CC2)C(C(C)C)C(=O)N)OC3=C(C=C(C=C3)S(=O)(=O)C)F ZBCHGXSMZAMUNT-UHFFFAOYSA-N 0.000 description 1
- QMOBJOJZTNPJCK-SHTZXODSSA-N CCCCC[C@H]1CC[C@@H](CC1)c1nnc(s1)-c1ccncc1 Chemical compound CCCCC[C@H]1CC[C@@H](CC1)c1nnc(s1)-c1ccncc1 QMOBJOJZTNPJCK-SHTZXODSSA-N 0.000 description 1
- WMEKMFAELSSUHV-SAABIXHNSA-N CCCCC[C@H]1CC[C@@H](CC1)c1noc(C=Cc2ccncc2)n1 Chemical compound CCCCC[C@H]1CC[C@@H](CC1)c1noc(C=Cc2ccncc2)n1 WMEKMFAELSSUHV-SAABIXHNSA-N 0.000 description 1
- ANVFIDPFLZUSGH-UHFFFAOYSA-N CCCCOC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C#N)F Chemical compound CCCCOC(=O)N1CCC(CC1)CNCC2=CC(=NC=N2)NC3=C(C=C(C=C3)C#N)F ANVFIDPFLZUSGH-UHFFFAOYSA-N 0.000 description 1
- BWJDFSPSPKWIGI-UHFFFAOYSA-N CCNC(=O)c1ccc(Nc2cc(CNCC3CCN(CC3)C(=O)OCC(C)C)ncn2)c(F)c1 Chemical compound CCNC(=O)c1ccc(Nc2cc(CNCC3CCN(CC3)C(=O)OCC(C)C)ncn2)c(F)c1 BWJDFSPSPKWIGI-UHFFFAOYSA-N 0.000 description 1
- RIMCUNGGLSBFMF-UHFFFAOYSA-N CCOC(=O)c1ccc(Nc2cc(CNCC3CCN(CC3)C(=O)OCC(C)C)ncn2)c(F)c1 Chemical compound CCOC(=O)c1ccc(Nc2cc(CNCC3CCN(CC3)C(=O)OCC(C)C)ncn2)c(F)c1 RIMCUNGGLSBFMF-UHFFFAOYSA-N 0.000 description 1
- KDKYIJIZKRIDSU-UHFFFAOYSA-N CS(=O)(=O)C1=CC(=C(C=C1)NC2=NC=NC(=C2)CNCC3CCN(CC3)C(=O)OC4CCC4)F Chemical compound CS(=O)(=O)C1=CC(=C(C=C1)NC2=NC=NC(=C2)CNCC3CCN(CC3)C(=O)OC4CCC4)F KDKYIJIZKRIDSU-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RIFRFLDNPDHUQJ-UHFFFAOYSA-N ClC1=CC(=C(C=N1)NC1=C(C(=NC=N1)OC1CCN(CC1)C(=O)O)C#N)F Chemical compound ClC1=CC(=C(C=N1)NC1=C(C(=NC=N1)OC1CCN(CC1)C(=O)O)C#N)F RIFRFLDNPDHUQJ-UHFFFAOYSA-N 0.000 description 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- HGOMIUOWPIJJJY-UHFFFAOYSA-N FC1=C(C=CC(=C1F)CCS(=O)(=O)C)NC1=C(C(=NC=N1)OC1CCN(CC1)C(=O)O)C Chemical compound FC1=C(C=CC(=C1F)CCS(=O)(=O)C)NC1=C(C(=NC=N1)OC1CCN(CC1)C(=O)O)C HGOMIUOWPIJJJY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 description 1
- 101000584177 Homo sapiens Myosin light chain kinase 3 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101100382265 Mus musculus Ca15 gene Proteins 0.000 description 1
- 102100030783 Myosin light chain kinase 3 Human genes 0.000 description 1
- ZMSOGOYNUKUCPE-UHFFFAOYSA-N N1=CN=C(N(CC2CC2)CC2CCN(CC2)C(O)=O)C(C)=C1OC1=CC=C(S(C)(=O)=O)C=C1F Chemical compound N1=CN=C(N(CC2CC2)CC2CCN(CC2)C(O)=O)C(C)=C1OC1=CC=C(S(C)(=O)=O)C=C1F ZMSOGOYNUKUCPE-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical compound COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940122344 Peptidase inhibitor Drugs 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000014675 Prion-associated disease Diseases 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001502514 Small round structured virus Species 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150115932 Tep1 gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XCYAJIWSUDCOAF-UHFFFAOYSA-N [1-[6-(1,3-benzodioxol-5-ylamino)-5-nitropyrimidin-4-yl]piperidin-4-yl]-(4-fluorophenyl)methanone Chemical compound [O-][N+](=O)C1=C(NC=2C=C3OCOC3=CC=2)N=CN=C1N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 XCYAJIWSUDCOAF-UHFFFAOYSA-N 0.000 description 1
- VAEPOXPGUPMLJK-UHFFFAOYSA-N [4-[2-nitro-5-(4-propylpiperidin-1-yl)phenoxy]phenyl]-phenylmethanone Chemical compound C1CC(CCC)CCN1C1=CC=C([N+]([O-])=O)C(OC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=C1 VAEPOXPGUPMLJK-UHFFFAOYSA-N 0.000 description 1
- GACZXTJOCSDCMT-UHFFFAOYSA-N [4-[3-[4-(methoxymethyl)piperidin-1-yl]-4-nitrophenoxy]phenyl]-phenylmethanone Chemical compound C1CC(COC)CCN1C1=CC(OC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=CC=C1[N+]([O-])=O GACZXTJOCSDCMT-UHFFFAOYSA-N 0.000 description 1
- ASJQIUWBRAKXBS-UHFFFAOYSA-N [4-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-6-[4-(thiadiazol-4-yl)phenoxy]pyrimidin-5-yl]methanol Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)C=3N=NSC=3)N=CN=2)CO)=N1 ASJQIUWBRAKXBS-UHFFFAOYSA-N 0.000 description 1
- WVUDQXPBMXVYBW-UHFFFAOYSA-N [4-[4-nitro-3-(4-propylpiperidin-1-yl)anilino]phenyl]-phenylmethanone Chemical compound C1CC(CCC)CCN1C1=CC(NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=CC=C1[N+]([O-])=O WVUDQXPBMXVYBW-UHFFFAOYSA-N 0.000 description 1
- ICWUHNPSRKLUBV-UHFFFAOYSA-N [4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]-phenylmethanone Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=CC=C1[N+]([O-])=O ICWUHNPSRKLUBV-UHFFFAOYSA-N 0.000 description 1
- BKBQNDQOCUNTTO-UHFFFAOYSA-N [4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]-(5-methylpyridin-3-yl)methanone Chemical compound CC1=CN=CC(C(=O)N2CCC(CC2)OC=2N=CN=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)C=2)=C1 BKBQNDQOCUNTTO-UHFFFAOYSA-N 0.000 description 1
- JXSSKFQIDFWXDP-UHFFFAOYSA-N [4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]-(6-fluoropyridin-2-yl)methanone Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)C=2N=C(F)C=CC=2)=NC=N1 JXSSKFQIDFWXDP-UHFFFAOYSA-N 0.000 description 1
- XTKWSNOOMQGGJJ-UHFFFAOYSA-N [4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]-(6-methylpyridin-2-yl)methanone Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)OC=2N=CN=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)C=2)=N1 XTKWSNOOMQGGJJ-UHFFFAOYSA-N 0.000 description 1
- GLOHGJMNGZPTQN-UHFFFAOYSA-N [4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidin-1-yl]-pyridin-2-ylmethanone Chemical compound FC1=CC(S(=O)(=O)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)C=2N=CC=CC=2)=NC=N1 GLOHGJMNGZPTQN-UHFFFAOYSA-N 0.000 description 1
- VWVLGJIQPZRFQV-UHFFFAOYSA-N [4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-(oxolan-2-yl)methanone Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(C)=C1OC(CC1)CCN1C(=O)C1CCCO1 VWVLGJIQPZRFQV-UHFFFAOYSA-N 0.000 description 1
- DADMJFSLSPECRO-UHFFFAOYSA-N [4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidin-1-yl]-pyridin-2-ylmethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)C=2N=CC=CC=2)=C1[N+]([O-])=O DADMJFSLSPECRO-UHFFFAOYSA-N 0.000 description 1
- ZOGSDONAVGUYKY-UHFFFAOYSA-N [4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidin-1-yl]-pyridin-3-ylmethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)C=2C=NC=CC=2)=C1[N+]([O-])=O ZOGSDONAVGUYKY-UHFFFAOYSA-N 0.000 description 1
- DRIFBFDYGLBJJR-UHFFFAOYSA-N [4-[[5-nitro-6-(4-pyridin-2-ylsulfanylpiperidin-1-yl)pyridin-2-yl]amino]phenyl]-phenylmethanone Chemical compound N1=C(N2CCC(CC2)SC=2N=CC=CC=2)C([N+](=O)[O-])=CC=C1NC(C=C1)=CC=C1C(=O)C1=CC=CC=C1 DRIFBFDYGLBJJR-UHFFFAOYSA-N 0.000 description 1
- NLQMYPRZFDDCOI-UHFFFAOYSA-N [4-[[5-nitro-6-(4-pyridin-2-ylsulfanylpiperidin-1-yl)pyrimidin-4-yl]amino]phenyl]-phenylmethanone Chemical compound N1=CN=C(N2CCC(CC2)SC=2N=CC=CC=2)C([N+](=O)[O-])=C1NC(C=C1)=CC=C1C(=O)C1=CC=CC=C1 NLQMYPRZFDDCOI-UHFFFAOYSA-N 0.000 description 1
- BILYYYDJGVAYCF-UHFFFAOYSA-N [4-methoxy-2-[5-nitro-6-(4-pyridin-2-ylsulfanylpiperidin-1-yl)pyrimidin-4-yl]oxyphenyl]-phenylmethanone Chemical compound N=1C=NC(N2CCC(CC2)SC=2N=CC=CC=2)=C([N+]([O-])=O)C=1OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 BILYYYDJGVAYCF-UHFFFAOYSA-N 0.000 description 1
- LPIURYDEKDUCPE-UHFFFAOYSA-N acetaldehyde 2,2,2-trifluoroacetic acid Chemical compound CC=O.OC(=O)C(F)(F)F LPIURYDEKDUCPE-UHFFFAOYSA-N 0.000 description 1
- ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XXXHSQBVHSJQKS-UHFFFAOYSA-N amino benzoate Chemical compound NOC(=O)C1=CC=CC=C1 XXXHSQBVHSJQKS-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005533 aryl carboxamido group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 1
- 125000004267 aziridin-2-yl group Chemical group [H]N1C([H])([H])C1([H])* 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QBBJFYQPYXKIEB-UHFFFAOYSA-N benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N#CC1=CC=CC=C1 QBBJFYQPYXKIEB-UHFFFAOYSA-N 0.000 description 1
- TUWZZXGAUMSUOB-UHFFFAOYSA-N benzyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OCC1=CC=CC=C1 TUWZZXGAUMSUOB-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 1
- UAFYIXULPCIKJV-UHFFFAOYSA-N butan-2-yl piperidine-1-carboxylate Chemical compound CCC(C)OC(=O)N1CCCCC1 UAFYIXULPCIKJV-UHFFFAOYSA-N 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- IPGMIYAOWRJGBE-UHFFFAOYSA-N butyl cyclohexanecarboxylate Chemical compound CCCCOC(=O)C1CCCCC1 IPGMIYAOWRJGBE-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- SCRLGCWSMQHRGD-UHFFFAOYSA-N cyclobutyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OC1CCC1 SCRLGCWSMQHRGD-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GLWFVBPRTKJJBY-UHFFFAOYSA-N cycloheptyl piperidine-1-carboxylate Chemical compound C1(CCCCCC1)OC(=O)N1CCCCC1 GLWFVBPRTKJJBY-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- KRQFSXUWRQEBFI-UHFFFAOYSA-N cyclohexyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OC1CCCCC1 KRQFSXUWRQEBFI-UHFFFAOYSA-N 0.000 description 1
- OFAUDLLOLVJRBX-UHFFFAOYSA-N cyclopentyl 4-[methyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC2CCCC2)CCC1N(C)CC(ON=1)=NC=1C1=CC=NC=C1 OFAUDLLOLVJRBX-UHFFFAOYSA-N 0.000 description 1
- SXBARASIAVJBJW-UHFFFAOYSA-N cyclopentyl-[4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidin-1-yl]methanone Chemical compound C1CC(OCC=2ON=C(N=2)C=2C=CN=CC=2)CCN1C(=O)C1CCCC1 SXBARASIAVJBJW-UHFFFAOYSA-N 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- WPHLWJZUHNZZCS-UHFFFAOYSA-N cyclopropylmethyl piperidine-1-carboxylate Chemical compound C1(CC1)COC(=O)N1CCCCC1 WPHLWJZUHNZZCS-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- USVYYPQABMCXKL-UHFFFAOYSA-N ethyl 1-[2-nitro-3-[4-(3-oxobutyl)phenoxy]phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC=CC(OC=2C=CC(CCC(C)=O)=CC=2)=C1[N+]([O-])=O USVYYPQABMCXKL-UHFFFAOYSA-N 0.000 description 1
- JFDVGACPVMKGDT-UHFFFAOYSA-N ethyl 1-[2-nitro-5-[4-(3-oxobutyl)phenoxy]phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C=CC(CCC(C)=O)=CC=2)=CC=C1[N+]([O-])=O JFDVGACPVMKGDT-UHFFFAOYSA-N 0.000 description 1
- PUJRIHHEFRZEKV-UHFFFAOYSA-N ethyl 1-[3-(4-benzoylphenoxy)-4-nitrophenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC=C([N+]([O-])=O)C(OC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=C1 PUJRIHHEFRZEKV-UHFFFAOYSA-N 0.000 description 1
- PKPCJQOGBQPTFY-UHFFFAOYSA-N ethyl 1-[4-nitro-3-[4-(3-oxobutyl)phenoxy]phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC=C([N+]([O-])=O)C(OC=2C=CC(CCC(C)=O)=CC=2)=C1 PKPCJQOGBQPTFY-UHFFFAOYSA-N 0.000 description 1
- QYMKMUMGXJOTQI-UHFFFAOYSA-N ethyl 1-[5-(2-amino-4-ethylsulfonylphenoxy)-2-nitrophenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C(=CC(=CC=2)S(=O)(=O)CC)N)=CC=C1[N+]([O-])=O QYMKMUMGXJOTQI-UHFFFAOYSA-N 0.000 description 1
- KZUORSGWSYEDSJ-UHFFFAOYSA-N ethyl 1-[5-(4-benzoylanilino)-2-nitrophenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=CC=C1[N+]([O-])=O KZUORSGWSYEDSJ-UHFFFAOYSA-N 0.000 description 1
- VQDBDBXTCUKZLR-UHFFFAOYSA-N ethyl 1-[5-(4-benzoylphenoxy)-2-nitrophenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)=CC=C1[N+]([O-])=O VQDBDBXTCUKZLR-UHFFFAOYSA-N 0.000 description 1
- GAAUTBFEIAPXEA-UHFFFAOYSA-N ethyl 1-[5-(4-ethenylphenoxy)-2-nitrophenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C=CC(C=C)=CC=2)=CC=C1[N+]([O-])=O GAAUTBFEIAPXEA-UHFFFAOYSA-N 0.000 description 1
- ZUHWCQOSEKJJSX-UHFFFAOYSA-N ethyl 1-[5-[4-(3-methoxy-3-oxopropanoyl)phenoxy]-2-nitrophenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=CC(OC=2C=CC(=CC=2)C(=O)CC(=O)OC)=CC=C1[N+]([O-])=O ZUHWCQOSEKJJSX-UHFFFAOYSA-N 0.000 description 1
- QTRCOWZRXOCIHP-UHFFFAOYSA-N ethyl 1-[5-nitro-6-(4-propanoylphenoxy)pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)C(=O)CC)=C1[N+]([O-])=O QTRCOWZRXOCIHP-UHFFFAOYSA-N 0.000 description 1
- DZBNWHGYBOGICD-UHFFFAOYSA-N ethyl 1-[5-nitro-6-[4-(1,2,4-triazol-1-yl)anilino]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)N2N=CN=C2)=C1[N+]([O-])=O DZBNWHGYBOGICD-UHFFFAOYSA-N 0.000 description 1
- BEQXVWQBFMRYNW-UHFFFAOYSA-N ethyl 1-[5-nitro-6-[4-(1,2,4-triazol-1-yl)phenoxy]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)N2N=CN=C2)=C1[N+]([O-])=O BEQXVWQBFMRYNW-UHFFFAOYSA-N 0.000 description 1
- TWNLUCSCGWJPQM-UHFFFAOYSA-N ethyl 1-[5-nitro-6-[4-(3-oxobutyl)phenoxy]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(CCC(C)=O)=CC=2)=C1[N+]([O-])=O TWNLUCSCGWJPQM-UHFFFAOYSA-N 0.000 description 1
- USROCANANSEKCK-UHFFFAOYSA-N ethyl 1-[5-nitro-6-[4-(thiadiazol-4-yl)anilino]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)C=2N=NSC=2)=C1[N+]([O-])=O USROCANANSEKCK-UHFFFAOYSA-N 0.000 description 1
- UNIAYOUJRVTMRW-UHFFFAOYSA-N ethyl 1-[5-nitro-6-[4-(thiadiazol-4-yl)phenoxy]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)C=2N=NSC=2)=C1[N+]([O-])=O UNIAYOUJRVTMRW-UHFFFAOYSA-N 0.000 description 1
- JCOFDFRBRSODDQ-UHFFFAOYSA-N ethyl 1-[5-nitro-6-[4-(trifluoromethylsulfonyl)anilino]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=C1[N+]([O-])=O JCOFDFRBRSODDQ-UHFFFAOYSA-N 0.000 description 1
- NFJRJWWWGWMHLP-UHFFFAOYSA-N ethyl 1-[6-(1,3-benzodioxol-5-ylamino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=C3OCOC3=CC=2)=C1[N+]([O-])=O NFJRJWWWGWMHLP-UHFFFAOYSA-N 0.000 description 1
- KLLWWSNLDYSKIH-UHFFFAOYSA-N ethyl 1-[6-(1,3-benzodioxol-5-ylmethylamino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NCC=2C=C3OCOC3=CC=2)=C1[N+]([O-])=O KLLWWSNLDYSKIH-UHFFFAOYSA-N 0.000 description 1
- MRDUOEHISUEQKO-UHFFFAOYSA-N ethyl 1-[6-(2,5-dimethoxyanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C(=CC=C(OC)C=2)OC)=C1[N+]([O-])=O MRDUOEHISUEQKO-UHFFFAOYSA-N 0.000 description 1
- OENAFZWTMADYCH-UHFFFAOYSA-N ethyl 1-[6-(2-amino-4-ethylsulfonylphenoxy)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C(=CC(=CC=2)S(=O)(=O)CC)N)=C1[N+]([O-])=O OENAFZWTMADYCH-UHFFFAOYSA-N 0.000 description 1
- MAISMEIJSAHGQK-UHFFFAOYSA-N ethyl 1-[6-(2-benzoyl-5-methoxyphenoxy)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C(=CC=C(OC)C=2)C(=O)C=2C=CC=CC=2)=C1[N+]([O-])=O MAISMEIJSAHGQK-UHFFFAOYSA-N 0.000 description 1
- GEZNIHVTVCTWLO-UHFFFAOYSA-N ethyl 1-[6-(2-fluoroanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C(=CC=CC=2)F)=C1[N+]([O-])=O GEZNIHVTVCTWLO-UHFFFAOYSA-N 0.000 description 1
- HMWRBNFHOJXPAJ-UHFFFAOYSA-N ethyl 1-[6-(2-methoxyanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C(=CC=CC=2)OC)=C1[N+]([O-])=O HMWRBNFHOJXPAJ-UHFFFAOYSA-N 0.000 description 1
- YCAIDNAZBUSZQV-UHFFFAOYSA-N ethyl 1-[6-(3,4-dihydro-2h-1,5-benzodioxepin-7-ylamino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=C3OCCCOC3=CC=2)=C1[N+]([O-])=O YCAIDNAZBUSZQV-UHFFFAOYSA-N 0.000 description 1
- QJZSZLBKUDJMSE-UHFFFAOYSA-N ethyl 1-[6-(3-fluoroanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=C(F)C=CC=2)=C1[N+]([O-])=O QJZSZLBKUDJMSE-UHFFFAOYSA-N 0.000 description 1
- BZOZLFDYKVNABV-UHFFFAOYSA-N ethyl 1-[6-(3-methoxyanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=C(OC)C=CC=2)=C1[N+]([O-])=O BZOZLFDYKVNABV-UHFFFAOYSA-N 0.000 description 1
- QIXRWHNWCLYVCF-UHFFFAOYSA-N ethyl 1-[6-(4-acetylphenoxy)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)C(C)=O)=C1[N+]([O-])=O QIXRWHNWCLYVCF-UHFFFAOYSA-N 0.000 description 1
- PBDKASMGVNGAJF-UHFFFAOYSA-N ethyl 1-[6-(4-cyclohexylanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)C2CCCCC2)=C1[N+]([O-])=O PBDKASMGVNGAJF-UHFFFAOYSA-N 0.000 description 1
- KYKWCYALXHOIOT-UHFFFAOYSA-N ethyl 1-[6-(4-imidazol-1-ylphenoxy)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)N2C=NC=C2)=C1[N+]([O-])=O KYKWCYALXHOIOT-UHFFFAOYSA-N 0.000 description 1
- NMFLPNKHJXTHLM-UHFFFAOYSA-N ethyl 1-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O NMFLPNKHJXTHLM-UHFFFAOYSA-N 0.000 description 1
- GXDYPCVLMNSCLA-UHFFFAOYSA-N ethyl 1-[6-(4-methylsulfonylphenoxy)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O GXDYPCVLMNSCLA-UHFFFAOYSA-N 0.000 description 1
- RYIPABQIIBFYJC-UHFFFAOYSA-N ethyl 1-[6-(4-morpholin-4-ylsulfonylanilino)-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=C1[N+]([O-])=O RYIPABQIIBFYJC-UHFFFAOYSA-N 0.000 description 1
- XNBABNCOAPFYAA-UHFFFAOYSA-N ethyl 1-[6-[4-(1,3-dioxoisoindol-2-yl)phenoxy]-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)N2C(C3=CC=CC=C3C2=O)=O)=C1[N+]([O-])=O XNBABNCOAPFYAA-UHFFFAOYSA-N 0.000 description 1
- USWBOYMNSYZWNF-UHFFFAOYSA-N ethyl 1-[6-[4-(2,5-dioxoimidazolidin-4-yl)phenoxy]-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)C2C(NC(=O)N2)=O)=C1[N+]([O-])=O USWBOYMNSYZWNF-UHFFFAOYSA-N 0.000 description 1
- MFVNFBBCWPFVQS-UHFFFAOYSA-N ethyl 1-[6-[4-(2-amino-2-oxoethyl)phenoxy]-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(CC(N)=O)=CC=2)=C1[N+]([O-])=O MFVNFBBCWPFVQS-UHFFFAOYSA-N 0.000 description 1
- WVXNTMHIBPWSRW-UHFFFAOYSA-N ethyl 1-[6-[4-(3-methoxy-3-oxopropanoyl)phenoxy]-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(=CC=2)C(=O)CC(=O)OC)=C1[N+]([O-])=O WVXNTMHIBPWSRW-UHFFFAOYSA-N 0.000 description 1
- COVKRAWWJVXGGD-UHFFFAOYSA-N ethyl 1-[6-[4-(3-oxobutyl)phenoxy]-5-[(2,2,2-trifluoroacetyl)amino]pyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(OC=2C=CC(CCC(C)=O)=CC=2)=C1NC(=O)C(F)(F)F COVKRAWWJVXGGD-UHFFFAOYSA-N 0.000 description 1
- WZRQWJLHODGALH-UHFFFAOYSA-N ethyl 1-[6-[4-(4,5-dichloroimidazol-1-yl)anilino]-5-nitropyrimidin-4-yl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)N2C(=C(Cl)N=C2)Cl)=C1[N+]([O-])=O WZRQWJLHODGALH-UHFFFAOYSA-N 0.000 description 1
- GVBFWCNJDPQJJX-UHFFFAOYSA-N ethyl 2-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C GVBFWCNJDPQJJX-UHFFFAOYSA-N 0.000 description 1
- LJBGACMVHUTXDX-UHFFFAOYSA-N ethyl 2-[4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]piperazin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCN1C1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O LJBGACMVHUTXDX-UHFFFAOYSA-N 0.000 description 1
- XSJKPDMYTHWJBA-UHFFFAOYSA-N ethyl 3-[4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound C1CN(CCC(=O)OCC)CCN1C1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 XSJKPDMYTHWJBA-UHFFFAOYSA-N 0.000 description 1
- ZPFPHIJNUJHJIJ-UHFFFAOYSA-N ethyl 4-[5-cyano-6-(4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1C#N ZPFPHIJNUJHJIJ-UHFFFAOYSA-N 0.000 description 1
- HNESUBILRWZIJH-UHFFFAOYSA-N ethyl 4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O HNESUBILRWZIJH-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- AQDDZAJCMCBECB-UHFFFAOYSA-N hexyl piperidine-1-carboxylate Chemical compound CCCCCCOC(=O)N1CCCCC1 AQDDZAJCMCBECB-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical group CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- ZUVAACFIEPYYOP-UHFFFAOYSA-N methoxycyclopropane Chemical compound COC1CC1 ZUVAACFIEPYYOP-UHFFFAOYSA-N 0.000 description 1
- HYZMYHIJRJWKSO-UHFFFAOYSA-N methyl 2-[1-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]piperidin-4-yl]acetate Chemical compound C1CC(CC(=O)OC)CCN1C1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 HYZMYHIJRJWKSO-UHFFFAOYSA-N 0.000 description 1
- QPBAZGXESLNBNB-UHFFFAOYSA-N methyl 3-[4-[4-nitro-3-(4-propylpiperidin-1-yl)phenoxy]phenyl]-3-oxopropanoate Chemical compound C1CC(CCC)CCN1C1=CC(OC=2C=CC(=CC=2)C(=O)CC(=O)OC)=CC=C1[N+]([O-])=O QPBAZGXESLNBNB-UHFFFAOYSA-N 0.000 description 1
- KWTBIADLTODBKF-UHFFFAOYSA-N methyl 3-[4-[5-nitro-6-(4-propylpiperidin-1-yl)pyridin-2-yl]oxyphenyl]-3-oxopropanoate Chemical compound C1CC(CCC)CCN1C1=NC(OC=2C=CC(=CC=2)C(=O)CC(=O)OC)=CC=C1[N+]([O-])=O KWTBIADLTODBKF-UHFFFAOYSA-N 0.000 description 1
- YKFLJYAKACCWMH-UHFFFAOYSA-N methyl piperidine-1-carboxylate Chemical compound COC(=O)N1CCCCC1 YKFLJYAKACCWMH-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- INKFQKXIPIYIOI-UHFFFAOYSA-N n,n-dimethyl-1-[4-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-6-[4-(thiadiazol-4-yl)phenoxy]pyrimidin-5-yl]methanamine Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(OC=3C=CC(=CC=3)C=3N=NSC=3)N=CN=2)CN(C)C)=N1 INKFQKXIPIYIOI-UHFFFAOYSA-N 0.000 description 1
- MIKPNFRHUSSWPW-UHFFFAOYSA-N n-(2-fluoro-4-methylsulfonylphenyl)-5-methyl-6-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]oxypyrimidin-4-amine Chemical compound CC(C)C1=NOC(N2CCC(CC2)OC=2C(=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)C)=N1 MIKPNFRHUSSWPW-UHFFFAOYSA-N 0.000 description 1
- DGBKNTVAKIFYNU-UHFFFAOYSA-N n-(2-fluoro-4-methylsulfonylphenyl)-5-nitro-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidin-4-amine Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(NC=3C(=CC(=CC=3)S(C)(=O)=O)F)N=CN=2)N(=O)=O)=N1 DGBKNTVAKIFYNU-UHFFFAOYSA-N 0.000 description 1
- BTBNZCCPHWAHGE-UHFFFAOYSA-N n-(2-methylphenyl)piperidine-1-carboxamide Chemical compound CC1=CC=CC=C1NC(=O)N1CCCCC1 BTBNZCCPHWAHGE-UHFFFAOYSA-N 0.000 description 1
- VRBVIBUXYLJGPL-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-(1-pyridin-2-ylpiperidin-4-yl)oxypyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C=2N=CC=CC=2)=C1[N+]([O-])=O VRBVIBUXYLJGPL-UHFFFAOYSA-N 0.000 description 1
- TUAJGEOZZGFFFZ-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-[1-(pyridin-3-ylmethyl)piperidin-4-yl]oxypyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCN(CC=3C=NC=CC=3)CC2)=C1[N+]([O-])=O TUAJGEOZZGFFFZ-UHFFFAOYSA-N 0.000 description 1
- GWURHCBAFSQBSE-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidin-4-amine Chemical compound CC(C)C1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)[N+]([O-])=O)=N1 GWURHCBAFSQBSE-UHFFFAOYSA-N 0.000 description 1
- HROYOPFZZRTECV-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-[4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidin-4-amine Chemical compound CCCC1=NOC(C2CCN(CC2)C=2C(=C(NC=3C=CC(=CC=3)S(C)(=O)=O)N=CN=2)[N+]([O-])=O)=N1 HROYOPFZZRTECV-UHFFFAOYSA-N 0.000 description 1
- JRHLLUIOJYVERA-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-[4-[3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]piperidin-1-yl]pyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(N2CCC(CC2)C=2ON=C(N=2)C=2C=C(C=CC=2)C(F)(F)F)=C1[N+]([O-])=O JRHLLUIOJYVERA-UHFFFAOYSA-N 0.000 description 1
- XUNXHDLCZVOLCL-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]pyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(N2CCC(CC2)OC=2C=CC(OC(F)(F)F)=CC=2)=C1[N+]([O-])=O XUNXHDLCZVOLCL-UHFFFAOYSA-N 0.000 description 1
- LFEOJANOTHGPSD-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-5-nitro-6-piperidin-4-yloxypyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=NC(OC2CCNCC2)=C1[N+]([O-])=O LFEOJANOTHGPSD-UHFFFAOYSA-N 0.000 description 1
- WPZQMLXTSSMDFM-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)-6-(1-methylsulfonylpiperidin-4-yl)oxy-5-nitropyrimidin-4-amine Chemical compound C1CN(S(=O)(=O)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O WPZQMLXTSSMDFM-UHFFFAOYSA-N 0.000 description 1
- OABPOTFGQCRYQD-UHFFFAOYSA-N n-(4-pentylcyclohexyl)-3-pyridin-4-yl-1,2,4-oxadiazole-5-carboxamide Chemical compound C1CC(CCCCC)CCC1NC(=O)C1=NC(C=2C=CN=CC=2)=NO1 OABPOTFGQCRYQD-UHFFFAOYSA-N 0.000 description 1
- ALLGAVICJHZNDU-UHFFFAOYSA-N n-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxycyclohexyl]-2-methylpropanamide Chemical compound C1CC(NC(=O)C(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C ALLGAVICJHZNDU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006095 n-butyl sulfinyl group Chemical group 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- YVWNKJAXQSRBPM-UHFFFAOYSA-N n-ethyl-n-methylmethanethioamide Chemical compound CCN(C)C=S YVWNKJAXQSRBPM-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- HXXAUIXTYRHFNO-UHFFFAOYSA-N n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=CC=CC=N1 HXXAUIXTYRHFNO-UHFFFAOYSA-N 0.000 description 1
- 125000006093 n-propyl sulfinyl group Chemical group 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- BYLSLFMFQJERRE-UHFFFAOYSA-N n-propylpiperidine-1-carboxamide Chemical compound CCCNC(=O)N1CCCCC1 BYLSLFMFQJERRE-UHFFFAOYSA-N 0.000 description 1
- DYQYKXUACSASLT-UHFFFAOYSA-N naphthalen-2-yl piperidine-1-carboxylate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=O)N1CCCCC1 DYQYKXUACSASLT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- NTTFOMBFOAWBPA-UHFFFAOYSA-N oxan-4-yl piperidine-1-carboxylate Chemical compound O=C(OC1CCOCC1)N1CCCCC1 NTTFOMBFOAWBPA-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002263 peptidergic effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- GGZDLAOKPXEJCP-UHFFFAOYSA-N phenyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OC1=CC=CC=C1 GGZDLAOKPXEJCP-UHFFFAOYSA-N 0.000 description 1
- BGSLLNIHQOTSTE-UHFFFAOYSA-N phenyl-[4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methoxy]piperidin-1-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)N(CC1)CCC1OCC(ON=1)=NC=1C1=CC=NC=C1 BGSLLNIHQOTSTE-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- GDMFMEIHLSAJSY-UHFFFAOYSA-N prop-2-ynyl piperidine-1-carboxylate Chemical compound C#CCOC(=O)N1CCCCC1 GDMFMEIHLSAJSY-UHFFFAOYSA-N 0.000 description 1
- VLSHTPJNQQKCJM-UHFFFAOYSA-N propan-2-yl 4-[2-(2-fluoro-4-methylsulfonylanilino)-3-methylpyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C VLSHTPJNQQKCJM-UHFFFAOYSA-N 0.000 description 1
- WTFZEZMAEDSYRC-UHFFFAOYSA-N propan-2-yl 4-[2-(2-fluoro-4-methylsulfonylanilino)pyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1 WTFZEZMAEDSYRC-UHFFFAOYSA-N 0.000 description 1
- WNTHAKJCMKXUDR-UHFFFAOYSA-N propan-2-yl 4-[2-[2,5-difluoro-4-(2-methylsulfonylethyl)phenoxy]-3-methylpyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC(OC=2C(=CC(CCS(C)(=O)=O)=C(F)C=2)F)=C1C WNTHAKJCMKXUDR-UHFFFAOYSA-N 0.000 description 1
- KBLJCVRPWDNHPJ-UHFFFAOYSA-N propan-2-yl 4-[2-[2,5-difluoro-4-(2-propan-2-yloxyethyl)phenoxy]-3-methylpyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(CCOC(C)C)=CC(F)=C1OC1=NC=CC(OC2CCN(CC2)C(=O)OC(C)C)=C1C KBLJCVRPWDNHPJ-UHFFFAOYSA-N 0.000 description 1
- LFSRYXORERTEMP-UHFFFAOYSA-N propan-2-yl 4-[2-[2-fluoro-4-[2-(6-methoxypyridin-2-yl)ethyl]phenoxy]-3-methylpyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound COC1=CC=CC(CCC=2C=C(F)C(OC=3C(=C(OC4CCN(CC4)C(=O)OC(C)C)C=CN=3)C)=CC=2)=N1 LFSRYXORERTEMP-UHFFFAOYSA-N 0.000 description 1
- CEUZULGFNSAYSX-UHFFFAOYSA-N propan-2-yl 4-[2-[[4-fluoro-6-(2-propan-2-yloxyethyl)pyridin-3-yl]amino]-3-methylpyridin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(CCOC(C)C)=CC(F)=C1NC1=NC=CC(OC2CCN(CC2)C(=O)OC(C)C)=C1C CEUZULGFNSAYSX-UHFFFAOYSA-N 0.000 description 1
- WDYHVUSCFINZEA-UHFFFAOYSA-N propan-2-yl 4-[3-(2,5-difluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=C(F)C=3)S(C)(=O)=O)F)C=NN12 WDYHVUSCFINZEA-UHFFFAOYSA-N 0.000 description 1
- POPWUQJCXNHYKH-UHFFFAOYSA-N propan-2-yl 4-[3-(2,5-difluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=C(F)C=3)S(N)(=O)=O)F)C(C)=NN12 POPWUQJCXNHYKH-UHFFFAOYSA-N 0.000 description 1
- PHJDWLNEKRKKHH-UHFFFAOYSA-N propan-2-yl 4-[3-(2,5-difluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=C(F)C=3)S(N)(=O)=O)F)C=NN12 PHJDWLNEKRKKHH-UHFFFAOYSA-N 0.000 description 1
- WLUXCCCLEHWGML-UHFFFAOYSA-N propan-2-yl 4-[3-(2-fluoro-4-methylsulfonylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)S(C)(=O)=O)F)C(C)=NN12 WLUXCCCLEHWGML-UHFFFAOYSA-N 0.000 description 1
- OXFRQGBZAOAAJP-UHFFFAOYSA-N propan-2-yl 4-[3-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)S(C)(=O)=O)F)C=NN12 OXFRQGBZAOAAJP-UHFFFAOYSA-N 0.000 description 1
- DRJMANHBGGZYIE-UHFFFAOYSA-N propan-2-yl 4-[3-(2-fluoro-4-sulfamoylphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)S(N)(=O)=O)F)C(C)=NN12 DRJMANHBGGZYIE-UHFFFAOYSA-N 0.000 description 1
- UFZCAEZHOSUKPD-UHFFFAOYSA-N propan-2-yl 4-[3-(2-fluoro-4-sulfamoylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)S(N)(=O)=O)F)C=NN12 UFZCAEZHOSUKPD-UHFFFAOYSA-N 0.000 description 1
- RPGQPTPPGWETOU-UHFFFAOYSA-N propan-2-yl 4-[3-(4-cyano-2-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)C#N)F)C(C)=NN12 RPGQPTPPGWETOU-UHFFFAOYSA-N 0.000 description 1
- JUWATTDUKJRXLE-UHFFFAOYSA-N propan-2-yl 4-[3-(4-cyano-2-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)C#N)F)C=NN12 JUWATTDUKJRXLE-UHFFFAOYSA-N 0.000 description 1
- JNDBXPXVCBVVAC-UHFFFAOYSA-N propan-2-yl 4-[3-(4-fluoro-6-methoxypyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(F)=C1C1=C2N=CC=C(OC3CCN(CC3)C(=O)OC(C)C)N2N=C1C JNDBXPXVCBVVAC-UHFFFAOYSA-N 0.000 description 1
- LHGFEAVUZHKAFX-UHFFFAOYSA-N propan-2-yl 4-[3-(4-fluoro-6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(F)=C1C1=C2N=CC=C(OC3CCN(CC3)C(=O)OC(C)C)N2N=C1 LHGFEAVUZHKAFX-UHFFFAOYSA-N 0.000 description 1
- LCBZIZFTFLYOOV-UHFFFAOYSA-N propan-2-yl 4-[3-(6-methoxy-2-methylpyridin-3-yl)-2-methylpyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(OC)=CC=C1C1=C2N=CC=C(OC3CCN(CC3)C(=O)OC(C)C)N2N=C1C LCBZIZFTFLYOOV-UHFFFAOYSA-N 0.000 description 1
- SQUYWSVDHNECNX-UHFFFAOYSA-N propan-2-yl 4-[3-(6-methoxy-2-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(OC)=CC=C1C1=C2N=CC=C(OC3CCN(CC3)C(=O)OC(C)C)N2N=C1 SQUYWSVDHNECNX-UHFFFAOYSA-N 0.000 description 1
- RIQAUXFZWARQFW-UHFFFAOYSA-N propan-2-yl 4-[3-[2-fluoro-4-(propanoylsulfamoyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C2N=CC=C(OC3CCN(CC3)C(=O)OC(C)C)N2N=C1 RIQAUXFZWARQFW-UHFFFAOYSA-N 0.000 description 1
- IRHPLMSUIKDMNJ-UHFFFAOYSA-N propan-2-yl 4-[4-(2,5-difluoro-4-propoxyanilino)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(OCCC)=CC(F)=C1NC1=CC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1 IRHPLMSUIKDMNJ-UHFFFAOYSA-N 0.000 description 1
- HXNTVPOOUIAYTL-UHFFFAOYSA-N propan-2-yl 4-[4-(2-fluoro-4-methylsulfonylanilino)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=CC=N1 HXNTVPOOUIAYTL-UHFFFAOYSA-N 0.000 description 1
- XOFFKTUZMXASTG-UHFFFAOYSA-N propan-2-yl 4-[5-(4,5-dihydro-1h-imidazol-2-yl)-6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C1=NCCN1 XOFFKTUZMXASTG-UHFFFAOYSA-N 0.000 description 1
- XJELELVSKDQYKQ-UHFFFAOYSA-N propan-2-yl 4-[5-[5-(aminomethyl)-4,5-dihydro-1,3-oxazol-2-yl]-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C1=NCC(CN)O1 XJELELVSKDQYKQ-UHFFFAOYSA-N 0.000 description 1
- SMWDTNDEYIYXGI-UHFFFAOYSA-N propan-2-yl 4-[5-bromo-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1Br SMWDTNDEYIYXGI-UHFFFAOYSA-N 0.000 description 1
- UFPPXZUZWIIQDL-UHFFFAOYSA-N propan-2-yl 4-[5-carbamimidoyl-6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C(N)=N UFPPXZUZWIIQDL-UHFFFAOYSA-N 0.000 description 1
- NVWKVJUUHMVAHP-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C#N NVWKVJUUHMVAHP-UHFFFAOYSA-N 0.000 description 1
- IIWJSOPCZMPNBO-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-(2-fluoro-4-morpholin-4-ylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)N2CCOCC2)F)=C1C#N IIWJSOPCZMPNBO-UHFFFAOYSA-N 0.000 description 1
- UVCUVCOHDKPTOG-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-(2-fluoro-4-propoxyanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#N UVCUVCOHDKPTOG-UHFFFAOYSA-N 0.000 description 1
- ZGOPWDALEZDINW-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-(4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1C#N ZGOPWDALEZDINW-UHFFFAOYSA-N 0.000 description 1
- ONEGEOSMERMMDR-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[(6-propylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(CCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#N ONEGEOSMERMMDR-UHFFFAOYSA-N 0.000 description 1
- MHIDRCFZWUCOSL-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[2-fluoro-4-(2-morpholin-4-ylethylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(NCCN3CCOCC3)=CC=2)F)=C1C#N MHIDRCFZWUCOSL-UHFFFAOYSA-N 0.000 description 1
- YVXGVLKPEQJEPG-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[2-fluoro-4-(2-pyrrolidin-1-ylethylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(NCCN3CCCC3)=CC=2)F)=C1C#N YVXGVLKPEQJEPG-UHFFFAOYSA-N 0.000 description 1
- VRVXDOBTSLINTI-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[2-fluoro-4-(3-methylbutylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCCC(C)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#N VRVXDOBTSLINTI-UHFFFAOYSA-N 0.000 description 1
- WEUFCMGXSAILNL-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[2-fluoro-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)N2CCN(C)CC2)F)=C1C#N WEUFCMGXSAILNL-UHFFFAOYSA-N 0.000 description 1
- OJWWCLRQAYXWHQ-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[2-fluoro-4-(propan-2-ylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NC(C)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#N OJWWCLRQAYXWHQ-UHFFFAOYSA-N 0.000 description 1
- ULKZWDWAKWQMCA-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[2-fluoro-4-(propylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#N ULKZWDWAKWQMCA-UHFFFAOYSA-N 0.000 description 1
- OKYGASFAGXYSMY-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[4-(dimethylamino)-2-fluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)N(C)C)F)=C1C#N OKYGASFAGXYSMY-UHFFFAOYSA-N 0.000 description 1
- RJHKZBZJQXUFBL-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[4-[2-(dimethylamino)ethylamino]-2-fluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(NCCN(C)C)=CC=2)F)=C1C#N RJHKZBZJQXUFBL-UHFFFAOYSA-N 0.000 description 1
- LRDAVDJNHCZLKV-UHFFFAOYSA-N propan-2-yl 4-[5-cyano-6-[4-[2-(dimethylamino)ethylsulfanyl]-2-fluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(SCCN(C)C)=CC=2)F)=C1C#N LRDAVDJNHCZLKV-UHFFFAOYSA-N 0.000 description 1
- GLEFIHVIKTXUSU-UHFFFAOYSA-N propan-2-yl 4-[5-cyclopropyl-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C1CC1 GLEFIHVIKTXUSU-UHFFFAOYSA-N 0.000 description 1
- JSBHSPILXBGXRZ-UHFFFAOYSA-N propan-2-yl 4-[5-cyclopropyl-6-[2,5-difluoro-4-(2-hydroxyethyl)phenoxy]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCO)=C(F)C=2)F)=C1C1CC1 JSBHSPILXBGXRZ-UHFFFAOYSA-N 0.000 description 1
- BLJFHEBWFZVSLY-UHFFFAOYSA-N propan-2-yl 4-[5-cyclopropyl-6-[2,5-difluoro-4-[2-(4-methoxypiperidin-1-yl)ethyl]phenoxy]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CC(OC)CCN1CCC(C(=C1)F)=CC(F)=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C1CC1 BLJFHEBWFZVSLY-UHFFFAOYSA-N 0.000 description 1
- DWGLJNMTLMWAGV-UHFFFAOYSA-N propan-2-yl 4-[5-ethyl-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)C(CC)=C1OC1CCN(C(=O)OC(C)C)CC1 DWGLJNMTLMWAGV-UHFFFAOYSA-N 0.000 description 1
- CQGLAULLZACUKX-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-(2-fluoro-4-methoxyphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#C CQGLAULLZACUKX-UHFFFAOYSA-N 0.000 description 1
- BRCVBBIOAMGPAQ-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-(2-fluoro-4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C#C BRCVBBIOAMGPAQ-UHFFFAOYSA-N 0.000 description 1
- CXIDIXBNGNNZDR-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-(6-methoxy-4-methylpyridin-3-yl)oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(OC)=CC(C)=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#C CXIDIXBNGNNZDR-UHFFFAOYSA-N 0.000 description 1
- XOCVTLMXWGXSKW-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-[2-fluoro-4-(1,2,4-triazol-1-yl)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)N2N=CN=C2)F)=C1C#C XOCVTLMXWGXSKW-UHFFFAOYSA-N 0.000 description 1
- XOJGSBQXOSXZOD-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-[2-fluoro-4-(1,2,4-triazol-4-yl)phenoxy]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)N2C=NN=C2)F)=C1C#C XOJGSBQXOSXZOD-UHFFFAOYSA-N 0.000 description 1
- QZAUTLFIZHJZLP-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-[2-fluoro-4-(4-methoxypyridin-2-yl)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound COC1=CC=NC(C=2C=C(F)C(NC=3C(=C(OC4CCN(CC4)C(=O)OC(C)C)N=CN=3)C#C)=CC=2)=C1 QZAUTLFIZHJZLP-UHFFFAOYSA-N 0.000 description 1
- PHMKVMKWZAJTMK-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-[2-methyl-6-(2-propan-2-yloxyethyl)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(CCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C#C PHMKVMKWZAJTMK-UHFFFAOYSA-N 0.000 description 1
- CVDNXRGLGVQJFR-UHFFFAOYSA-N propan-2-yl 4-[5-ethynyl-6-[4-fluoro-6-(2-methylsulfonylethyl)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCS(C)(=O)=O)=NC=2)F)=C1C#C CVDNXRGLGVQJFR-UHFFFAOYSA-N 0.000 description 1
- VXAYEYXNJNTNAB-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-(2-methyl-6-pentylpyridin-3-yl)oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(CCCCC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C VXAYEYXNJNTNAB-UHFFFAOYSA-N 0.000 description 1
- UAJJBUQONDWWPA-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-(4-methylsulfonylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C=CC(=CC=2)S(C)(=O)=O)=C1C UAJJBUQONDWWPA-UHFFFAOYSA-N 0.000 description 1
- AJMIEGQEMQXZKV-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-(5-methylsulfonylpyridin-2-yl)oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2N=CC(=CC=2)S(C)(=O)=O)=C1C AJMIEGQEMQXZKV-UHFFFAOYSA-N 0.000 description 1
- OMFIOAPERIXSTF-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[(2-methyl-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=NC(=CC=2)N2CCOCC2)C)=C1C OMFIOAPERIXSTF-UHFFFAOYSA-N 0.000 description 1
- VAUJLOXTAATAGO-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[(4-methyl-6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=NC=2)N2CCOCC2)C)=C1C VAUJLOXTAATAGO-UHFFFAOYSA-N 0.000 description 1
- SFFCCSGCCWMUIC-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-(2-methylsulfonylethylamino)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(NCCS(C)(=O)=O)=CC=2)C)=C1C SFFCCSGCCWMUIC-UHFFFAOYSA-N 0.000 description 1
- RLTJJAPYYDVBHI-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-(2-propan-2-yloxyethyl)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(CCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C RLTJJAPYYDVBHI-UHFFFAOYSA-N 0.000 description 1
- ZPWICAYIOJFSAF-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-(2-propan-2-yloxyethylamino)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(NCCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C ZPWICAYIOJFSAF-UHFFFAOYSA-N 0.000 description 1
- WSSOKQLEYYKNIE-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-(2-propan-2-yloxyethylsulfonyl)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(S(=O)(=O)CCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C WSSOKQLEYYKNIE-UHFFFAOYSA-N 0.000 description 1
- BHJOPJYQRQJFEX-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-(2-pyridin-2-ylethoxy)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(OCCC=3N=CC=CC=3)=CC=2)C)=C1C BHJOPJYQRQJFEX-UHFFFAOYSA-N 0.000 description 1
- YEFYWAQUIUARHT-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-(3-methylsulfonylpyrrolidin-1-yl)pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(=CC=2)N2CC(CC2)S(C)(=O)=O)C)=C1C YEFYWAQUIUARHT-UHFFFAOYSA-N 0.000 description 1
- QEMUYKYQTXITIU-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-[methyl(2-methylsulfonylethyl)amino]pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(=CC=2)N(C)CCS(C)(=O)=O)C)=C1C QEMUYKYQTXITIU-UHFFFAOYSA-N 0.000 description 1
- PXAAOZABLFMNNP-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[2-methyl-6-[methyl(2-propan-2-yloxyethyl)amino]pyridin-3-yl]oxypyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(N(C)CCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C PXAAOZABLFMNNP-UHFFFAOYSA-N 0.000 description 1
- RJEHJUKIPGAJNJ-UHFFFAOYSA-N propan-2-yl 4-[6-(2,4,5-trifluoroanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(F)=C(F)C=2)F)=NC=N1 RJEHJUKIPGAJNJ-UHFFFAOYSA-N 0.000 description 1
- GUWYXKOISXHDFW-UHFFFAOYSA-N propan-2-yl 4-[6-(2,4-difluoroanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(F)=CC=2)F)=NC=N1 GUWYXKOISXHDFW-UHFFFAOYSA-N 0.000 description 1
- NSLQLEXVLQPFCZ-UHFFFAOYSA-N propan-2-yl 4-[6-(2,4-difluorophenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(F)=CC=2)F)=C1C NSLQLEXVLQPFCZ-UHFFFAOYSA-N 0.000 description 1
- FUVPFNOSJYGLPK-UHFFFAOYSA-N propan-2-yl 4-[6-(2,5-difluoro-4-morpholin-4-ylanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=C(F)C=2)N2CCOCC2)F)=C1C FUVPFNOSJYGLPK-UHFFFAOYSA-N 0.000 description 1
- LDHMSVQGFURJOB-UHFFFAOYSA-N propan-2-yl 4-[6-(2,5-difluoro-4-propoxyanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(OCCC)=CC(F)=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C LDHMSVQGFURJOB-UHFFFAOYSA-N 0.000 description 1
- MVZDLBRCXWICSU-UHFFFAOYSA-N propan-2-yl 4-[6-(2,5-difluoro-4-propoxyanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(OCCC)=CC(F)=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 MVZDLBRCXWICSU-UHFFFAOYSA-N 0.000 description 1
- ZJWHLPLVFLFBFU-UHFFFAOYSA-N propan-2-yl 4-[6-(2-amino-4-ethylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound NC1=CC(S(=O)(=O)CC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C ZJWHLPLVFLFBFU-UHFFFAOYSA-N 0.000 description 1
- NHOPPOBAPJWQNM-UHFFFAOYSA-N propan-2-yl 4-[6-(2-ethynylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC=CC=2)C#C)=NC=N1 NHOPPOBAPJWQNM-UHFFFAOYSA-N 0.000 description 1
- JLWYHPYPRUVGBA-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-3-sulfamoylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=C(C=CC=2)S(N)(=O)=O)F)=C1C JLWYHPYPRUVGBA-UHFFFAOYSA-N 0.000 description 1
- VOYBGWALQDKVPD-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-iodoanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(I)=CC=2)F)=C1C VOYBGWALQDKVPD-UHFFFAOYSA-N 0.000 description 1
- DMTFDIDWLOADAJ-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-iodoanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(I)=CC=2)F)=NC=N1 DMTFDIDWLOADAJ-UHFFFAOYSA-N 0.000 description 1
- SUECYWWAVKOOKM-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-methylsulfonylanilino)-2-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC(C)=N1 SUECYWWAVKOOKM-UHFFFAOYSA-N 0.000 description 1
- CETAULDFJQHIIO-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-methylsulfonylanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C CETAULDFJQHIIO-UHFFFAOYSA-N 0.000 description 1
- ITOGFNYAJTTZDR-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-methylsulfonylanilino)-5-methylpyrimidin-4-yl]sulfanylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1SC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C ITOGFNYAJTTZDR-UHFFFAOYSA-N 0.000 description 1
- YZOGMKANXVWJME-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-methylsulfonylanilino)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 YZOGMKANXVWJME-UHFFFAOYSA-N 0.000 description 1
- PSTAUCWYFNORSZ-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 PSTAUCWYFNORSZ-UHFFFAOYSA-N 0.000 description 1
- FEGPUMZPRQGWFH-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C FEGPUMZPRQGWFH-UHFFFAOYSA-N 0.000 description 1
- DNEKWRVZWQYSII-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-morpholin-4-ylanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)N2CCOCC2)F)=C1C DNEKWRVZWQYSII-UHFFFAOYSA-N 0.000 description 1
- PKUSJNJJEBPHPA-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-morpholin-4-ylphenoxy)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(OC=2C(=CC(=CC=2)N2CCOCC2)F)=NC=N1 PKUSJNJJEBPHPA-UHFFFAOYSA-N 0.000 description 1
- YBGCQDOWMFZLQE-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-propoxyanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C YBGCQDOWMFZLQE-UHFFFAOYSA-N 0.000 description 1
- AUPWVYJZIQROJT-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluoro-4-sulfamoylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(N)(=O)=O)F)=C1C AUPWVYJZIQROJT-UHFFFAOYSA-N 0.000 description 1
- WRUCYROGZMLUFE-UHFFFAOYSA-N propan-2-yl 4-[6-(2-fluorophenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC=CC=2)F)=C1C WRUCYROGZMLUFE-UHFFFAOYSA-N 0.000 description 1
- RYCBZUIEKBLZGV-UHFFFAOYSA-N propan-2-yl 4-[6-(4-bromo-2,5-difluoroanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(Br)=C(F)C=2)F)=C1C RYCBZUIEKBLZGV-UHFFFAOYSA-N 0.000 description 1
- CMXAMJYUNZOYQN-UHFFFAOYSA-N propan-2-yl 4-[6-(4-bromo-2-fluorophenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(Br)=CC=2)F)=C1C CMXAMJYUNZOYQN-UHFFFAOYSA-N 0.000 description 1
- WBDSWKYSCKAMGZ-UHFFFAOYSA-N propan-2-yl 4-[6-(4-carbamimidoyl-2,5-difluoroanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=C(F)C=2)C(N)=N)F)=C1C WBDSWKYSCKAMGZ-UHFFFAOYSA-N 0.000 description 1
- VWBNSZCNUFREEU-UHFFFAOYSA-N propan-2-yl 4-[6-(4-carbamoyl-2,5-difluoroanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=C(F)C=2)C(N)=O)F)=C1C VWBNSZCNUFREEU-UHFFFAOYSA-N 0.000 description 1
- IIKFADUSHOWPEI-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2,5-difluoroanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=C(F)C=2)C#N)F)=C1C IIKFADUSHOWPEI-UHFFFAOYSA-N 0.000 description 1
- AFNALQQZDHLFHJ-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2,5-difluoroanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=C(F)C=2)C#N)F)=NC=N1 AFNALQQZDHLFHJ-UHFFFAOYSA-N 0.000 description 1
- LSAQYHDOWUSTHV-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2-fluoroanilino)-5-ethynylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)C#N)F)=C1C#C LSAQYHDOWUSTHV-UHFFFAOYSA-N 0.000 description 1
- YYTDPKRUHUGFKM-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2-fluoroanilino)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)C#N)F)=C1C YYTDPKRUHUGFKM-UHFFFAOYSA-N 0.000 description 1
- BFWSSKYVKIASLC-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2-fluoroanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=CC=2)C#N)F)=NC=N1 BFWSSKYVKIASLC-UHFFFAOYSA-N 0.000 description 1
- RROARNPQYHNTRB-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2-fluorophenoxy)-5-ethynylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C#N)F)=C1C#C RROARNPQYHNTRB-UHFFFAOYSA-N 0.000 description 1
- VRPRJOLHBHNXHS-UHFFFAOYSA-N propan-2-yl 4-[6-(4-cyano-2-fluorophenoxy)-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C#N)F)=C1C VRPRJOLHBHNXHS-UHFFFAOYSA-N 0.000 description 1
- KGEKANHOHUUFPI-UHFFFAOYSA-N propan-2-yl 4-[6-(4-iodo-2-methylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(I)=CC=2)C)=NC=N1 KGEKANHOHUUFPI-UHFFFAOYSA-N 0.000 description 1
- IUEPHVITGHGTSH-UHFFFAOYSA-N propan-2-yl 4-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O IUEPHVITGHGTSH-UHFFFAOYSA-N 0.000 description 1
- RDLIZLWKOVXEBQ-UHFFFAOYSA-N propan-2-yl 4-[6-(4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C=CC(=CC=2)S(C)(=O)=O)=NC=N1 RDLIZLWKOVXEBQ-UHFFFAOYSA-N 0.000 description 1
- YJITXWBXZZJMMH-UHFFFAOYSA-N propan-2-yl 4-[6-(5-iodopyridin-2-yl)oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2N=CC(I)=CC=2)=C1C YJITXWBXZZJMMH-UHFFFAOYSA-N 0.000 description 1
- AQVCVWMEYVQWBA-UHFFFAOYSA-N propan-2-yl 4-[6-(6-amino-2-methylpyridin-3-yl)oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(N)=CC=2)C)=C1C AQVCVWMEYVQWBA-UHFFFAOYSA-N 0.000 description 1
- CLODCVKGSVBCJT-UHFFFAOYSA-N propan-2-yl 4-[6-(6-chloro-2-methylpyridin-3-yl)oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(Cl)=CC=2)C)=C1C CLODCVKGSVBCJT-UHFFFAOYSA-N 0.000 description 1
- VBTKBUZLFSWDGM-UHFFFAOYSA-N propan-2-yl 4-[6-(n-acetyl-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(N(C(C)=O)C=2C=CC(=CC=2)S(C)(=O)=O)=NC=N1 VBTKBUZLFSWDGM-UHFFFAOYSA-N 0.000 description 1
- GMMNFFBWOIDBJZ-UHFFFAOYSA-N propan-2-yl 4-[6-(pyridin-3-ylamino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C=NC=CC=2)=NC=N1 GMMNFFBWOIDBJZ-UHFFFAOYSA-N 0.000 description 1
- NWDXYBFROZSNDM-UHFFFAOYSA-N propan-2-yl 4-[6-[(1-oxo-2,3-dihydroinden-5-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C=C3CCC(=O)C3=CC=2)=NC=N1 NWDXYBFROZSNDM-UHFFFAOYSA-N 0.000 description 1
- VIAFFAAKTXVMPH-UHFFFAOYSA-N propan-2-yl 4-[6-[(2-chloro-6-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=NC(C)=CC=2)Cl)=NC=N1 VIAFFAAKTXVMPH-UHFFFAOYSA-N 0.000 description 1
- WYKSVJYZJYJDFZ-UHFFFAOYSA-N propan-2-yl 4-[6-[(2-methyl-6-propoxypyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(OCCC)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 WYKSVJYZJYJDFZ-UHFFFAOYSA-N 0.000 description 1
- JOLWHJBMEAPQHG-UHFFFAOYSA-N propan-2-yl 4-[6-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2N(N=CC=2)C)=NC=N1 JOLWHJBMEAPQHG-UHFFFAOYSA-N 0.000 description 1
- OZWCAPHECOBYMY-UHFFFAOYSA-N propan-2-yl 4-[6-[(2-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=NC=CC=2)C)=NC=N1 OZWCAPHECOBYMY-UHFFFAOYSA-N 0.000 description 1
- HUFHYMFDZNCAIZ-UHFFFAOYSA-N propan-2-yl 4-[6-[(2-phenylpyrazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2N(N=CC=2)C=2C=CC=CC=2)=NC=N1 HUFHYMFDZNCAIZ-UHFFFAOYSA-N 0.000 description 1
- LGKZUVYLBVGYDD-UHFFFAOYSA-N propan-2-yl 4-[6-[(3,5-dimethyl-1,2-oxazol-4-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC2=C(ON=C2C)C)=NC=N1 LGKZUVYLBVGYDD-UHFFFAOYSA-N 0.000 description 1
- NKANVGOIVSOFDH-UHFFFAOYSA-N propan-2-yl 4-[6-[(4-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC=NC=2)C)=NC=N1 NKANVGOIVSOFDH-UHFFFAOYSA-N 0.000 description 1
- AMXCWWVGJXBZAW-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-bromo-3-methylpyridin-2-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(Br)=CN=2)C)=NC=N1 AMXCWWVGJXBZAW-UHFFFAOYSA-N 0.000 description 1
- YZNTXXIRSQUESH-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-carbamoylpyridin-2-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2N=CC(=CC=2)C(N)=O)=NC=N1 YZNTXXIRSQUESH-UHFFFAOYSA-N 0.000 description 1
- VFRMOBNVNQRJHQ-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC2=NNC(=C2)C2CC2)=NC=N1 VFRMOBNVNQRJHQ-UHFFFAOYSA-N 0.000 description 1
- FLONPPLQPMEXDM-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC2=NNC(C)=C2)=NC=N1 FLONPPLQPMEXDM-UHFFFAOYSA-N 0.000 description 1
- LKIWURSDKHECEH-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-oxo-1-phenyl-4h-pyrazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2CC(=O)N(N=2)C=2C=CC=CC=2)=NC=N1 LKIWURSDKHECEH-UHFFFAOYSA-N 0.000 description 1
- UIWIZRHAFOBCIU-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-pyridin-2-ylthiophen-2-yl)methylamino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NCC=2SC(=CC=2)C=2N=CC=CC=2)=NC=N1 UIWIZRHAFOBCIU-UHFFFAOYSA-N 0.000 description 1
- IHGHQSGRWVNGMP-UHFFFAOYSA-N propan-2-yl 4-[6-[(5-tert-butyl-1h-pyrazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC2=NNC(=C2)C(C)(C)C)=NC=N1 IHGHQSGRWVNGMP-UHFFFAOYSA-N 0.000 description 1
- AZOJZEMNGYADTQ-UHFFFAOYSA-N propan-2-yl 4-[6-[(6-chloro-2-methylpyridin-3-yl)amino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=NC(Cl)=CC=2)C)=C1C AZOJZEMNGYADTQ-UHFFFAOYSA-N 0.000 description 1
- ZLAWJAASCHLJCK-UHFFFAOYSA-N propan-2-yl 4-[6-[(6-chloro-4-methylpyridin-3-yl)amino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(Cl)=NC=2)C)=C1C ZLAWJAASCHLJCK-UHFFFAOYSA-N 0.000 description 1
- GGYUKZAQLVTASR-UHFFFAOYSA-N propan-2-yl 4-[6-[(6-methoxy-5-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(C)C(OC)=NC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 GGYUKZAQLVTASR-UHFFFAOYSA-N 0.000 description 1
- XAEYTTRKVBAYIB-UHFFFAOYSA-N propan-2-yl 4-[6-[(6-methyl-1h-pyrazolo[3,4-b]pyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C3=CC=C(C)N=C3NN=2)=NC=N1 XAEYTTRKVBAYIB-UHFFFAOYSA-N 0.000 description 1
- VDBCCUGLGGFEIB-UHFFFAOYSA-N propan-2-yl 4-[6-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C=NC(=CC=2)N2CCOCC2)=NC=N1 VDBCCUGLGGFEIB-UHFFFAOYSA-N 0.000 description 1
- BMQSCHGXCKJSKE-UHFFFAOYSA-N propan-2-yl 4-[6-[2,3-difluoro-4-(2-methylsulfonylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=C(F)C(CCS(C)(=O)=O)=CC=2)F)=C1C BMQSCHGXCKJSKE-UHFFFAOYSA-N 0.000 description 1
- CTOMSGBVBCDWOU-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-methoxyethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(OCCOC)=CC(F)=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C CTOMSGBVBCDWOU-UHFFFAOYSA-N 0.000 description 1
- BDAMTBLEWDZXRW-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-methoxyethylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(NCCOC)=CC(F)=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 BDAMTBLEWDZXRW-UHFFFAOYSA-N 0.000 description 1
- BBVNUJZNCLCSPS-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-methylsulfonylethyl)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(CCS(C)(=O)=O)=C(F)C=2)F)=C1C BBVNUJZNCLCSPS-UHFFFAOYSA-N 0.000 description 1
- TWOGYGUGMDXEQY-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-methylsulfonylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCS(C)(=O)=O)=C(F)C=2)F)=C1C TWOGYGUGMDXEQY-UHFFFAOYSA-N 0.000 description 1
- QYMAMNRZZIRWOD-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-morpholin-4-ylethoxy)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(OCCN3CCOCC3)=C(F)C=2)F)=NC=N1 QYMAMNRZZIRWOD-UHFFFAOYSA-N 0.000 description 1
- JNLNGMYUDUZZRW-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-morpholin-4-ylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCN3CCOCC3)=C(F)C=2)F)=C1C JNLNGMYUDUZZRW-UHFFFAOYSA-N 0.000 description 1
- AHVJNESGMPGPKN-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-morpholin-4-ylethylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(NCCN3CCOCC3)=C(F)C=2)F)=NC=N1 AHVJNESGMPGPKN-UHFFFAOYSA-N 0.000 description 1
- UWAOBSJCCOLEOK-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(OCCN3CCCC3)=C(F)C=2)F)=NC=N1 UWAOBSJCCOLEOK-UHFFFAOYSA-N 0.000 description 1
- AHBZBSIQXPCAGE-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(2-sulfamoylethyl)phenoxy]-5-ethynylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCS(N)(=O)=O)=C(F)C=2)F)=C1C#C AHBZBSIQXPCAGE-UHFFFAOYSA-N 0.000 description 1
- YUZGOHPWZZQSQC-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(3-methylbutylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(NCCC(C)C)=CC(F)=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 YUZGOHPWZZQSQC-UHFFFAOYSA-N 0.000 description 1
- CLUPQVQBTZWALO-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=C(F)C=2)N2CCN(C)CC2)F)=NC=N1 CLUPQVQBTZWALO-UHFFFAOYSA-N 0.000 description 1
- IRUWASXJUJMAEU-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(morpholin-4-ylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(NN3CCOCC3)=C(F)C=2)F)=NC=N1 IRUWASXJUJMAEU-UHFFFAOYSA-N 0.000 description 1
- DOBNBZHQAKHFLH-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(oxolan-2-ylmethoxy)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(OCC3OCCC3)=C(F)C=2)F)=NC=N1 DOBNBZHQAKHFLH-UHFFFAOYSA-N 0.000 description 1
- CVCJKAXSNXNZRB-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(oxolan-2-ylmethylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(NCC3OCCC3)=C(F)C=2)F)=NC=N1 CVCJKAXSNXNZRB-UHFFFAOYSA-N 0.000 description 1
- QGCFLMKKPXDPKJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(trifluoromethoxy)phenoxy]-5-ethynylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(OC(F)(F)F)=C(F)C=2)F)=C1C#C QGCFLMKKPXDPKJ-UHFFFAOYSA-N 0.000 description 1
- VEBXRJLVZHNWFN-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-(trifluoromethoxy)phenoxy]-5-prop-1-ynylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC=2C(=CC(OC(F)(F)F)=C(F)C=2)F)C(C#CC)=C1OC1CCN(C(=O)OC(C)C)CC1 VEBXRJLVZHNWFN-UHFFFAOYSA-N 0.000 description 1
- PISKBNYLTUJSMW-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-[2-(1,2,4-triazol-1-yl)ethyl]anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(CCN3N=CN=C3)=C(F)C=2)F)=C1C PISKBNYLTUJSMW-UHFFFAOYSA-N 0.000 description 1
- CNVZZGBGSOXLBJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2,5-difluoro-4-[2-(3-methoxypiperidin-1-yl)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1C(OC)CCCN1CCC(C(=C1)F)=CC(F)=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C CNVZZGBGSOXLBJ-UHFFFAOYSA-N 0.000 description 1
- HAXGOWDKEMRTJS-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-hydroxyethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(OCCO)=CC=2)F)=C1C HAXGOWDKEMRTJS-UHFFFAOYSA-N 0.000 description 1
- YMLFKNYAQKEKMT-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-hydroxyethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCO)=CC=2)F)=C1C YMLFKNYAQKEKMT-UHFFFAOYSA-N 0.000 description 1
- HETOYGUJFDGINB-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-imidazol-1-ylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCN3C=NC=C3)=CC=2)F)=C1C HETOYGUJFDGINB-UHFFFAOYSA-N 0.000 description 1
- VSWMTWPKJUWSID-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methoxyethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCOC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C VSWMTWPKJUWSID-UHFFFAOYSA-N 0.000 description 1
- KTUPQVPEEPMWCU-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methoxyethylamino)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCCOC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C KTUPQVPEEPMWCU-UHFFFAOYSA-N 0.000 description 1
- IOIOUGPZHCNRGS-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methoxyethylcarbamoyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(C(=O)NCCOC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C IOIOUGPZHCNRGS-UHFFFAOYSA-N 0.000 description 1
- RNCHRLLIKRUBPX-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methylsulfonylethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(OCCS(C)(=O)=O)=CC=2)F)=C1C RNCHRLLIKRUBPX-UHFFFAOYSA-N 0.000 description 1
- OAZAGUDHDAWCOR-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methylsulfonylethyl)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(CCS(C)(=O)=O)=CC=2)F)=C1C OAZAGUDHDAWCOR-UHFFFAOYSA-N 0.000 description 1
- VGCRHIKAKZKWOF-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methylsulfonylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCS(C)(=O)=O)=CC=2)F)=C1C VGCRHIKAKZKWOF-UHFFFAOYSA-N 0.000 description 1
- AJHLWZLACIOZMR-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-methylsulfonylethylamino)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(NCCS(C)(=O)=O)=CC=2)F)=C1C AJHLWZLACIOZMR-UHFFFAOYSA-N 0.000 description 1
- ZIFKIAIXOVSZIK-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-morpholin-4-yl-2-oxoethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(=O)N3CCOCC3)=CC=2)F)=C1C ZIFKIAIXOVSZIK-UHFFFAOYSA-N 0.000 description 1
- XVLAZRKHCAGQJJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-morpholin-4-ylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCN3CCOCC3)=CC=2)F)=C1C XVLAZRKHCAGQJJ-UHFFFAOYSA-N 0.000 description 1
- UNPIQRIPQOOGHZ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-phosphonooxyethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCOP(O)(O)=O)=CC=2)F)=C1C UNPIQRIPQOOGHZ-UHFFFAOYSA-N 0.000 description 1
- CHSMDZOJSOXXBI-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-propan-2-yloxyethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCOC(C)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C CHSMDZOJSOXXBI-UHFFFAOYSA-N 0.000 description 1
- XPJGMUJGHYDECJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-propan-2-yloxyethoxy)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C XPJGMUJGHYDECJ-UHFFFAOYSA-N 0.000 description 1
- HOQBUTBSIIHOCH-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-propan-2-yloxyethylamino)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C HOQBUTBSIIHOCH-UHFFFAOYSA-N 0.000 description 1
- SWLODEVQVQOHEQ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-propan-2-yloxyethylcarbamoyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(C(=O)NCCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C SWLODEVQVQOHEQ-UHFFFAOYSA-N 0.000 description 1
- ZXPCYPDCHABJBF-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-propan-2-yloxyethylsulfamoyl)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(S(=O)(=O)NCCOC(C)C)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C ZXPCYPDCHABJBF-UHFFFAOYSA-N 0.000 description 1
- UEZRYSSOLPIHEX-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-pyridin-2-ylethoxy)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(OCCC=3N=CC=CC=3)=CC=2)F)=C1C UEZRYSSOLPIHEX-UHFFFAOYSA-N 0.000 description 1
- LHDMASOMIFRFMQ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-pyrrolidin-1-ylethylcarbamoyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C(=O)NCCN2CCCC2)F)=C1C LHDMASOMIFRFMQ-UHFFFAOYSA-N 0.000 description 1
- NSROGMISPOBHDP-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-sulfamoylethyl)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(CCS(N)(=O)=O)=CC=2)F)=C1C NSROGMISPOBHDP-UHFFFAOYSA-N 0.000 description 1
- AXGSNYXPMJFUFJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(2-sulfamoylethyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCS(N)(=O)=O)=CC=2)F)=C1C AXGSNYXPMJFUFJ-UHFFFAOYSA-N 0.000 description 1
- PGKJGOFQPMALGJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(3-methoxypropoxy)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCCOC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C PGKJGOFQPMALGJ-UHFFFAOYSA-N 0.000 description 1
- OMLJEUKKPUKHNB-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(3-methoxypropylsulfonyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(S(=O)(=O)CCCOC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C OMLJEUKKPUKHNB-UHFFFAOYSA-N 0.000 description 1
- WMZJVGAPOFVIPY-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(3-methoxypyridin-2-yl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound COC1=CC=CN=C1C(C=C1F)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C WMZJVGAPOFVIPY-UHFFFAOYSA-N 0.000 description 1
- GZZYBQOCRCVABA-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(4-propan-2-ylpiperazine-1-carbonyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C(=O)N2CCN(CC2)C(C)C)F)=C1C GZZYBQOCRCVABA-UHFFFAOYSA-N 0.000 description 1
- CZZOGDHQLJVGGT-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(5-methoxypyridin-2-yl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CC(OC)=CC=C1C(C=C1F)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C CZZOGDHQLJVGGT-UHFFFAOYSA-N 0.000 description 1
- JHJZKZFLAKFXNO-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(6-methoxypyridin-3-yl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(OC)=CC=C1C(C=C1F)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C JHJZKZFLAKFXNO-UHFFFAOYSA-N 0.000 description 1
- YHHNQILYCFQVQT-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(hydroxycarbamoyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C(=O)NO)F)=C1C YHHNQILYCFQVQT-UHFFFAOYSA-N 0.000 description 1
- RLKURVUAVXZLFI-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(methanesulfonamido)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(NS(C)(=O)=O)=CC=2)F)=C1C RLKURVUAVXZLFI-UHFFFAOYSA-N 0.000 description 1
- YVSXJZZJZWCCJF-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(methoxymethylcarbamoyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(C(=O)NCOC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C YVSXJZZJZWCCJF-UHFFFAOYSA-N 0.000 description 1
- QKQJBMVIEJGIOY-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(oxan-4-yloxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(OC3CCOCC3)=CC=2)F)=C1C QKQJBMVIEJGIOY-UHFFFAOYSA-N 0.000 description 1
- UMCWFDFYNNIRQR-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(oxan-4-yloxy)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(OC3CCOCC3)=CC=2)F)=C1C UMCWFDFYNNIRQR-UHFFFAOYSA-N 0.000 description 1
- MTKZPBCCWLLISS-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(oxolan-2-ylmethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(OCC3OCCC3)=CC=2)F)=C1C MTKZPBCCWLLISS-UHFFFAOYSA-N 0.000 description 1
- IIIXUUQXURBVAR-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(oxolan-2-ylmethylamino)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(NCC3OCCC3)=CC=2)F)=C1C IIIXUUQXURBVAR-UHFFFAOYSA-N 0.000 description 1
- MSTPEBZHISIWGK-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(oxolan-2-ylmethylamino)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(NCC3OCCC3)=CC=2)F)=C1C MSTPEBZHISIWGK-UHFFFAOYSA-N 0.000 description 1
- CMQOFQFAKRAPHM-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(propan-2-ylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NC(C)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 CMQOFQFAKRAPHM-UHFFFAOYSA-N 0.000 description 1
- ITQKJDJHZHDFBJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(propanoylsulfamoyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(S(=O)(=O)NC(=O)CC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C ITQKJDJHZHDFBJ-UHFFFAOYSA-N 0.000 description 1
- BOJBCSGXZJNGMP-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(propylamino)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C BOJBCSGXZJNGMP-UHFFFAOYSA-N 0.000 description 1
- BADXTZJPHIUESB-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(propylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCCC)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 BADXTZJPHIUESB-UHFFFAOYSA-N 0.000 description 1
- DKKNGXJPBDPDPJ-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(pyridin-2-ylmethoxy)anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(OCC=3N=CC=CC=3)=CC=2)F)=C1C DKKNGXJPBDPDPJ-UHFFFAOYSA-N 0.000 description 1
- MZRJRANLKQTSCY-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(pyridine-2-carbonyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C(=O)C=2N=CC=CC=2)F)=C1C MZRJRANLKQTSCY-UHFFFAOYSA-N 0.000 description 1
- ADTXKBXANHVSEM-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-(thiophene-2-carbonyl)phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)C(=O)C=2SC=CC=2)F)=C1C ADTXKBXANHVSEM-UHFFFAOYSA-N 0.000 description 1
- OCSZWDWXPKBLIU-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(2-hydroxyethylamino)-2-oxoethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(=O)NCCO)=CC=2)F)=C1C OCSZWDWXPKBLIU-UHFFFAOYSA-N 0.000 description 1
- TZLYKVMHYOOBQU-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(2-methylpropoxy)ethoxy]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCOCC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C TZLYKVMHYOOBQU-UHFFFAOYSA-N 0.000 description 1
- HXSYZXQFYPIFBR-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(=O)N3CC(O)CCC3)=CC=2)F)=C1C HXSYZXQFYPIFBR-UHFFFAOYSA-N 0.000 description 1
- ZXGDYIPXLFRCPE-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(3-methoxypyridin-2-yl)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound COC1=CC=CN=C1CCC(C=C1F)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C ZXGDYIPXLFRCPE-UHFFFAOYSA-N 0.000 description 1
- ZCPRPRVOYMCSSS-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(4-methoxypiperidin-1-yl)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CC(OC)CCN1CCC(C=C1F)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C ZCPRPRVOYMCSSS-UHFFFAOYSA-N 0.000 description 1
- MZTIUKUCEMABKC-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(propanoylsulfamoyl)ethyl]anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(CCS(=O)(=O)NC(=O)CC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C MZTIUKUCEMABKC-UHFFFAOYSA-N 0.000 description 1
- OLMMVFWYFBTBAH-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(propanoylsulfamoyl)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(CCS(=O)(=O)NC(=O)CC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C OLMMVFWYFBTBAH-UHFFFAOYSA-N 0.000 description 1
- CMPLAQWCNXONKG-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-(triazol-1-yl)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCN3N=NC=C3)=CC=2)F)=C1C CMPLAQWCNXONKG-UHFFFAOYSA-N 0.000 description 1
- DCTPZDGHGAHJOX-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-[(2-methylpropan-2-yl)oxy]ethoxy]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(OCCOC(C)(C)C)=CC=2)F)=C1C DCTPZDGHGAHJOX-UHFFFAOYSA-N 0.000 description 1
- MWORHDZZZNKAQP-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-oxo-2-(2-propan-2-yloxyethylamino)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(CC(=O)NCCOC(C)C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C MWORHDZZZNKAQP-UHFFFAOYSA-N 0.000 description 1
- KSVUUENBLNDRQS-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[2-oxo-2-(oxolan-2-ylmethylamino)ethyl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(=O)NCC3OCCC3)=CC=2)F)=C1C KSVUUENBLNDRQS-UHFFFAOYSA-N 0.000 description 1
- FZVLKVYJGJARPW-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[5-(propan-2-yloxymethyl)-1,2,4-oxadiazol-3-yl]phenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound O1C(COC(C)C)=NC(C=2C=C(F)C(OC=3C(=C(OC4CCN(CC4)C(=O)OC(C)C)N=CN=3)C)=CC=2)=N1 FZVLKVYJGJARPW-UHFFFAOYSA-N 0.000 description 1
- NMNURQZBLKKXDM-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-4-[methyl(2-methylsulfonylethyl)amino]anilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)N(C)CCS(C)(=O)=O)F)=C1C NMNURQZBLKKXDM-UHFFFAOYSA-N 0.000 description 1
- PFJDFXKWNAFGNO-UHFFFAOYSA-N propan-2-yl 4-[6-[2-fluoro-n-(2-methoxyethyl)-4-methylsulfonylanilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N=1C=NC(OC2CCN(CC2)C(=O)OC(C)C)=C(C)C=1N(CCOC)C1=CC=C(S(C)(=O)=O)C=C1F PFJDFXKWNAFGNO-UHFFFAOYSA-N 0.000 description 1
- GLPVKFIEYGYEFU-UHFFFAOYSA-N propan-2-yl 4-[6-[2-methyl-4-(propylamino)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=CC(NCCC)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 GLPVKFIEYGYEFU-UHFFFAOYSA-N 0.000 description 1
- UGZUKYYKHCYYRU-UHFFFAOYSA-N propan-2-yl 4-[6-[3-(1,3-oxazol-5-yl)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C=C(C=CC=2)C=2OC=NC=2)=NC=N1 UGZUKYYKHCYYRU-UHFFFAOYSA-N 0.000 description 1
- BUOFPIKGFFDFBG-UHFFFAOYSA-N propan-2-yl 4-[6-[4-(2-amino-2-oxoethyl)-2-fluorophenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(N)=O)=CC=2)F)=C1C BUOFPIKGFFDFBG-UHFFFAOYSA-N 0.000 description 1
- HMGKNQLILIKVCU-UHFFFAOYSA-N propan-2-yl 4-[6-[4-(2-cyclopropyloxyethoxy)-2-fluorophenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(OCCOC3CC3)=CC=2)F)=C1C HMGKNQLILIKVCU-UHFFFAOYSA-N 0.000 description 1
- OQDMPMMIRNANGW-UHFFFAOYSA-N propan-2-yl 4-[6-[4-(2-ethoxyethoxy)-2-fluoroanilino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCOCC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C OQDMPMMIRNANGW-UHFFFAOYSA-N 0.000 description 1
- VODFVJZYYILJHH-UHFFFAOYSA-N propan-2-yl 4-[6-[4-(2-ethoxyethoxy)-2-fluorophenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(OCCOCC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C VODFVJZYYILJHH-UHFFFAOYSA-N 0.000 description 1
- VROSBPZTZWSYAT-UHFFFAOYSA-N propan-2-yl 4-[6-[4-(dimethylamino)-2-fluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(=CC=2)N(C)C)F)=NC=N1 VROSBPZTZWSYAT-UHFFFAOYSA-N 0.000 description 1
- VYAHXCMINHUNRB-UHFFFAOYSA-N propan-2-yl 4-[6-[4-(ethylamino)-2-fluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(NCC)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 VYAHXCMINHUNRB-UHFFFAOYSA-N 0.000 description 1
- VLEWEXAJLISORE-UHFFFAOYSA-N propan-2-yl 4-[6-[4-[2-(dimethylamino)-2-oxoethyl]-2-fluorophenoxy]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CC(=O)N(C)C)=CC=2)F)=C1C VLEWEXAJLISORE-UHFFFAOYSA-N 0.000 description 1
- MFGMJLPMHJBFQX-UHFFFAOYSA-N propan-2-yl 4-[6-[4-[2-(dimethylamino)ethoxy]-2,5-difluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(OCCN(C)C)=C(F)C=2)F)=NC=N1 MFGMJLPMHJBFQX-UHFFFAOYSA-N 0.000 description 1
- VHHZNXHSWUSETL-UHFFFAOYSA-N propan-2-yl 4-[6-[4-bromo-2-(trifluoromethoxy)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(Br)=CC=2)OC(F)(F)F)=NC=N1 VHHZNXHSWUSETL-UHFFFAOYSA-N 0.000 description 1
- NUAHGRCIOZSGKL-UHFFFAOYSA-N propan-2-yl 4-[6-[4-chloro-2-(trifluoromethoxy)anilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CC(Cl)=CC=2)OC(F)(F)F)=NC=N1 NUAHGRCIOZSGKL-UHFFFAOYSA-N 0.000 description 1
- WGEATORUYINAEO-UHFFFAOYSA-N propan-2-yl 4-[6-[4-fluoro-6-(2-methylsulfonylethyl)pyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCS(C)(=O)=O)=NC=2)F)=C1C WGEATORUYINAEO-UHFFFAOYSA-N 0.000 description 1
- CXXCDNSAIZTFEO-UHFFFAOYSA-N propan-2-yl 4-[6-[4-fluoro-6-(2-morpholin-4-ylethyl)pyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=CC(CCN3CCOCC3)=NC=2)F)=C1C CXXCDNSAIZTFEO-UHFFFAOYSA-N 0.000 description 1
- JWMZGUNZIJMGJJ-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-cyclopropyloxyethylamino)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(NCCOC3CC3)=CC=2)C)=C1C JWMZGUNZIJMGJJ-UHFFFAOYSA-N 0.000 description 1
- CGTLTGSMTRRXDP-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-fluoroethyl)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(CCF)=CC=2)C)=C1C CGTLTGSMTRRXDP-UHFFFAOYSA-N 0.000 description 1
- RFJSAXOECRNQBN-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-hydroxyethylamino)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(NCCO)=CC=2)C)=C1C RFJSAXOECRNQBN-UHFFFAOYSA-N 0.000 description 1
- BGLOVVLGQRTTDT-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-hydroxyethylsulfanyl)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(SCCO)=CC=2)C)=C1C BGLOVVLGQRTTDT-UHFFFAOYSA-N 0.000 description 1
- QLLZZXJBHZBUTF-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-hydroxyethylsulfonyl)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(=CC=2)S(=O)(=O)CCO)C)=C1C QLLZZXJBHZBUTF-UHFFFAOYSA-N 0.000 description 1
- VLLDZFQVXIVCLZ-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-methoxyethylsulfanyl)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(SCCOC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C VLLDZFQVXIVCLZ-UHFFFAOYSA-N 0.000 description 1
- QDXHFGRNGGKXSM-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(2-methoxyethylsulfonyl)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(S(=O)(=O)CCOC)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C QDXHFGRNGGKXSM-UHFFFAOYSA-N 0.000 description 1
- HXLXAAZWRJAZSF-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(5-methoxypyridin-2-yl)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CC(OC)=CC=C1C(N=C1C)=CC=C1OC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C HXLXAAZWRJAZSF-UHFFFAOYSA-N 0.000 description 1
- DDJZLAWIGUBOAG-UHFFFAOYSA-N propan-2-yl 4-[6-[6-(benzylamino)-2-methylpyridin-3-yl]oxy-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(OC=2C(=NC(NCC=3C=CC=CC=3)=CC=2)C)=C1C DDJZLAWIGUBOAG-UHFFFAOYSA-N 0.000 description 1
- FGVGCWYIRFIJGJ-UHFFFAOYSA-N propan-2-yl 4-[6-[[2-methyl-6-(propan-2-ylamino)pyridin-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(NC(C)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 FGVGCWYIRFIJGJ-UHFFFAOYSA-N 0.000 description 1
- ZMKTXMDBICQJDS-UHFFFAOYSA-N propan-2-yl 4-[6-[[2-methyl-6-(propylamino)pyridin-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(NCCC)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)C)=NC=N1 ZMKTXMDBICQJDS-UHFFFAOYSA-N 0.000 description 1
- BHGQKSLCMQRTOO-UHFFFAOYSA-N propan-2-yl 4-[6-[[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2SC=C(N=2)C=2C=C(F)C(F)=CC=2)=NC=N1 BHGQKSLCMQRTOO-UHFFFAOYSA-N 0.000 description 1
- ZJARUQPGVWWHEV-UHFFFAOYSA-N propan-2-yl 4-[6-[[4-(benzenesulfonyl)thiophen-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2C(=CSC=2)S(=O)(=O)C=2C=CC=CC=2)=NC=N1 ZJARUQPGVWWHEV-UHFFFAOYSA-N 0.000 description 1
- SUYWFKMZQAJLJA-UHFFFAOYSA-N propan-2-yl 4-[6-[[4-(trifluoromethyl)pyridin-2-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2N=CC=C(C=2)C(F)(F)F)=NC=N1 SUYWFKMZQAJLJA-UHFFFAOYSA-N 0.000 description 1
- AJXXWARSTYGSGI-UHFFFAOYSA-N propan-2-yl 4-[6-[[5-(1-methylpyrrolidin-2-yl)pyridin-2-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2N=CC(=CC=2)C2N(CCC2)C)=NC=N1 AJXXWARSTYGSGI-UHFFFAOYSA-N 0.000 description 1
- QGUGUBVGIHLYJS-UHFFFAOYSA-N propan-2-yl 4-[6-[[5-(4-chlorophenyl)-1h-pyrazol-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2NN=C(C=2)C=2C=CC(Cl)=CC=2)=NC=N1 QGUGUBVGIHLYJS-UHFFFAOYSA-N 0.000 description 1
- JVYZXJDITRCHBH-UHFFFAOYSA-N propan-2-yl 4-[6-[[5-(4-methylphenyl)-1h-pyrazol-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC2=NNC(=C2)C=2C=CC(C)=CC=2)=NC=N1 JVYZXJDITRCHBH-UHFFFAOYSA-N 0.000 description 1
- RDPCWCWIQMFMHE-UHFFFAOYSA-N propan-2-yl 4-[6-[[5-(trifluoromethyl)pyridin-2-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(NC=2N=CC(=CC=2)C(F)(F)F)=NC=N1 RDPCWCWIQMFMHE-UHFFFAOYSA-N 0.000 description 1
- JNOSANWQSCUMSZ-UHFFFAOYSA-N propan-2-yl 4-[6-[[6-(2-fluoroethyl)-2-methylpyridin-3-yl]amino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=NC(CCF)=CC=2)C)=C1C JNOSANWQSCUMSZ-UHFFFAOYSA-N 0.000 description 1
- WEFRNQBFKWOJDG-UHFFFAOYSA-N propan-2-yl 4-[6-[[6-(2-methoxyethoxy)-2-methylpyridin-3-yl]amino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(OCCOC)=CC=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C WEFRNQBFKWOJDG-UHFFFAOYSA-N 0.000 description 1
- OFCDUFVHTJERRH-UHFFFAOYSA-N propan-2-yl 4-[6-[[6-(2-methoxyethoxy)-4-methylpyridin-3-yl]amino]-5-methylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(OCCOC)=CC(C)=C1NC1=NC=NC(OC2CCN(CC2)C(=O)OC(C)C)=C1C OFCDUFVHTJERRH-UHFFFAOYSA-N 0.000 description 1
- AXFRSAXWXRXOFO-UHFFFAOYSA-N propan-2-yl 4-[6-[methyl-(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC(N(C)C=2N(N=C3CCCCC3=2)C)=NC=N1 AXFRSAXWXRXOFO-UHFFFAOYSA-N 0.000 description 1
- GOCSITBVDHDJHT-UHFFFAOYSA-N propan-2-yl 4-[8-(2-fluoro-4-sulfamoylphenyl)quinolin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)S(N)(=O)=O)F)C=CC=C12 GOCSITBVDHDJHT-UHFFFAOYSA-N 0.000 description 1
- KWVKNZLQBIVWTK-UHFFFAOYSA-N propan-2-yl 4-[8-(4-bromo-2-fluorophenyl)quinolin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(Br)=CC=3)F)C=CC=C12 KWVKNZLQBIVWTK-UHFFFAOYSA-N 0.000 description 1
- VEBDAVVHENSIOX-UHFFFAOYSA-N propan-2-yl 4-[8-(4-cyano-2-fluorophenyl)quinolin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=CC=NC2=C(C=3C(=CC(=CC=3)C#N)F)C=CC=C12 VEBDAVVHENSIOX-UHFFFAOYSA-N 0.000 description 1
- WTFHPOOIFOLZQJ-UHFFFAOYSA-N propan-2-yl 4-[8-[2-fluoro-4-(propanoylsulfamoyl)phenyl]quinolin-4-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C(C1=NC=C2)=CC=CC1=C2OC1CCN(C(=O)OC(C)C)CC1 WTFHPOOIFOLZQJ-UHFFFAOYSA-N 0.000 description 1
- UKNFCUURCPKXPX-UHFFFAOYSA-N propan-2-yl 4-[9-(2-fluoro-4-sulfamoylphenyl)purin-6-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC2=C1N=CN2C1=CC=C(S(N)(=O)=O)C=C1F UKNFCUURCPKXPX-UHFFFAOYSA-N 0.000 description 1
- QUJYLFXDSLGUMV-UHFFFAOYSA-N propan-2-yl 4-[9-(4-cyano-2-fluorophenyl)purin-6-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC2=C1N=CN2C1=CC=C(C#N)C=C1F QUJYLFXDSLGUMV-UHFFFAOYSA-N 0.000 description 1
- VRKJJBNLZPWRNH-UHFFFAOYSA-N propan-2-yl 4-[9-[2-fluoro-4-(propanoylsulfamoyl)phenyl]purin-6-yl]oxypiperidine-1-carboxylate Chemical compound FC1=CC(S(=O)(=O)NC(=O)CC)=CC=C1N1C2=NC=NC(OC3CCN(CC3)C(=O)OC(C)C)=C2N=C1 VRKJJBNLZPWRNH-UHFFFAOYSA-N 0.000 description 1
- ACHYHTWFOZFNOJ-UHFFFAOYSA-N propan-2-yl 4-[[[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1CNC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 ACHYHTWFOZFNOJ-UHFFFAOYSA-N 0.000 description 1
- AUSHIJSUMCQIIA-UHFFFAOYSA-N propan-2-yl 4-[[[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]-propan-2-ylamino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1CN(C(C)C)C1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C AUSHIJSUMCQIIA-UHFFFAOYSA-N 0.000 description 1
- JKZKXXAGJHLJPM-UHFFFAOYSA-N propan-2-yl 4-[[cyclopropyl-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1CN(C=1C(=C(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)N=CN=1)C)C1CC1 JKZKXXAGJHLJPM-UHFFFAOYSA-N 0.000 description 1
- AUGNGWPXCWDUTA-UHFFFAOYSA-N propan-2-yl 4-[[ethyl-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=NC=1N(CC)CC1CCN(C(=O)OC(C)C)CC1 AUGNGWPXCWDUTA-UHFFFAOYSA-N 0.000 description 1
- YNHVYQBXAFEGAV-UHFFFAOYSA-N propan-2-yl azetidine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCC1 YNHVYQBXAFEGAV-UHFFFAOYSA-N 0.000 description 1
- XQEPLYLEYBCDLB-UHFFFAOYSA-N propan-2-yl pyrrolidine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCCC1 XQEPLYLEYBCDLB-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- UBEVLTHYAFYOEU-UHFFFAOYSA-N propyl cyclohexanecarboxylate Chemical compound CCCOC(=O)C1CCCCC1 UBEVLTHYAFYOEU-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- RGAGQFGWAAKYGB-UHFFFAOYSA-N tert-butyl 3-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O RGAGQFGWAAKYGB-UHFFFAOYSA-N 0.000 description 1
- IUORNUVLBGKOPB-UHFFFAOYSA-N tert-butyl 3-[[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxymethyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1COC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O IUORNUVLBGKOPB-UHFFFAOYSA-N 0.000 description 1
- WESIASPLBWOSTO-UHFFFAOYSA-N tert-butyl 4-[(2-pyridin-4-yl-1,3-thiazol-4-yl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CC1=CSC(C=2C=CN=CC=2)=N1 WESIASPLBWOSTO-UHFFFAOYSA-N 0.000 description 1
- ZZEWRWKLEJRGPU-UHFFFAOYSA-N tert-butyl 4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=NC(C=2C=CN=CC=2)=NO1 ZZEWRWKLEJRGPU-UHFFFAOYSA-N 0.000 description 1
- QKGFZALRECXFAU-UHFFFAOYSA-N tert-butyl 4-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCC1=NC(C=2C=CN=CC=2)=NO1 QKGFZALRECXFAU-UHFFFAOYSA-N 0.000 description 1
- YALVKLUUJAEPSP-UHFFFAOYSA-N tert-butyl 4-[(3-pyridin-4-yl-1h-1,2,4-triazol-5-yl)methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=NN=C(C=2C=CN=CC=2)N1 YALVKLUUJAEPSP-UHFFFAOYSA-N 0.000 description 1
- DHIBFGHZLMBADV-UHFFFAOYSA-N tert-butyl 4-[(4-pyridin-4-yl-1,3-thiazol-2-yl)methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=NC(C=2C=CN=CC=2)=CS1 DHIBFGHZLMBADV-UHFFFAOYSA-N 0.000 description 1
- FDRHMAIJPIXWBZ-UHFFFAOYSA-N tert-butyl 4-[(5-pyridin-4-yl-1,2-oxazol-3-yl)methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=NOC(C=2C=CN=CC=2)=C1 FDRHMAIJPIXWBZ-UHFFFAOYSA-N 0.000 description 1
- OKPNANBGMBXLNA-UHFFFAOYSA-N tert-butyl 4-[(5-pyridin-4-yl-1,2-oxazol-3-yl)methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CC1=NOC(C=2C=CN=CC=2)=C1 OKPNANBGMBXLNA-UHFFFAOYSA-N 0.000 description 1
- GRXJWZVRGPMVQI-UHFFFAOYSA-N tert-butyl 4-[(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=NN=C(C=2C=CN=CC=2)S1 GRXJWZVRGPMVQI-UHFFFAOYSA-N 0.000 description 1
- RQQQYPCTPNNFSJ-UHFFFAOYSA-N tert-butyl 4-[2-(1-methyl-5-pyridin-4-ylpyrazol-3-yl)ethyl]piperidine-1-carboxylate Chemical compound C1=C(C=2C=CN=CC=2)N(C)N=C1CCC1CCN(C(=O)OC(C)(C)C)CC1 RQQQYPCTPNNFSJ-UHFFFAOYSA-N 0.000 description 1
- DBPSZYKBBJUSMW-UHFFFAOYSA-N tert-butyl 4-[2-(2-methyl-5-pyridin-4-ylpyrazol-3-yl)ethyl]piperidine-1-carboxylate Chemical compound CN1N=C(C=2C=CN=CC=2)C=C1CCC1CCN(C(=O)OC(C)(C)C)CC1 DBPSZYKBBJUSMW-UHFFFAOYSA-N 0.000 description 1
- RQTQJJFTLHQWLJ-UHFFFAOYSA-N tert-butyl 4-[2-(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCC1=NC(C=2C=CN=CC=2)=NO1 RQTQJJFTLHQWLJ-UHFFFAOYSA-N 0.000 description 1
- BHOGBIUUVFUONZ-UHFFFAOYSA-N tert-butyl 4-[2-(5-pyridin-4-yl-1,2-oxazol-3-yl)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCC1=NOC(C=2C=CN=CC=2)=C1 BHOGBIUUVFUONZ-UHFFFAOYSA-N 0.000 description 1
- FKIHXQMQMOEAMV-UHFFFAOYSA-N tert-butyl 4-[2-[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxyethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCOC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O FKIHXQMQMOEAMV-UHFFFAOYSA-N 0.000 description 1
- ZHSPOWRFUYEPHG-UHFFFAOYSA-N tert-butyl 4-[5-(2-fluoro-4-methylsulfonylanilino)pyridin-3-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CN=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1 ZHSPOWRFUYEPHG-UHFFFAOYSA-N 0.000 description 1
- SAMVLAMRISVWGR-UHFFFAOYSA-N tert-butyl 4-[5-acetyl-6-[(6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC2CCN(CC2)C(=O)OC(C)(C)C)C(C(=O)C)=C1NC1=CC=C(S(C)(=O)=O)N=C1 SAMVLAMRISVWGR-UHFFFAOYSA-N 0.000 description 1
- NQAAIDPRSHSKTI-UHFFFAOYSA-N tert-butyl 4-[5-amino-6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1N NQAAIDPRSHSKTI-UHFFFAOYSA-N 0.000 description 1
- KEKFIYXWIZJMKJ-UHFFFAOYSA-N tert-butyl 4-[5-cyano-6-(3-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C=C(F)C(=CC=2)S(C)(=O)=O)=C1C#N KEKFIYXWIZJMKJ-UHFFFAOYSA-N 0.000 description 1
- QVKBITMZDPTZKG-UHFFFAOYSA-N tert-butyl 4-[5-cyano-6-(4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1C#N QVKBITMZDPTZKG-UHFFFAOYSA-N 0.000 description 1
- VXORJLAWVPWALQ-UHFFFAOYSA-N tert-butyl 4-[6-(2,5-difluoro-4-methylsulfonylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(NC=2C(=CC(=C(F)C=2)S(C)(=O)=O)F)=NC=N1 VXORJLAWVPWALQ-UHFFFAOYSA-N 0.000 description 1
- NKIHODQBENXCGU-UHFFFAOYSA-N tert-butyl 4-[6-(2-fluoro-4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1[N+]([O-])=O NKIHODQBENXCGU-UHFFFAOYSA-N 0.000 description 1
- FMPYGAQRCLKNPN-UHFFFAOYSA-N tert-butyl 4-[6-(2-fluoro-4-methylsulfonylanilino)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=N1 FMPYGAQRCLKNPN-UHFFFAOYSA-N 0.000 description 1
- UTWYXOUKEBYLSY-UHFFFAOYSA-N tert-butyl 4-[6-(4-cyano-2,5-difluoroanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(NC=2C(=CC(=C(F)C=2)C#N)F)=NC=N1 UTWYXOUKEBYLSY-UHFFFAOYSA-N 0.000 description 1
- PHWQPKNWYHOPCW-UHFFFAOYSA-N tert-butyl 4-[6-(4-propan-2-ylsulfanylanilino)pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=CC(SC(C)C)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 PHWQPKNWYHOPCW-UHFFFAOYSA-N 0.000 description 1
- OYOOWRHZGKHKCD-UHFFFAOYSA-N tert-butyl 4-[6-[(5-chloro-3-methylpyridin-2-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=CC(Cl)=CN=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 OYOOWRHZGKHKCD-UHFFFAOYSA-N 0.000 description 1
- MHCGMFYDBQLSBG-UHFFFAOYSA-N tert-butyl 4-[6-[(5-fluoro-4-methylpyridin-2-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(F)C(C)=CC(NC=2N=CN=C(OC3CCN(CC3)C(=O)OC(C)(C)C)C=2)=N1 MHCGMFYDBQLSBG-UHFFFAOYSA-N 0.000 description 1
- GFQYDMFPQRMJTH-UHFFFAOYSA-N tert-butyl 4-[6-[(6-acetamido-4-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=NC(NC(=O)C)=CC(C)=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 GFQYDMFPQRMJTH-UHFFFAOYSA-N 0.000 description 1
- NWWQTKSOSNGVFO-UHFFFAOYSA-N tert-butyl 4-[6-[(6-methoxy-2-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound CC1=NC(OC)=CC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 NWWQTKSOSNGVFO-UHFFFAOYSA-N 0.000 description 1
- UMCCJEZRYHJXRD-UHFFFAOYSA-N tert-butyl 4-[6-[(6-methoxy-5-methylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(C)C(OC)=NC=C1NC1=CC(OC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 UMCCJEZRYHJXRD-UHFFFAOYSA-N 0.000 description 1
- MRONFGQLGIAZRT-UHFFFAOYSA-N tert-butyl 4-[6-[(6-methylsulfonylpyridin-3-yl)amino]-5-nitropyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC(NC=2C=NC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O MRONFGQLGIAZRT-UHFFFAOYSA-N 0.000 description 1
- DUUPUBWFRFCDSF-UHFFFAOYSA-N tert-butyl 4-[6-[4-cyano-5-(ethylamino)-2-fluoroanilino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1=C(C#N)C(NCC)=CC(NC=2N=CN=C(OC3CCN(CC3)C(=O)OC(C)(C)C)C=2)=C1F DUUPUBWFRFCDSF-UHFFFAOYSA-N 0.000 description 1
- JEOZIJHJXPFRCE-UHFFFAOYSA-N tert-butyl 4-[[5-(2-cyanopyridin-4-yl)-1,2,4-oxadiazol-3-yl]methyl-ethylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(CC)CC(N=1)=NOC=1C1=CC=NC(C#N)=C1 JEOZIJHJXPFRCE-UHFFFAOYSA-N 0.000 description 1
- SGGXQSIJAIBUMH-UHFFFAOYSA-N tert-butyl 4-[[5-(2-cyanopyridin-4-yl)-1,2,4-oxadiazol-3-yl]methylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCC1=NOC(C=2C=C(N=CC=2)C#N)=N1 SGGXQSIJAIBUMH-UHFFFAOYSA-N 0.000 description 1
- BEHIWMRJLUNCOY-UHFFFAOYSA-N tert-butyl 4-[[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 BEHIWMRJLUNCOY-UHFFFAOYSA-N 0.000 description 1
- SICOPNJXZQOBFL-UHFFFAOYSA-N tert-butyl 4-[[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]methylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 SICOPNJXZQOBFL-UHFFFAOYSA-N 0.000 description 1
- NRKBXROHFGYKMJ-UHFFFAOYSA-N tert-butyl 4-[[6-(4-methylsulfonylanilino)-5-nitropyrimidin-4-yl]oxymethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1COC1=NC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=C1[N+]([O-])=O NRKBXROHFGYKMJ-UHFFFAOYSA-N 0.000 description 1
- QUFUTDMNYRSZNI-UHFFFAOYSA-N tert-butyl 4-[[[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]-propan-2-ylamino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=NC=1N(C(C)C)CC1CCN(C(=O)OC(C)(C)C)CC1 QUFUTDMNYRSZNI-UHFFFAOYSA-N 0.000 description 1
- KECPMOIAERUKQU-UHFFFAOYSA-N tert-butyl 4-[[[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CNC1=CC(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=N1 KECPMOIAERUKQU-UHFFFAOYSA-N 0.000 description 1
- NDHJNDFBRYXBSE-UHFFFAOYSA-N tert-butyl 4-[[ethyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]piperidine-1-carboxylate Chemical compound N=1C(C=2C=CN=CC=2)=NOC=1CN(CC)CC1CCN(C(=O)OC(C)(C)C)CC1 NDHJNDFBRYXBSE-UHFFFAOYSA-N 0.000 description 1
- HJVPPPPOUXXWKN-UHFFFAOYSA-N tert-butyl 4-[[ethyl-[6-(2,4,5-trifluoroanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C(=CC(F)=C(F)C=2)F)=NC=NC=1N(CC)CC1CCN(C(=O)OC(C)(C)C)CC1 HJVPPPPOUXXWKN-UHFFFAOYSA-N 0.000 description 1
- CZXJYRKHVPJLIV-UHFFFAOYSA-N tert-butyl 4-[[ethyl-[6-(2-fluoro-4-methylsulfonylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C(=CC(=CC=2)S(C)(=O)=O)F)=NC=NC=1N(CC)CC1CCN(C(=O)OC(C)(C)C)CC1 CZXJYRKHVPJLIV-UHFFFAOYSA-N 0.000 description 1
- XWBXPBSNFIOUKV-UHFFFAOYSA-N tert-butyl 4-[[methyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]piperidine-1-carboxylate Chemical compound N=1C(C=2C=CN=CC=2)=NOC=1CN(C)CC1CCN(C(=O)OC(C)(C)C)CC1 XWBXPBSNFIOUKV-UHFFFAOYSA-N 0.000 description 1
- NSHXMCFAMXKGHS-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(2,3,5-trifluoroanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C(=C(F)C=C(F)C=2)F)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 NSHXMCFAMXKGHS-UHFFFAOYSA-N 0.000 description 1
- JSXRYRFEBMQSSM-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NCCC=2C=NC=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 JSXRYRFEBMQSSM-UHFFFAOYSA-N 0.000 description 1
- KXFQWSZPMPHTHY-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(2-pyridin-4-ylethylamino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NCCC=2C=CN=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 KXFQWSZPMPHTHY-UHFFFAOYSA-N 0.000 description 1
- VWTIPKYMROXKLJ-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(4-methylsulfonylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(=CC=2)S(C)(=O)=O)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 VWTIPKYMROXKLJ-UHFFFAOYSA-N 0.000 description 1
- ZMEQMUGHODIJRJ-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(4-morpholin-4-ylsulfonylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 ZMEQMUGHODIJRJ-UHFFFAOYSA-N 0.000 description 1
- ZQXXHOFNMCOCGN-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(4-pyrazol-1-ylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(=CC=2)N2N=CC=C2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 ZQXXHOFNMCOCGN-UHFFFAOYSA-N 0.000 description 1
- MRZSQTDHZCASIQ-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(4-sulfamoylanilino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 MRZSQTDHZCASIQ-UHFFFAOYSA-N 0.000 description 1
- RJFVCLXPHFRRTN-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-(pyridin-3-ylmethylamino)pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NCC=2C=NC=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 RJFVCLXPHFRRTN-UHFFFAOYSA-N 0.000 description 1
- VHBOMXNCXSIEKS-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[2-(pyridine-2-carbonyl)anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C(=CC=CC=2)C(=O)C=2N=CC=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 VHBOMXNCXSIEKS-UHFFFAOYSA-N 0.000 description 1
- KYYANLTTXKQREV-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-(1,2,4-triazol-1-yl)anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(=CC=2)N2N=CN=C2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 KYYANLTTXKQREV-UHFFFAOYSA-N 0.000 description 1
- WHYADOYVTMAVEJ-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-(1,2,4-triazol-1-ylmethyl)anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(CN3N=CN=C3)=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 WHYADOYVTMAVEJ-UHFFFAOYSA-N 0.000 description 1
- WQRRGUDMOZLDRA-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-(methylsulfamoyl)anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC1=CC(N(C)CC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 WQRRGUDMOZLDRA-UHFFFAOYSA-N 0.000 description 1
- LXXGFONTXGIWAP-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-(methylsulfamoylmethyl)anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1=CC(CS(=O)(=O)NC)=CC=C1NC1=CC(N(C)CC2CCN(CC2)C(=O)OC(C)(C)C)=NC=N1 LXXGFONTXGIWAP-UHFFFAOYSA-N 0.000 description 1
- CZCFYSYUAQRLFQ-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-(trifluoromethylsulfonyl)anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 CZCFYSYUAQRLFQ-UHFFFAOYSA-N 0.000 description 1
- RRWFPIOXQUMZBY-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-[(2-oxo-1,3-oxazolidin-4-yl)methyl]anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(CC3NC(=O)OC3)=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 RRWFPIOXQUMZBY-UHFFFAOYSA-N 0.000 description 1
- UYLSYTGEVPUVOB-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[4-[2-(1,2,4-triazol-1-yl)ethyl]anilino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2C=CC(CCN3N=CN=C3)=CC=2)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 UYLSYTGEVPUVOB-UHFFFAOYSA-N 0.000 description 1
- SBLGYKMIWXUSJX-UHFFFAOYSA-N tert-butyl 4-[[methyl-[6-[[5-(trifluoromethyl)pyridin-2-yl]amino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C=1C(NC=2N=CC(=CC=2)C(F)(F)F)=NC=NC=1N(C)CC1CCN(C(=O)OC(C)(C)C)CC1 SBLGYKMIWXUSJX-UHFFFAOYSA-N 0.000 description 1
- IOVIMIZIEVHIRC-UHFFFAOYSA-N tert-butyl 4-[butyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(CCCC)CC(ON=1)=NC=1C1=CC=NC=C1 IOVIMIZIEVHIRC-UHFFFAOYSA-N 0.000 description 1
- VEUFPBDVOHMIPH-UHFFFAOYSA-N tert-butyl 4-[cyclopropylmethyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(CC=1ON=C(N=1)C=1C=CN=CC=1)CC1CC1 VEUFPBDVOHMIPH-UHFFFAOYSA-N 0.000 description 1
- PEEHJFFHPDUBTQ-UHFFFAOYSA-N tert-butyl 4-[methyl-[(3-pyridin-4-yl-1,2,4-oxadiazol-5-yl)methyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N(C)CC(ON=1)=NC=1C1=CC=NC=C1 PEEHJFFHPDUBTQ-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- OMCJHLKGBPICRV-UHFFFAOYSA-N tert-butyl n-[1-[4-[6-(2-fluoro-4-methylsulfonylphenoxy)-5-methylpyrimidin-4-yl]oxypiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound C1CN(C(=O)C(NC(=O)OC(C)(C)C)C(C)C)CCC1OC1=NC=NC(OC=2C(=CC(=CC=2)S(C)(=O)=O)F)=C1C OMCJHLKGBPICRV-UHFFFAOYSA-N 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001391 thioamide group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- GQHWSLKNULCZGI-UHFFFAOYSA-N trifluoromethoxybenzene Chemical compound FC(F)(F)OC1=CC=CC=C1 GQHWSLKNULCZGI-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64308605P | 2005-01-10 | 2005-01-10 | |
| US68317205P | 2005-05-19 | 2005-05-19 | |
| US72688005P | 2005-10-14 | 2005-10-14 | |
| PCT/US2006/000510 WO2006076231A2 (en) | 2005-01-10 | 2006-01-09 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200701469A1 EA200701469A1 (ru) | 2008-02-28 |
| EA011883B1 true EA011883B1 (ru) | 2009-06-30 |
Family
ID=36570727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200701469A EA011883B1 (ru) | 2005-01-10 | 2006-01-09 | Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови |
Country Status (35)
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286975B6 (sk) * | 2001-02-24 | 2009-08-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| ATE408414T1 (de) * | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| HRP20050696B1 (en) | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| MX2007007553A (es) * | 2004-12-24 | 2007-08-15 | Prosidion Ltd | Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes. |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US8354241B2 (en) | 2005-04-27 | 2013-01-15 | Arena Pharmaceuticals, Inc. | Methods for identifying a GLP-1 secretagogue |
| JP2008545009A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20070179123A1 (en) * | 2005-11-08 | 2007-08-02 | Chiang Peter K | Methods and compositions for treating diseases associated with pathogenic proteins |
| DE602007010420D1 (de) | 2006-04-11 | 2010-12-23 | Arena Pharm Inc | Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP2043744A2 (en) * | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
| US20080103141A1 (en) * | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
| EP2112880A4 (en) * | 2006-12-14 | 2011-12-21 | Merck Sharp & Dohme | ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| ATE523507T1 (de) * | 2007-01-04 | 2011-09-15 | Prosidion Ltd | Piperidin-gpcr-agonisten |
| PE20081659A1 (es) * | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
| CL2008000017A1 (es) * | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| WO2008141074A1 (en) * | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
| EP2185544B1 (en) | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
| WO2009117421A2 (en) * | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CA2719507C (en) * | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| CA2724426A1 (en) * | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| ES2387865T3 (es) * | 2008-07-10 | 2012-10-03 | Prosidion Ltd | Agonistas de GPCR de piperidina |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0919288A2 (pt) * | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
| CN101723947B (zh) * | 2008-10-21 | 2012-05-30 | 山东轩竹医药科技有限公司 | 二肽酶-ⅳ抑制剂化合物 |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| WO2010074271A1 (ja) * | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| US20220387305A1 (en) * | 2009-01-12 | 2022-12-08 | Biokier, Inc. | Composition and method for treatment of diabetes |
| PE20120017A1 (es) | 2009-02-13 | 2012-02-12 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos |
| EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| JP2012528847A (ja) * | 2009-06-05 | 2012-11-15 | ファイザー・インク | Gpr119調節因子としてのl−(ピペリジン−4−イル)−ピラゾール誘導体 |
| BR112012000831A2 (pt) | 2009-06-24 | 2019-09-24 | Boehringer Ingelheim Int | compostos, composições farmacêuticas e métodos relacionados |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| DK2462246T3 (da) * | 2009-09-28 | 2017-11-06 | Intarcia Therapeutics Inc | Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| CN102812011A (zh) | 2009-11-16 | 2012-12-05 | 梅利科技公司 | [1,5]-二氮杂环辛间四烯衍生物 |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| US20120035103A1 (en) * | 2010-01-29 | 2012-02-09 | Pillion Dennis J | Method for administration of insulin and pharmaceutical composition thereof |
| JP2013522279A (ja) * | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ |
| WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| MX2013003184A (es) | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo. |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN103344773B (zh) * | 2013-06-19 | 2015-04-15 | 天津美德太平洋科技有限公司 | 一种胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒 |
| WO2015016682A1 (ko) | 2013-08-01 | 2015-02-05 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
| KR101688639B1 (ko) | 2013-08-01 | 2016-12-21 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
| WO2018236896A1 (en) | 2017-06-19 | 2018-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of nafld and nash |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| RS66907B1 (sr) | 2018-09-12 | 2025-07-31 | Dong A St Co Ltd | Farmaceutska kompozicija za primenu u prevenciji ili lečenju nealkoholne masne bolesti jetre, koja sadrži ligand gpr119 kao aktivni sastojak |
| US20220265652A1 (en) | 2019-07-08 | 2022-08-25 | Mankind Pharma Ltd. | Combination therapy of gpr119 agonists and dpp-4 inhibitors |
| US20230143119A1 (en) * | 2020-03-11 | 2023-05-11 | Dong-A St Co., Ltd. | Pharmaceutical composition for prevention or treatment of diabetes and metabolic diseases associated therewith |
| WO2022078152A1 (zh) * | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| AU2023375560A1 (en) * | 2022-11-10 | 2025-06-19 | Acerand Therapeutics (Hong Kong) Limited | Sos1 inhibitors |
Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038501A2 (en) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| WO2000031258A2 (en) * | 1998-11-20 | 2000-06-02 | Arena Pharmaceuticals, Inc. | Human orphan g protein-coupled receptors |
| WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
| WO2001052825A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| US6468756B1 (en) * | 1999-02-22 | 2002-10-22 | Synaptic Pharmaceutical Corporation | Methods of identifying compounds that bind to SNORF25 receptors |
| WO2002083128A1 (en) * | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
| WO2003026661A1 (fr) * | 2001-09-14 | 2003-04-03 | Yamanouchi Pharmaceutical Co., Ltd. | Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine |
| EP1338651A1 (en) * | 2000-12-01 | 2003-08-27 | Yamanouchi Pharmaceutical Co. Ltd. | Method of screening remedy for diabetes |
| WO2004065380A1 (en) * | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| WO2004076413A2 (en) * | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| JP2004269469A (ja) * | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| JP2004269468A (ja) * | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| WO2005007647A1 (en) * | 2003-07-11 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2005007658A2 (en) * | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| EP1538217A1 (en) * | 2002-09-11 | 2005-06-08 | Yamanouchi Pharmaceutical Co. Ltd. | Method of screening insulin content enhancer |
| WO2005061489A1 (en) * | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
| WO2005121121A2 (en) * | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006047248A1 (en) * | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
Family Cites Families (268)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US751426A (en) * | 1904-02-02 | Safety hair-pin | ||
| US747699A (en) * | 1903-09-05 | 1903-12-22 | Achilles C Gough | Universal sanding-machine. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DD296075A5 (de) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
| EP0528858B1 (en) | 1990-04-14 | 1997-01-22 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
| US5462856A (en) | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
| ES2153831T3 (es) | 1991-10-22 | 2001-03-16 | New England Medical Center Inc | Inhibidores de dipeptidil-aminopeptidasa de tipo iv. |
| MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
| US6100042A (en) * | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| WO1998018763A1 (en) | 1996-10-25 | 1998-05-07 | Tanabe Seiyaku Co., Ltd. | Tetrahydroisoquinoline derivatives |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6040145A (en) * | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
| US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| US6183974B1 (en) * | 1997-07-31 | 2001-02-06 | The General Hospital Corporation | Screening assays for G protein coupled receptor agonists and antagonists |
| IL135068A (en) | 1997-09-29 | 2004-03-28 | Point Therapeutics Inc | Stimulation of hematopoietic cells in vitro |
| CA2310400C (en) | 1997-11-18 | 2008-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel physiologically active substance sulphostin, process for producing the same, and use thereof |
| US5922576A (en) * | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
| KR20010052302A (ko) | 1998-05-04 | 2001-06-25 | 바바라 피. 월너 | 조혈 자극 |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| WO1999062914A1 (en) | 1998-06-05 | 1999-12-09 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
| DE19828114A1 (de) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| IL141471A0 (en) | 1998-08-21 | 2002-03-10 | Point Therapeutics Inc | Regulation of substrate activity |
| AU6294899A (en) * | 1998-10-07 | 2000-04-26 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| JP2000191616A (ja) | 1998-12-24 | 2000-07-11 | Senju Pharmaceut Co Ltd | 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬 |
| US20030125539A1 (en) * | 1999-02-22 | 2003-07-03 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| JP4121215B2 (ja) | 1999-05-17 | 2008-07-23 | 財団法人微生物化学研究会 | スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法 |
| AU781897B2 (en) | 1999-05-25 | 2005-06-23 | Point Therapeutics, Inc. | Anti-tumor comprising boroproline compounds |
| US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| DE19940130A1 (de) * | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| US6653064B1 (en) | 1999-09-23 | 2003-11-25 | Boehringer Ingelheim International Gmbh | Method for identifying compounds useful in the therapy of bone disorders |
| GB9923177D0 (en) | 1999-09-30 | 1999-12-01 | Pfizer Ltd | Novel polypeptide |
| WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| AU2001228309A1 (en) | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| ATE348162T1 (de) | 2000-05-18 | 2007-01-15 | Bayer Healthcare Ag | Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor. |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| EP1360495B1 (en) * | 2000-06-13 | 2007-04-11 | Glaxo Group Limited | High throughput screening of compounds for biological activity |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| HUP0301622A3 (en) | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
| WO2002008188A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| DE60140708D1 (de) | 2000-08-10 | 2010-01-14 | Mitsubishi Tanabe Pharma Corp | Prolinderivative und deren Verwendung als Medikamente |
| JP4329291B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
| JP2004035574A (ja) | 2000-10-06 | 2004-02-05 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
| AU2001294196B2 (en) | 2000-10-06 | 2005-11-17 | Tanabe Seiyaku Co., Ltd. | Nitrogenous five-membered ring compounds |
| JP4329290B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
| AUPR107800A0 (en) | 2000-10-27 | 2000-11-23 | University Of Sydney, The | Peptide and nucleic acid molecule ii |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| WO2002042461A2 (en) | 2000-11-27 | 2002-05-30 | Arena Pharmaceuticals, Inc. | Endogenous and non-endogenous versions of human g protein-coupled receptors |
| US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| US20040038942A1 (en) | 2001-01-16 | 2004-02-26 | Takumi Yamashita | Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes |
| US6397767B1 (en) * | 2001-02-01 | 2002-06-04 | Case Corporation | Knife applicator for applying liquid fertilizer in the ground |
| JP4213390B2 (ja) | 2001-02-02 | 2009-01-21 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| BR0206831A (pt) | 2001-02-02 | 2004-07-06 | Takeda Chemical Industries Ltd | Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto |
| SK286975B6 (sk) | 2001-02-24 | 2009-08-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| JP2002265439A (ja) | 2001-03-08 | 2002-09-18 | Mitsubishi Pharma Corp | シアノピロリジン誘導体およびその医薬用途 |
| EP1385508B1 (en) | 2001-03-27 | 2008-05-21 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EA006556B1 (ru) * | 2001-03-27 | 2006-02-24 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0109146D0 (en) | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2450475A1 (en) | 2001-06-20 | 2003-01-03 | Linda Brockunier | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US7098239B2 (en) | 2001-06-20 | 2006-08-29 | Merck & Co., Inc | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| DE60222667T2 (de) | 2001-06-27 | 2008-07-17 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| US7368421B2 (en) * | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| US7196201B2 (en) | 2001-06-27 | 2007-03-27 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| US7183290B2 (en) | 2001-06-27 | 2007-02-27 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| CA2424645A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | New use of dipeptidyl peptidase iv inhibitors |
| US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| DE60225556D1 (de) | 2001-07-03 | 2008-04-24 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| DE10143840A1 (de) | 2001-09-06 | 2003-03-27 | Probiodrug Ag | Neue Inhibitoren der Dipeptidylpeptidase I |
| US6844316B2 (en) * | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
| KR20040033048A (ko) | 2001-09-14 | 2004-04-17 | 미츠비시 웰파마 가부시키가이샤 | 티아졸리딘 유도체 및 이의 약학적 용도 |
| JP2005509603A (ja) | 2001-09-19 | 2005-04-14 | ノボ ノルディスク アクティーゼルスカブ | Dpp−iv酵素の阻害剤であるヘテロ環化合物 |
| US7238670B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| CA2464995A1 (en) | 2001-10-31 | 2003-05-08 | Novartis Ag | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| US20030125304A1 (en) * | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
| JP2005511636A (ja) | 2001-11-26 | 2005-04-28 | トラスティーズ オブ タフツ カレッジ | 自己免疫疾患の治療方法及びそれに関する試薬 |
| WO2003045977A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes |
| AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| WO2003072528A2 (en) | 2002-02-08 | 2003-09-04 | Idun Pharmaceuticals, Inc. | (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| RU2293731C2 (ru) | 2002-02-13 | 2007-02-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение |
| DE60302336T2 (de) | 2002-02-13 | 2006-08-03 | F. Hoffmann-La Roche Ag | Neue pyridin- und quinolin-derivate |
| US6906074B2 (en) | 2002-02-22 | 2005-06-14 | Nippon Zoki Pharmaceutical Co., Ltd. | 2-phenylpiperazine derivatives |
| JP2004043429A (ja) | 2002-02-25 | 2004-02-12 | Eisai Co Ltd | 新規キサンチン誘導体およびdppiv阻害剤 |
| US7074798B2 (en) * | 2002-02-25 | 2006-07-11 | Eisai Co., Ltd | Xanthine derivative and DPPIV inhibitor |
| DK1480961T3 (da) | 2002-02-28 | 2007-05-07 | Prosidion Ltd | Glutaminylbaserede DPIV-inhibitorer |
| HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| ATE373660T1 (de) | 2002-03-25 | 2007-10-15 | Merck & Co Inc | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes |
| CA2479898A1 (en) | 2002-03-25 | 2003-10-02 | Masatoshi Abe | Novel .alpha.-amino-n-(diaminophosphinyl)lactam derivatives |
| JP4329382B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4329381B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| KR20040105853A (ko) | 2002-04-08 | 2004-12-16 | 토렌트 파마슈티칼스 리미티드 | 티아졸리딘-4-카르보니트릴 및 유사체와디펩티딜-펩티다아제 억제제로서의 용도 |
| JP2003300977A (ja) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
| JPWO2003095425A1 (ja) | 2002-05-09 | 2005-09-15 | 大正製薬株式会社 | シアノピロリジン誘導体 |
| JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
| JP2003327532A (ja) | 2002-05-10 | 2003-11-19 | Takeda Chem Ind Ltd | ペプチダーゼ阻害剤 |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| JP2005532338A (ja) | 2002-06-03 | 2005-10-27 | ノバルティス アクチエンゲゼルシャフト | 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤 |
| US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| AU2003232405A1 (en) | 2002-06-04 | 2003-12-19 | Pfizer Products Inc. | Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| AU2003233010A1 (en) | 2002-06-04 | 2003-12-19 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
| CN100348599C (zh) * | 2002-06-06 | 2007-11-14 | 卫材R&D管理有限公司 | 新的稠合咪唑衍生物 |
| HUP0202001A2 (hu) | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
| JP2004026678A (ja) | 2002-06-24 | 2004-01-29 | Microbial Chem Res Found | 2型糖尿病治療剤 |
| JP2006506442A (ja) | 2002-07-09 | 2006-02-23 | ポイント セラピューティクス, インコーポレイテッド | ボロプロリン化合物併用療法 |
| JPWO2004007446A1 (ja) | 2002-07-10 | 2005-11-10 | アステラス製薬株式会社 | 新規なアゼチジン誘導体又はその塩 |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200401635A (en) | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
| AU2003254852A1 (en) | 2002-08-08 | 2004-02-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as peptidase inhibitors |
| JP4542757B2 (ja) | 2002-08-08 | 2010-09-15 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| DE10236667B4 (de) * | 2002-08-09 | 2007-06-06 | J. Eberspächer GmbH & Co. KG | Abgasanlage für den Verbrennungsmotor eines Kraftfahrzeugs |
| US20050101542A1 (en) * | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
| US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| EP1532149B9 (de) | 2002-08-21 | 2011-04-20 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel |
| DE10238243A1 (de) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| CN1310885C (zh) | 2002-08-29 | 2007-04-18 | 大正制药株式会社 | 4-氟-2-氰基吡咯烷衍生物苯磺酸盐 |
| EP1537880A4 (en) * | 2002-09-11 | 2009-07-01 | Takeda Pharmaceutical | Sustained release preparation |
| US7390809B2 (en) | 2002-10-07 | 2008-06-24 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes |
| WO2004033455A2 (en) | 2002-10-08 | 2004-04-22 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
| AR041470A1 (es) * | 2002-10-17 | 2005-05-18 | Upjohn Co | Compuestos de pirrolo (1,2 - b) piridazina y sus usos |
| RU2301803C2 (ru) | 2002-10-18 | 2007-06-27 | Мерк Энд Ко., Инк. | Производные гексагидродиазепинона, фармацевтическая композиция, их содержащая, и применение для получения лекарственного средства для лечения инсулиннезависимого диабета |
| ATE469645T1 (de) | 2002-10-23 | 2010-06-15 | Bristol Myers Squibb Co | Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv |
| AU2003286776A1 (en) | 2002-10-30 | 2004-06-07 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
| WO2004048379A1 (ja) | 2002-11-01 | 2004-06-10 | Sumitomo Pharmaceuticals Co., Ltd. | キサンチン化合物 |
| CA2504735C (en) | 2002-11-07 | 2009-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| WO2004046106A1 (en) | 2002-11-18 | 2004-06-03 | Pfizer Products Inc. | Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides |
| UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
| DE10256264A1 (de) | 2002-12-03 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2003297564A1 (en) | 2002-12-04 | 2004-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| ATE404191T1 (de) | 2002-12-10 | 2008-08-15 | Novartis Pharma Ag | Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist |
| JP4504924B2 (ja) * | 2002-12-20 | 2010-07-14 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体 |
| US6982164B2 (en) * | 2003-01-10 | 2006-01-03 | Mgp Ingredients, Inc. | Unhydrolyzed jojoba protein products having high simmondsin concentration |
| CA2512546A1 (en) | 2003-01-17 | 2004-08-05 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP2004244412A (ja) | 2003-01-20 | 2004-09-02 | Kotobuki Seiyaku Kk | 4位に置換基を有する2−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤 |
| KR100998796B1 (ko) | 2003-01-31 | 2010-12-06 | 가부시키가이샤산와카가쿠켄큐쇼 | 디펩티딜 펩티다아제 iv를 저해하는 화합물 |
| EP1592689A4 (en) | 2003-01-31 | 2008-12-24 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| WO2004076433A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| AR043515A1 (es) | 2003-03-19 | 2005-08-03 | Merck & Co Inc | Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica |
| WO2004085661A2 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc | Process to chiral beta-amino acid derivatives |
| US20040242566A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| WO2004087650A2 (en) | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors |
| WO2004092128A1 (en) | 2003-04-10 | 2004-10-28 | Smithkline Beecham Corporation | Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile |
| JPWO2004096806A1 (ja) | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| US7371871B2 (en) * | 2003-05-05 | 2008-05-13 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2004099134A2 (en) | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| WO2004103276A2 (en) | 2003-05-14 | 2004-12-02 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| EP1627870A1 (en) | 2003-05-15 | 2006-02-22 | Taisho Pharmaceutical Co., Ltd | Cyanofluoropyrrolidine derivative |
| EP1631680A2 (en) | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| EP1631679A2 (en) | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7) |
| AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| US7332520B2 (en) | 2003-06-06 | 2008-02-19 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| US7456204B2 (en) | 2003-06-17 | 2008-11-25 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| BRPI0411713B8 (pt) | 2003-06-20 | 2021-05-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização |
| RU2339636C2 (ru) | 2003-06-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг | Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv) |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| JP2005023038A (ja) | 2003-07-04 | 2005-01-27 | Taisho Pharmaceut Co Ltd | 慢性腎疾患治療薬 |
| MXPA06000725A (es) | 2003-07-21 | 2006-03-30 | Smithkline Beecham Corp | Sal de acido (2s-4s)-4 -fluoro-1 -[4-fluoro- beta-(4- fluorofenil) -l-fenilalanil] -2-pirrolidincarbonitril p-toluenosulfonico y formas cristalinas anhidras del mismo. |
| DE10333935A1 (de) | 2003-07-25 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PE20050249A1 (es) | 2003-07-25 | 2005-06-01 | Aventis Pharma Gmbh | Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos |
| US7008957B2 (en) * | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
| US7094800B2 (en) * | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
| CN1882551A (zh) | 2003-07-31 | 2006-12-20 | 麦克公司 | 用作用于治疗或预防糖尿病的二肽基肽酶-iv酶抑制剂的六氢二氮杂吖庚因酮 |
| US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
| US20070082908A1 (en) | 2003-08-29 | 2007-04-12 | Dainippon Sumitomo Pharma Co., Ltd. | Bicycle pyrazole derivative |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| AU2004268024B2 (en) | 2003-09-02 | 2007-07-12 | Merck Sharp & Dohme Llc | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
| WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| US20050065144A1 (en) | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| US20070021430A1 (en) | 2003-09-23 | 2007-01-25 | Chen Alex M | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| WO2005033099A2 (en) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| US20070072810A1 (en) | 2003-10-03 | 2007-03-29 | Takeda Pharmaceutical Company, Limited | Agent for treating diabetes |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| GB0324236D0 (en) | 2003-10-16 | 2003-11-19 | Astrazeneca Ab | Chemical compounds |
| TW200519105A (en) | 2003-10-20 | 2005-06-16 | Lg Life Science Ltd | Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| PE20050444A1 (es) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
| JP2007510651A (ja) | 2003-11-04 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−iv阻害剤としての縮合フェニルアラニン誘導体 |
| DK1689757T3 (en) | 2003-11-12 | 2014-12-08 | Sino Med Internat Alliance Inc | HETEROCYCLIC DRY ACID COMPOUNDS |
| KR20120008093A (ko) | 2003-11-17 | 2012-01-25 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| DE10355304A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2005058849A1 (en) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them |
| US7217711B2 (en) * | 2003-12-17 | 2007-05-15 | Boehringer Ingelheim International Gmbh | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions |
| DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
| WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 dpp ⅳ 억제제 |
| DE102004009039A1 (de) * | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| CN101090885A (zh) | 2004-02-23 | 2007-12-19 | 塔夫茨大学信托人 | 作为构象限定的肽模拟物抑制剂的内酰胺类化合物 |
| KR101292707B1 (ko) | 2004-02-23 | 2013-08-02 | 트러스티즈 오브 터프츠 칼리지 | 디펩티딜펩티다아제 ⅳ의 억제제 |
| CN1942186B (zh) | 2004-03-09 | 2010-10-06 | 国家卫生研究院 | 吡咯烷化合物 |
| US20060024313A1 (en) * | 2004-07-06 | 2006-02-02 | Xin Chen | Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases |
| WO2006019965A2 (en) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| DE102004037554A1 (de) | 2004-08-03 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102004038268A1 (de) | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20060046978A1 (en) * | 2004-08-31 | 2006-03-02 | Morphochem Ag | Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE) |
| DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006041797A2 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Acyclic hydrazides as cannabinoid receptor modulators |
| US7411093B2 (en) * | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| EP1828192B1 (en) * | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US20080318922A1 (en) | 2004-12-24 | 2008-12-25 | Dainippon Sumitomo Pharma Co., Ltd. | Bicyclic Pyrrole Derivatives |
| US7589088B2 (en) * | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2006086727A2 (en) * | 2005-02-09 | 2006-08-17 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
| US8354241B2 (en) * | 2005-04-27 | 2013-01-15 | Arena Pharmaceuticals, Inc. | Methods for identifying a GLP-1 secretagogue |
| WO2006132406A1 (ja) | 2005-06-09 | 2006-12-14 | Banyu Pharmaceutical Co., Ltd. | 下痢を伴う疾患の治療剤としてのnpy y2アゴニスト |
| JP2008545008A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
| US20090203676A1 (en) * | 2005-06-30 | 2009-08-13 | Oscar Barba | G-protein Coupled Receptor Agonists |
| JP5114395B2 (ja) * | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Gpcrアゴニスト |
| US7708191B2 (en) * | 2005-07-28 | 2010-05-04 | Edwin Vega | Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet |
| JP4827483B2 (ja) * | 2005-10-04 | 2011-11-30 | キヤノン株式会社 | 核酸試料処理装置 |
| DE602007010420D1 (de) * | 2006-04-11 | 2010-12-23 | Arena Pharm Inc | Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person |
| PE20071221A1 (es) * | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2043744A2 (en) * | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
| US20080103141A1 (en) * | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
| EP2094683B1 (en) * | 2006-12-06 | 2011-10-12 | GlaxoSmithKline LLC | Bicyclic compounds and use as antidiabetics |
| EP2112880A4 (en) * | 2006-12-14 | 2011-12-21 | Merck Sharp & Dohme | ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD |
| CA2719507C (en) * | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| WO2009150144A1 (en) * | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
| BRPI0919288A2 (pt) * | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| WO2010074271A1 (ja) * | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| US20140193463A1 (en) * | 2013-01-04 | 2014-07-10 | China Medical University | Peptide for inhibiting dipeptidyl-peptidase iv |
-
2006
- 2006-01-05 DO DO2006000008A patent/DOP2006000008A/es unknown
- 2006-01-06 PE PE2010000178A patent/PE20100398A1/es not_active Application Discontinuation
- 2006-01-06 PE PE2006000045A patent/PE20061116A1/es not_active Application Discontinuation
- 2006-01-06 GT GT200600004A patent/GT200600004A/es unknown
- 2006-01-09 EP EP06717678A patent/EP1758565B2/en active Active
- 2006-01-09 PL PL06717678T patent/PL1758565T5/pl unknown
- 2006-01-09 SG SG201000208-7A patent/SG158876A1/en unknown
- 2006-01-09 ES ES06717678T patent/ES2327268T5/es active Active
- 2006-01-09 SG SG2013026273A patent/SG189762A1/en unknown
- 2006-01-09 AT AT06717678T patent/ATE431139T1/de active
- 2006-01-09 DE DE602006007093T patent/DE602006007093D1/de active Active
- 2006-01-09 EP EP10010659A patent/EP2322157A1/en not_active Withdrawn
- 2006-01-09 EA EA200701469A patent/EA011883B1/ru not_active IP Right Cessation
- 2006-01-09 EP EP10010820A patent/EP2322152A1/en not_active Withdrawn
- 2006-01-09 JP JP2007550512A patent/JP4118323B1/ja not_active Expired - Fee Related
- 2006-01-09 AU AU2006205164A patent/AU2006205164B2/en not_active Ceased
- 2006-01-09 EP EP09006268A patent/EP2116235A1/en not_active Withdrawn
- 2006-01-09 NZ NZ578504A patent/NZ578504A/en not_active IP Right Cessation
- 2006-01-09 NZ NZ587368A patent/NZ587368A/en not_active IP Right Cessation
- 2006-01-09 HR HRP20090403TT patent/HRP20090403T4/hr unknown
- 2006-01-09 KR KR1020107023765A patent/KR20100129328A/ko not_active Ceased
- 2006-01-09 SI SI200630362T patent/SI1758565T1/sl unknown
- 2006-01-09 WO PCT/US2006/000510 patent/WO2006076231A2/en not_active Ceased
- 2006-01-09 PT PT07004743T patent/PT1808168E/pt unknown
- 2006-01-09 CA CA2593427A patent/CA2593427C/en not_active Expired - Fee Related
- 2006-01-09 DK DK07004743T patent/DK1808168T3/da active
- 2006-01-09 NZ NZ578502A patent/NZ578502A/en not_active IP Right Cessation
- 2006-01-09 DK DK06717678.4T patent/DK1758565T4/da active
- 2006-01-09 HN HN2006000971A patent/HN2006000971A/es unknown
- 2006-01-09 KR KR1020127029863A patent/KR20120139849A/ko not_active Withdrawn
- 2006-01-09 CN CN201310606771.0A patent/CN103611161A/zh active Pending
- 2006-01-09 EP EP10010818A patent/EP2322150A3/en not_active Withdrawn
- 2006-01-09 CA CA2654733A patent/CA2654733C/en not_active Expired - Fee Related
- 2006-01-09 EP EP10010656A patent/EP2322156A1/en not_active Withdrawn
- 2006-01-09 KR KR1020077018318A patent/KR20070095400A/ko not_active Ceased
- 2006-01-09 SI SI200630363T patent/SI1808168T1/sl unknown
- 2006-01-09 BR BRPI0606727-1A patent/BRPI0606727A/pt not_active IP Right Cessation
- 2006-01-09 US US11/328,405 patent/US20060154866A1/en not_active Abandoned
- 2006-01-09 EP EP10010819A patent/EP2322151A3/en not_active Withdrawn
- 2006-01-09 PT PT06717678T patent/PT1758565E/pt unknown
- 2006-01-09 KR KR1020107010978A patent/KR101016890B1/ko not_active Expired - Fee Related
- 2006-01-09 EP EP08009893A patent/EP1997484A3/en not_active Withdrawn
- 2006-01-09 RS RSP-2009/0366A patent/RS51174B/sr unknown
- 2006-01-09 AR ARP060100072A patent/AR052082A1/es unknown
- 2006-01-09 CN CN2011100978256A patent/CN102218141A/zh active Pending
- 2006-01-09 TW TW095100807A patent/TW200637534A/zh unknown
- 2006-01-09 DE DE602006006765T patent/DE602006006765D1/de active Active
- 2006-01-09 AT AT07004743T patent/ATE432693T1/de active
- 2006-01-09 NZ NZ556219A patent/NZ556219A/en not_active IP Right Cessation
- 2006-01-09 PL PL07004743T patent/PL1808168T3/pl unknown
- 2006-01-09 RS RSP-2009/0354A patent/RS51127B/sr unknown
- 2006-01-09 KR KR1020137032119A patent/KR20130140226A/ko not_active Ceased
- 2006-01-09 ES ES07004743T patent/ES2327872T3/es active Active
- 2006-01-09 EP EP07004743A patent/EP1808168B1/en not_active Revoked
- 2006-01-09 MX MX2007008376A patent/MX2007008376A/es active IP Right Grant
- 2006-01-10 PA PA20068659301A patent/PA8659301A1/es unknown
- 2006-11-22 US US11/603,410 patent/US7803753B2/en not_active Expired - Fee Related
- 2006-11-22 US US11/603,417 patent/US7803754B2/en not_active Expired - Fee Related
-
2007
- 2007-07-02 IL IL184364A patent/IL184364A0/en unknown
- 2007-07-02 CR CR9220A patent/CR9220A/es not_active Application Discontinuation
- 2007-07-09 NI NI200700174A patent/NI200700174A/es unknown
- 2007-07-20 NO NO20073816A patent/NO331089B1/no not_active IP Right Cessation
- 2007-09-06 JP JP2007232094A patent/JP4787804B2/ja not_active Expired - Fee Related
-
2008
- 2008-03-17 JP JP2008068597A patent/JP4221444B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068596A patent/JP4807887B2/ja not_active Expired - Fee Related
- 2008-03-17 JP JP2008068598A patent/JP4237243B2/ja not_active Expired - Fee Related
- 2008-04-16 JP JP2008107320A patent/JP4912349B2/ja not_active Expired - Fee Related
-
2009
- 2009-07-17 AU AU2009202900A patent/AU2009202900B8/en not_active Ceased
- 2009-07-17 AU AU2009202898A patent/AU2009202898B2/en not_active Ceased
- 2009-08-03 CY CY20091100816T patent/CY1109260T1/el unknown
- 2009-08-19 CY CY20091100881T patent/CY1109321T1/el unknown
- 2009-08-20 HR HR20090446T patent/HRP20090446T1/hr unknown
- 2009-10-30 US US12/609,599 patent/US20100137293A1/en not_active Abandoned
- 2009-11-02 US US12/610,490 patent/US20100285494A1/en not_active Abandoned
- 2009-11-02 US US12/610,885 patent/US20100286168A1/en not_active Abandoned
- 2009-11-02 US US12/610,877 patent/US8022034B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,918 patent/US20100286153A1/en not_active Abandoned
- 2009-11-02 US US12/610,639 patent/US8198232B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,967 patent/US20100298333A1/en not_active Abandoned
- 2009-11-02 US US12/610,682 patent/US8003597B2/en not_active Expired - Fee Related
- 2009-11-02 US US12/610,674 patent/US8030270B2/en not_active Expired - Fee Related
-
2010
- 2010-05-31 CL CL2010000565A patent/CL2010000565A1/es unknown
- 2010-12-09 NO NO20101746A patent/NO20101746L/no not_active Application Discontinuation
-
2011
- 2011-02-01 DO DO2011000040A patent/DOP2011000040A/es unknown
- 2011-06-07 JP JP2011127707A patent/JP2011184458A/ja not_active Withdrawn
- 2011-08-05 JP JP2011172381A patent/JP2012017330A/ja not_active Withdrawn
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038501A2 (en) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| WO2000031258A2 (en) * | 1998-11-20 | 2000-06-02 | Arena Pharmaceuticals, Inc. | Human orphan g protein-coupled receptors |
| US6468756B1 (en) * | 1999-02-22 | 2002-10-22 | Synaptic Pharmaceutical Corporation | Methods of identifying compounds that bind to SNORF25 receptors |
| WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
| WO2001052825A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| EP1338651A1 (en) * | 2000-12-01 | 2003-08-27 | Yamanouchi Pharmaceutical Co. Ltd. | Method of screening remedy for diabetes |
| WO2002083128A1 (en) * | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
| WO2003026661A1 (fr) * | 2001-09-14 | 2003-04-03 | Yamanouchi Pharmaceutical Co., Ltd. | Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine |
| EP1538217A1 (en) * | 2002-09-11 | 2005-06-08 | Yamanouchi Pharmaceutical Co. Ltd. | Method of screening insulin content enhancer |
| WO2004065380A1 (en) * | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| WO2004076413A2 (en) * | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| JP2004269469A (ja) * | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| JP2004269468A (ja) * | 2003-03-12 | 2004-09-30 | Yamanouchi Pharmaceut Co Ltd | ピリミジン誘導体又はその塩 |
| WO2005007647A1 (en) * | 2003-07-11 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2005007658A2 (en) * | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2005061489A1 (en) * | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
| WO2005121121A2 (en) * | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006047248A1 (en) * | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
Non-Patent Citations (8)
| Title |
|---|
| AHREN BO ET AL.: "Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes." DIABETES CARE. MAY 2002, vol. 25, no. 5, May 2002 (2002-05), pages 869-875, XP007900711, ISSN: 0149-5992, the whole document * |
| BRUBAKER P.L. ET AL.: "Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line." ENDOCRINOLOGY. OCT 1998, vol. 139, no. 10, October 1998 (1998-10), pages 4108-4114, XP002403176, ISSN: 0013-7227, the whole document * |
| DRUCKER DANIEL J.: "Enhancing incretin action for the treatment of type 2 diabetes." DIABETES CARE. OCT 2003, vol. 26, no. 10, October 2003 (2003-10), pages 2929-2940, XP002386376, ISSN: 0149-5992, the whole document * |
| FREDRIKSSON R. ET AL.: "Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 554, no. 3, 20 November 2003 (2003-11-20), pages 381-388, XP004472955, ISSN: 0014-5793, the whole document * |
| HOLZ G.G. ET AL.: "GLUCAGON-LIKE PEPTIDE-1 SYNTHETIC ANALOGS: NEW THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF DIABETES MELLITUS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 10, no. 22, November 2003 (2003-11), pages 2471-2483, XP009035149, ISSN: 0929-8673, page 2471, paragraph 1, page 2473, column 2, paragraphs 1, 2, page 2474, column 2, paragraph 2 - page 2475, column 1, paragraph 1; figure 2 * |
| TAKASAKI KOTARO ET AL.: "Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats" JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 95, no. 2, June 2004 (2004-06), pages 291-293, XP007900710, ISSN: 1347-8613, the whole document * |
| WEBER A.E.: "DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 47, 2004, pages 4135-4141, XP002329845, ISSN: 0022-2623, pages 540-541 * |
| XU J.: "Metabolic Diseases Drug Discovery - Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors" IDRUGS 2004 UNITED KINGDOM, vol. 7, no. 9, 2004, pages 839-840, XP007900708, ISSN: 1369-7056, the whole document * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA011883B1 (ru) | Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови | |
| JP7060694B2 (ja) | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 | |
| TW200811178A (en) | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | |
| TWI686394B (zh) | 有機化合物 | |
| US20170260168A1 (en) | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases | |
| CN101332303B (zh) | 用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法 | |
| AU2011213703A1 (en) | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |